# Methods of vascular occlusion for elective liver resections (Review)

Gurusamy KS, Sheth H, Kumar Y, Sharma D, Davidson BR



This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in *The Cochrane Library* 2009, Issue 1

http://www.thecochranelibrary.com



# TABLE OF CONTENTS

ABSTRACT	HEADER	1
PLAIN LANGUAGE SUMMARY 222 ARCKGROUND 00BJECTIVES 33 METHODS	ABSTRACT	1
<ul> <li>BACKGROUND</li> <li>BACKGROUND</li> <li>OBJECTIVES</li> <li>METHODS</li> <li>Figure 1.</li> <li>Figure 2.</li> <li>Figure 3.</li> <li>THORS' CONCLUSIONS</li> <li>AUTHORS' CONCLUSIONS</li> <li>AUTHORS' CONCLUSIONS</li> <li>ACKNOWILDGEMENTS</li> <li>EEFERENCES</li> <li>CHARACTERISTICS OF STUDIES</li> <li>DATA AND ANALYSES</li> <li>Analysis 1.2. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 1 Mortality:</li> <li>Analysis 1.3. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 2 Hever</li> <li>failure.</li> <li>f</li></ul>	PLAIN LANGUAGE SUMMARY	2
OBJECTIVES       3         RETHODS       3         RESULTS       6         Figure 1.       7         Figure 2.       9         Figure 3.       10         DISCUSSION       13         AUTHORS' CONCLUSIONS       15         ACKNOWLEDGEMENTS       16         REFERENCES       16         CHARACTERISTICS OF STUDIES       19         DATA AND ANALYSES       38         Analysis 1.2. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 1 Mortality.         Analysis 1.3. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 2 Iver         failure.       45         Analysis 1.4. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 4 Number         needing transfusion.       51         Analysis 1.5. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 5 Number of         units transfused.       51         Analysis 1.6. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 7 Operating         time (minutes).       52         Analysis 1.8. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 8         Haemodynamic changes.       52         Analy	BACKGROUND	3
METHODS	OBJECTIVES	3
RESULTS       6         Figure 1.       7         Figure 2.       9         Figure 3.       10         DISCUSSION       13         AUTHORS' CONCLUSIONS       15         ACKNOWLEDGEMENTS       16         REFFRENCES       16         CANANAUSES       38         Analysis 1.1. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 1 Mortality.         44       Analysis 1.3. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 1 Mortality.         45       Analysis 1.3. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 4 Number         needing transfusion.       45         Analysis 1.6. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 4 Number         needing transfusion.       50         Analysis 1.6. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 7 Mortality.         41       Analysis 1.6. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 7 Operating time (minutes).         42       Analysis 1.8. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 8         43       Haemodynamic changes.       52         Analysis 1.10. Comparison 1 Hepatic vascular exclusion (HVE) versus portal tri	METHODS	3
Figure 1.       7         Figure 3.       90         DISCUSSION       13         AUTTHORS' CONCLUSIONS       15         ACKNOWLEDGEMENTS       16         REFERENCES       16         CHARACTERISTICS OF STUDIES       19         DATA AND ANALYSES       19         Analysis 1.1. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 1 Mortality.       44         Analysis 1.3. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 3 Peri- operative motibidity.       45         Analysis 1.3. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 4 Number needing transfusion.       50         Analysis 1.5. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 4 Number of units transfused.       51         Analysis 1.6. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 6 Hospital stay (days).       51         Analysis 1.6. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 7 Operating time (minutes).       52         Analysis 1.10. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 8       52         Analysis 1.10. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 8       52         Analysis 1.10. Comparison 1 Hepatic vascular exclusion (HVE) vers	RESULTS	6
Figure 2.       10         Figure 3.       10         DISCUSSION       13         AUTTHORS' CONCLUSIONS       15         ACKNOWLEDGEMENTS       16         REFERENCES       16         CHARACTERISTICS OF STUDIES       19         DAITA AND ANALYSES       16         Analysis 1.1. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 1 Mortality.       44         Analysis 1.2. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 3 Peri-       50         Analysis 1.3. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 4 Number       50         Analysis 1.4. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 5 Number of       51         Analysis 1.5. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 6 Hospital       51         Analysis 1.6. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 7 Operating       51         Analysis 1.7. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 7 Operating       52         Analysis 1.8. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 7 Operating       52         Analysis 1.10. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 15       54	Figure 1	7
Figure 3.       10         DISCUSSION       13         AUTHORS' CONCLUSIONS       13         AUTHORS' CONCLUSIONS       15         ACKNOWLEDGEMENTS       16         REFERENCES       16         CHARACTERISTICS OF STUDIES       19         DATA AND ANALYSES       19         DATA AND ANALYSES       19         Analysis 1.1. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 1 Mortality.       44         Analysis 1.2. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 3 Peri-operative morbidity.       45         Analysis 1.3. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 5 Number of units transfused.       50         Analysis 1.6. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 7 Number of units transfused.       51         Analysis 1.7. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 7 Portating trime (minutes).       52         Analysis 1.8. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 1 Minutes).       52         Analysis 1.10. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 1 Minutes).       52         Analysis 1.11. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 1 Minutes).       53 </td <td>Figure 2</td> <td>9</td>	Figure 2	9
<ul> <li>DISCUSSION</li> <li>DISCUSSION</li> <li>AUTTHORS: CONCLUSIONS</li> <li>ACKNOWLEDGEMENTS</li> <li>REFERENCES</li> <li>CHARACTERISTICS OF STUDIES</li> <li>DATA AND ANALYSES</li> <li>Analysis 1.1. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 1 Mortality.</li> <li>Analysis 1.2. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 3 Peri-</li> <li>operative morbidity.</li> <li>Analysis 1.3. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 4 Number</li> <li>needing transfusion.</li> <li>needing transfusion.</li> <li>Analysis 1.5. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 4 Number</li> <li>needing transfusion.</li> <li>Analysis 1.6. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 4 Number</li> <li>needing transfusion.</li> <li>Analysis 1.6. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 6 Hospital</li> <li>stay (days).</li> <li>st</li></ul>	Figure 3	10
AUTHORS' CONCLUSIONS       15         REFERENCES       16         REFERENCES       16         Analysis 1.1. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 1 Mortality.       44         Analysis 1.2. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 2 Liver       45         Analysis 1.3. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 3 Perioperative morbidity.       45         Analysis 1.3. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 4 Number       51         Analysis 1.5. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 4 Number       51         Analysis 1.6. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 6 Hongital       51         Analysis 1.7. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 7 Operating       52         Analysis 1.8. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 7 Deprating       52         Analysis 1.9. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 10 Biltrubin       52         Analysis 1.10. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 10       52         Analysis 1.10. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 10 Biltrubin       52 <td>DISCUSSION</td> <td>13</td>	DISCUSSION	13
ACKNOWLEDGEMENTS       16         CHARACTERISTICS OF STUDIES       19         DATA AND ANALYSES       38         Analysis 1.1. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 1 Mortality.       44         Analysis 1.2. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 2 Liver       55         Analysis 1.3. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 4 Number       50         Analysis 1.4. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 4 Number       51         Analysis 1.5. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 6 Hospital       51         Analysis 1.6. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 6 Hospital       51         Analysis 1.6. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 7 Operating       51         Analysis 1.7. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 8       52         Analysis 1.8. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 8       52         Analysis 1.9. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 9 Blood loss       53         Analysis 1.10. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 12 AST       54	AUTHORS' CONCLUSIONS	15
<ul> <li>REFERENCES</li> <li>II. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 1 Mortality.</li> <li>Analysis 1.1. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 2 Liver failure.</li> <li>Analysis 1.3. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 3 Perioperative morbidity.</li> <li>Analysis 1.4. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 4 Number needing transfusion.</li> <li>Analysis 1.5. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 6 Moumber needing transfusion.</li> <li>Analysis 1.6. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 6 Hospital stay (days).</li> <li>Analysis 1.6. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 6 Hospital stay (days).</li> <li>Analysis 1.8. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 7 Operating time (minutes).</li> <li>Analysis 1.9. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 7 Operating time (minutes).</li> <li>Analysis 1.0. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 8 Haemodynamic changes.</li> <li>Analysis 1.10. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 10 Biliubin (micromol/itrine).</li> <li>Analysis 1.11. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 10 Biliubin (micromol/itrine).</li> <li>Analysis 1.12. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 12 AST (aspartate transaminase) (IU/Itre).</li> <li>Analysis 1.13. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 12 AST (aspartate transaminase) (IU/Itre).</li> <li>Analysis 2.1. Comparison 1 Hepatic vascular exc</li></ul>	ACKNOWLEDGEMENTS	16
CHARACTERISTICS OF STUDIES       19         DATA AND ANALYSES       38         Analysis 1.1. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 1 Mortality.       44         Analysis 1.3. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 3 Peri-operative morbidity.       45         Analysis 1.3. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 3 Peri-operative morbidity.       45         Analysis 1.4. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 5 Number of units transfused.       50         Analysis 1.6. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 6 Hospital stay (day).       51         Analysis 1.6. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 6 Hospital stay (day).       52         Analysis 1.8. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 8       52         Analysis 1.9. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 8       52         Analysis 1.10. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 10 Bilrubin (micromole/litre).       56         Analysis 1.10. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 10 Silrubin (micromole/litre).       56         Analysis 1.11. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PT	REFERENCES	16
<ul> <li>DATA AND ANALYSES</li></ul>	CHARACTERISTICS OF STUDIES	19
<ul> <li>Analysis 1.1. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 1 Mortality.</li> <li>Analysis 1.2. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 3 Perioperative morbidity.</li> <li>Analysis 1.3. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 4 Number needing transfusion.</li> <li>Analysis 1.5. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 5 Number of units transfused.</li> <li>Analysis 1.6. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 6 Hospital stay (days).</li> <li>Analysis 1.6. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 6 Hospital stay (days).</li> <li>Analysis 1.7. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 7 Operating trime (minutes).</li> <li>Analysis 1.8. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 7 Operating trime (minutes).</li> <li>Analysis 1.9. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 8</li> <li>Haemodynamic changes.</li> <li>Analysis 1.9. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 8</li> <li>Maalysis 1.10. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 10 Bilirubin (micromole/litre).</li> <li>Analysis 1.10. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 11 Prothrombin activity (percentage of normal).</li> <li>Analysis 1.12. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 13 ALT (alanine transminase) (IU/litre).</li> <li>Analysis 1.13. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 14 ALT (alanine transminase) (IU/litre).</li> <li>Analysis 2.1. Comparison 1 Hepatic vascular excl</li></ul>	DATA AND ANALYSES	38
Analysis 1.2. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 2 Liver       45         Analysis 1.3. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 3 Peri-       45         Analysis 1.4. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 4 Number       45         Analysis 1.5. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 5 Number of       51         Analysis 1.6. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 6 Hospital       51         Analysis 1.6. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 7 Operating       51         Analysis 1.6. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 7 Operating       52         Analysis 1.8. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 8       52         Analysis 1.8. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 8 Bilaromolynamic changes.       52         Analysis 1.10. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 10 Bilirubin       56         Analysis 1.11. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 11       59         Analysis 1.12. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 12       59         Analysis 1.12. Compa	Analysis 1.1. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 1 Mortality.	44
failure.       45         Analysis 1.3. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 3 Peri- operative morbidity.       45         Analysis 1.4. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 4 Number needing transfusion.       50         Analysis 1.5. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 5 Number of units transfused.       51         Analysis 1.6. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 6 Hospital stay (days).       51         Analysis 1.7. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 7 Operating time (minutes).       52         Analysis 1.8. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 7 Operating time (minutes).       52         Analysis 1.9. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 8       52         Analysis 1.9. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 9 Blood loss (ml).       55         (ml).       56       51         Analysis 1.10. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 10       51         Analysis 1.10. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 13       52         Analysis 1.12. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 12 AST	Analysis 1.2. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 2 Liver	
Analysis 1.3. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 3 Peri- operative morbidity.       45         Analysis 1.4. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 4 Number needing transfusion.       50         Analysis 1.5. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 5 Number of units transfused.       51         Analysis 1.6. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 6 Hospital stay (days).       51         Analysis 1.7. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 7 Operating time (minutes).       52         Analysis 1.8. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 8       52         Analysis 1.8. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 8       52         Analysis 1.9. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 10 Bilirubin (micromole/litre).       55         Analysis 1.10. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 10 Bilirubin (micromole/litre).       56         Analysis 1.12. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 12 AST (aspartate transaminase) (IU/litre).       60         Analysis 1.13. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 13 ALT (alanine transaminase) (IU/litre).       63         A	failure	45
operative morbidity.       45         Analysis 1.4. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 4 Number needing transfusion.       50         Analysis 1.5. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 5 Number of units transfused.       51         Analysis 1.6. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 6 Hospital stay (days).       51         Analysis 1.7. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 7 Operating time (minutes).       52         Analysis 1.8. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 7 Operating time (minutes).       52         Analysis 1.9. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 9 Blood loss (ml).       55         (ml).       55       52         Analysis 1.10. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 10 Blilrubin (micromole/litre).       56         Analysis 1.10. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 12 AST (aspartate transaminase) (IU/litre).       59         Analysis 1.13. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 12 AST (aspartate transaminase) (IU/litre).       63         Analysis 1.13. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 13 ALT (alanine transaminase) (IU/litre).       63	Analysis 1.3. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 3 Peri-	
Analysis 1.4. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 4 Number of units transfused.       50         Analysis 1.5. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 6 Hospital stay (days).       51         Analysis 1.6. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 6 Hospital stay (days).       51         Analysis 1.7. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 7 Operating time (minutes).       52         Analysis 1.8. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 8       52         Analysis 1.8. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 8       52         Analysis 1.9. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 8 Blood loss (ml).       55         Analysis 1.10. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 10 Bilrubin (micromole/litre).       56         Analysis 1.11. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 12 AST (aspartate transaminase) (IU/litre).       59         Analysis 1.12. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 13 ALT (alanine transaminase) (IU/litre).       60         Analysis 1.13. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 13 ALT (alanine transaminase) (IU/litre).       61         Analysi	operative morbidity	45
needing transfusion.       50         Analysis 1.5. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 5 Number of units transfused.       51         Analysis 1.6. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 6 Hospital stay (days).       51         Analysis 1.7. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 7 Operating time (minutes).       52         Analysis 1.8. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 8       52         Haemodynamic changes.       52         Analysis 1.9. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 8       55         (ml).       55         Analysis 1.10. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 10       56         Analysis 1.11. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 11       59         Analysis 1.11. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 12 AST       60         Analysis 1.13. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 13 ALT       61         (alarine transaminase) (IU/litre).       60       61         Analysis 2.1.0. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 1 Mortality.       66         Analysis 2.3. Comparison 2 Por	Analysis 1.4. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 4 Number	
Analysis 1.5. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 5 Number of units transfused.       51         Analysis 1.6. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 6 Hospital stay (days).       51         Analysis 1.7. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 7 Operating time (minutes).       52         Analysis 1.8. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 8 Haemodynamic changes.       52         Analysis 1.9. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 9 Blood loss (ml).       52         Analysis 1.9. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 9 Blood loss (ml).       55         Analysis 1.10. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 10 Bilirubin (micromole/litre).       56         Analysis 1.11. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 11 Prothrombin activity (percentage of normal).       59         Analysis 1.12. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 13 ALT (aspartate transaminase) (IU/litre).       63         Analysis 2.1.13. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 1 Mortality.       65         Analysis 2.3. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 1 Mortality.       66         Analysis 2.4. Compa	needing transfusion.	50
units transfused.       51         Analysis 1.6. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 6 Hospital       51         Analysis 1.7. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 7 Operating       52         Analysis 1.8. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 7 Operating       52         Analysis 1.8. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 8       52         Analysis 1.9. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 9 Blood loss       52         (ml).       .       .       .         (micromole/litre).       .       .       .         (micromole/litre).       .       .       .         Prothrombin activity (percurates of normal).       .       .       .         Analysis 1.12. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 12 AST       60         Analysis 1.13. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 12 AST       63         (alanine transaminase) (IU/litre).       .       .       .       .         (alanine transaminase) 2 Portal triad clamping; 'continuous' versus 'intermittent', Outcome 1 Mortality.       .       .       .         Analysis 2.3. Comparison 2 Port	Analysis 1.5. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 5 Number of	
Analysis 1.6. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 6 Hospital stay (days).       51         Analysis 1.7. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 7 Operating time (minutes).       52         Analysis 1.8. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 8       52         Analysis 1.9. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 8       52         Analysis 1.9. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 9 Blood loss (ml).       55         Analysis 1.10. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 10 Bilirubin (micromole/litre).       56         Analysis 1.11. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 11       59         Prothrombin activity (percentage of normal).       59         Analysis 1.12. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 12 AST (aspartate transaminase) (IU/litre).       60         Analysis 2.1.2. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 13 ALT (alanine transaminase) (IU/litre).       63         Analysis 2.1.3. Comparison 2 Portal triad clamping; 'continuous' versus 'intermittent', Outcome 1 Mortality.       66         Analysis 2.2. Comparison 2 Portal triad clamping; 'continuous' versus 'intermittent', Outcome 3 Peri-operative morbidity.       66 <td>units transfused.</td> <td>51</td>	units transfused.	51
stay (days).       51         Analysis 1.7. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 7 Operating       52         Analysis 1.8. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 8       52         Analysis 1.9. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 9 Blood loss       52         Analysis 1.9. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 9 Blood loss       52         Analysis 1.10. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 10 Bilrubin       56         Analysis 1.11. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 11       59         Prothrombin activity (percentage of normal).       59         Analysis 1.12. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 12 AST       60         Analysis 1.13. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 13 ALT       61         (alanine transaminase) (IU/litre).       60       60         Analysis 2.3. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 3 Peri-operative morbidity.       66         Analysis 2.3. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 4 Number needing       71         Analysis 2.4. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outc	Analysis 1.6. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 6 Hospital	
Analysis 1.7. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (P1C), Outcome 7 Operating time (minutes).       52         Analysis 1.8. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 8       52         Analysis 1.9. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 9 Blood loss (ml).       55         Analysis 1.10. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 10 Bilirubin (micromole/litre).       56         Analysis 1.11. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 10 Bilirubin (micromole/litre).       56         Analysis 1.11. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 10 Bilirubin (micromole/litre).       56         Analysis 1.12. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 11       57         Prothrombin activity (percentage of normal).       59         Analysis 1.13. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 13 ALT (alanine transaminase) (IU/litre).       60         Analysis 2.1. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 3 Deri- operative morbidity.       66         Analysis 2.2. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 4 Number needing transfusion.       71         Analysis 2.4. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 5 Number of units transfused.<	stay (days)	51
time (minutes).       1	Analysis 1.7. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 7 Operating	
Analysis 1.8. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 8       52         Analysis 1.9. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 9 Blood loss       55         (ml)		52
Haemodynamic changes.       52         Analysis 1.9. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 9 Blood loss (ml).       55         Analysis 1.10. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 10 Bilirubin (micromole/litre).       56         Analysis 1.11. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 10 Bilirubin (micromole/litre).       56         Analysis 1.11. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 11       59         Analysis 1.12. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 12 AST (aspartate transaminase) (IU/litre).       60         Analysis 1.13. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 13 ALT (alanine transaminase) (IU/litre).       63         Analysis 2.1. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 1 Mortality.       65         Analysis 2.2. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 2 Liver failure.       66         Analysis 2.4. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 5 Number needing transfusion.       71         Analysis 2.5. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 6 Hospital stay (in days).       71         Analysis 2.6. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 7 Operating time (in minutes).       71	Analysis 1.8. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (P1C), Outcome 8	50
Analysis 1.9. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 9 Blood loss (ml).       55         Analysis 1.10. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 10 Bilirubin (micromole/litre).       56         Analysis 1.11. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 11 Prothrombin activity (percentage of normal).       59         Analysis 1.12. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 12 AST (aspartate transaminase) (IU/litre).       60         Analysis 1.13. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 13 ALT (alanine transaminase) (IU/litre).       63         Analysis 2.1. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 1 Mortality.       65         Analysis 2.3. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 3 Peri-operative morbidity.       66         Analysis 2.4. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 4 Number needing transfusion.       71         Analysis 2.5. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 5 Number of units transfused.       71         Analysis 2.6. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 6 Hospital stay (in days).       72         Analysis 2.6. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 7 Operating time (in minutes).       72		52
(mi).	Analysis 1.9. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (P1C), Outcome 9 blood loss	<i></i>
Analysis 1.10. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 10 Biliruoin (micromole/litre).       56         Analysis 1.11. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 11       59         Analysis 1.12. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 12 AST (aspartate transaminase) (IU/litre).       60         Analysis 1.13. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 13 ALT (alanine transaminase) (IU/litre).       63         Analysis 2.1. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 1 Mortality.       65         Analysis 2.3. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 2 Liver failure.       66         Analysis 2.4. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 4 Number needing transfusion.       71         Analysis 2.5. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 5 Number of units transfused.       71         Analysis 2.6. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 6 Hospital stay (in days).       72         Analysis 2.7. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 7 Operating time (in minutes).       72		))
Analysis 1.11. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 11       59         Analysis 1.12. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 12 AST       60         Analysis 1.12. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 12 AST       60         Analysis 1.13. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 13 ALT       61         (alanine transaminase) (IU/litre).       63         Analysis 2.1. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 1 Mortality.       65         Analysis 2.2. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 3 Peri-operative morbidity.       66         Analysis 2.3. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 4 Number needing transfusion.       71         Analysis 2.5. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 5 Number of units transfused.       71         Analysis 2.6. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 6 Hospital stay (in days).       72         Analysis 2.7. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 7 Operating time (in minutes).       72	Analysis 1.10. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 10 Bilirubin	5(
Analysis 1.11. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (FTC), Outcome 11       59         Analysis 1.12. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 12 AST       60         Analysis 1.13. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 13 ALT       61         (alanine transaminase) (IU/litre).       63         Analysis 2.1. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 1 Mortality.       65         Analysis 2.2. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 2 Liver failure.       66         Analysis 2.3. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 3 Peri-operative morbidity.       66         Analysis 2.4. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 4 Number needing transfusion.       71         Analysis 2.5. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 5 Number of units transfused.       71         Analysis 2.6. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 6 Hospital stay (in days).       72         Analysis 2.7. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 7 Operating time (in minutes).       72         Methods of vascular orclusion for elective liver resertions (Review)       72	(Interior 1.11, Comparison 1, Hanatic vacuular evaluation (HVE) various portal triad elemping (DTC). Outcome 11	50
Analysis 1.12. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 12 AST       60         Analysis 1.13. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 13 ALT       61         (alanine transaminase) (IU/litre).       63         Analysis 2.1. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 1 Mortality.       65         Analysis 2.2. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 2 Liver failure.       66         Analysis 2.3. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 3 Peri-operative morbidity.       66         Analysis 2.4. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 4 Number needing transfusion.       71         Analysis 2.5. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 5 Number of units transfused.       71         Analysis 2.6. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 6 Hospital stay (in days).       72         Analysis 2.7. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 7 Operating time (in minutes).       72	Prothrombin activity (percentage of normal)	59
Analysis 1.12. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (FTC), Outcome 12 AS1       60         Analysis 1.13. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 13 ALT       63         (alanine transaminase) (IU/litre).       63         Analysis 2.1. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 1 Mortality.       65         Analysis 2.2. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 2 Liver failure.       66         Analysis 2.3. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 3 Peri-operative morbidity.       66         Analysis 2.4. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 4 Number needing transfusion.       71         Analysis 2.5. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 5 Number of units transfused.       71         Analysis 2.6. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 6 Hospital stay (in days).       72         Analysis 2.7. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 7 Operating time (in minutes).       72	Analyzis 1.12 Comparison 1 Hanatic vaccular avaluation (HVE) varsus portal triad clamping (PTC). Outcome 12 AST	))
Analysis 1.13. Comparison 1 Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 13 ALT       63         Analysis 2.1. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 1 Mortality.       65         Analysis 2.2. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 2 Liver failure.       66         Analysis 2.3. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 3 Peri-operative morbidity.       66         Analysis 2.4. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 4 Number needing transfusion.       71         Analysis 2.5. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 5 Number of units transfused.       71         Analysis 2.6. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 6 Hospital stay (in days).       72         Mathods of vascular occlusion for elective liver resections (Review)       72	(asportato transpinaso) (III/litro)	60
Analysis 1.15. Comparison 1 Prepare vascular exclusion (11VE) versus portal triad clamping (11C), Outcome 15 AEF       63         Analysis 2.1. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 1 Mortality.       65         Analysis 2.2. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 2 Liver failure.       66         Analysis 2.3. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 3 Peri-operative morbidity.       66         Analysis 2.4. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 4 Number needing transfusion.       71         Analysis 2.5. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 5 Number of units transfused.       71         Analysis 2.6. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 6 Hospital stay (in days).       72         Mathods of vascular occlusion for elective liver resections (Review)       72	Analysis 1.13 Comparison 1 Henotic vaccular evolusion (HVE) versus portal triad clamping (PTC). Outcome 13 AIT	00
Analysis 2.1. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 1 Mortality.       65         Analysis 2.2. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 2 Liver failure.       66         Analysis 2.3. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 3 Peri-operative morbidity.       66         Analysis 2.4. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 4 Number needing transfusion.       71         Analysis 2.5. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 5 Number of units transfused.       71         Analysis 2.6. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 6 Hospital stay (in days).       72         Analysis 2.7. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 7 Operating time (in minutes).       72	(alapine transaminase) (III/litre)	63
Analysis 2.1. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 2 Liver failure	Analysis 2.1. Comparison 2 Portal triad clamping: "continuous" versus "intermittent". Outcome 1 Mortality	65
Analysis 2.2. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 3 Peri-operative morbidity.       66         Analysis 2.4. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 4 Number needing transfusion.       71         Analysis 2.5. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 5 Number needing transfused.       71         Analysis 2.5. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 5 Number of units transfused.       71         Analysis 2.6. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 6 Hospital stay (in days).       72         Analysis 2.7. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 7 Operating time (in minutes).       72	Analysis 2.1. Comparison 2 Portal triad clamping: continuous versus 'intermittent', Outcome 2 Liver failure	66
Analysis 2.9. Comparison 2 Portal triad clamping: "continuous" versus "intermittent", Outcome 4 Number needing transfusion.       71         Analysis 2.5. Comparison 2 Portal triad clamping: "continuous" versus "intermittent", Outcome 5 Number of units transfused.       71         Analysis 2.6. Comparison 2 Portal triad clamping: "continuous" versus "intermittent", Outcome 5 Number of units transfused.       71         Analysis 2.6. Comparison 2 Portal triad clamping: "continuous" versus "intermittent", Outcome 6 Hospital stay (in days).       72         Analysis 2.7. Comparison 2 Portal triad clamping: "continuous" versus "intermittent", Outcome 7 Operating time (in minutes).       72         Methods of vascular occlusion for elective liver resections (Beview)       72	Analysis 2.3. Comparison 2 Portal triad clamping: continuous' versus 'intermittent', Outcome 3 Peri-operative morbidity	66
Analysis 2.4. Comparison 2 Portal triad clamping: Continuous' versus intermittent', Outcome 4 Number incenting       71         Analysis 2.5. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 5 Number of units       71         Analysis 2.6. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 6 Hospital stay (in days).       72         Analysis 2.7. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 7 Operating time (in minutes).       72         Methods of vascular occlusion for elective liver resections (Beview)       72	Analysis 2.4. Comparison 2 Portal triad clamping: "continuous" versus "intermittent", Outcome 4 Number needing	00
Analysis 2.5. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 5 Number of units transfused.       71         Analysis 2.6. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 6 Hospital stay (in days).       72         Analysis 2.7. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 7 Operating time (in minutes).       72	transfusion	71
Intravision 2.1.9. Comparison 2.1.9.1.4 that exampling: Continuous Versus Intermittent', Outcome 9.1.4 that of units       71         Analysis 2.6. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 6 Hospital stay (in days).       72         Analysis 2.7. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 7 Operating time (in minutes).       72         Methods of vascular occlusion for elective liver resections (Review)       72	Analysis 2.5 Comparison 2 Portal triad clamping: "continuous" versus "intermittent". Outcome 5 Number of units	/ 1
Analysis 2.6. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 6 Hospital stay (in days).       72         Analysis 2.7. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 7 Operating time (in minutes).       72         Methods of vascular occlusion for elective liver resections (Beview)       72	transfused	71
Analysis 2.7. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 7 Operating time (in minutes).       72         Methods of vascular occlusion for elective liver resections (Beview)       3	Analysis 2.6. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent'. Outcome 6 Hospital stav (in days)	72
minutes)	Analysis 2.7. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent'. Outcome 7 Operating time (in	. =
Methods of vascular occlusion for elective liver resections (Review)	minutes).	72
	Methods of vascular occlusion for elective liver resections (Beview)	<del>;</del>

Analysis 2.9. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 10 Prothrombin activity         (prerentage of normal).       74         Analysis 2.10. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 11 AST (apartate         transaminasy) (IU/Itre).       81         Analysis 2.11. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 11 AST (apartate         transaminasy) (IU/Itre).       81         Analysis 2.12. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 2 Liver failure.       89         Analysis 3.2. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 2 Liver failure.       89         Analysis 3.3. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 7 Unitos transfusion.       95         Analysis 3.5. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 7 Unitos transfusion.       96         Analysis 3.6. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 7 Mespiral arsy (in day).       96         Analysis 3.8. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 7 Mespiral arsy (in day).       97         Analysis 3.1. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 7 Blinobin Selective', and analysis 3.1. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 7 Mespiral arsy (in day).       96         Analysis 3.1. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 8 Blinobin (micromole/lire).       99         Analysis 3.1. Comparison 3 Inflow occlusion: 'selective' vers	Analysis 2.8. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 8 Blood loss.	73
Analysis 2.10. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 10 Prothrombin activity (precentage of normal).       78         Analysis 2.11. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 11 AST (aspartate transaminase) (IU/Itre).       81         Analysis 2.12. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 1 Mortality.       88         Analysis 3.2. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 2 Liver failure.       89         Analysis 3.3. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 3 Pari-operative morbidity.       89         Analysis 3.4. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 7 Mumber ot mits transfuscion.       95         Analysis 3.4. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 7 Moperal ray (in day).       96         Analysis 3.8. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 7 Operating time (min).       96         Analysis 3.1. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 7 Moperal exp (in day).       97         Analysis 3.1. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 7 Moperal exp (in day).       96         Analysis 3.1. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 1 Most (incromolel/lice).       99         Analysis 3.1. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 1 Most (incromolel/lice).       97         Analysis 3.1. Comparison 3 Inflow occlusion: 'selective' versu	Analysis 2.9. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 9 Bilirubin (micromole/litre).	74
<ul> <li>(percentage of normal). 78</li> <li>Analysis 2.11. Comparison 2 Portal trial clamping: 'continuous' versus 'intermittent', Outcome 11 AST (aspartate transminase) (IU/Jirry). 81</li> <li>Analysis 2.12. Comparison 3 Inflow occlusion: 'kelective' versus 'total', Outcome 1 Mortality. 88</li> <li>Analysis 3.1. Comparison 3 Inflow occlusion: 'kelective' versus 'total', Outcome 2 Liver failure. 89</li> <li>Analysis 3.2. Comparison 3 Inflow occlusion: 'kelective' versus 'total', Outcome 2 Liver failure. 89</li> <li>Analysis 3.3. Comparison 3 Inflow occlusion: 'kelective' versus 'total', Outcome 4 Number of mitter transfused. 95</li> <li>Analysis 3.5. Comparison 3 Inflow occlusion: 'kelective' versus 'total', Outcome 7 Operating time (min). 96</li> <li>Analysis 3.6. Comparison 3 Inflow occlusion: 'kelective' versus 'total', Outcome 7 Operating time (min). 96</li> <li>Analysis 3.7. Comparison 3 Inflow occlusion: 'kelective' versus 'total', Outcome 7 Operating time (min). 96</li> <li>Analysis 3.7. Comparison 3 Inflow occlusion: 'kelective' versus 'total', Outcome 7 Bleod bass (min). 98</li> <li>Analysis 3.10. Comparison 3 Inflow occlusion: 'kelective' versus 'total', Outcome 1 Remodynamics Change (10 min after release of clamping). 91</li> <li>Analysis 3.11. Comparison 3 Inflow occlusion: 'kelective' versus 'total', Outcome 10 Bilirubin (micromole/litre). 99</li> <li>Analysis 3.12. Comparison 3 Inflow occlusion: 'kelective' versus 'total', Outcome 11 AST (aspartate transminase) (U/Jitre). 90</li> <li>Analysis 3.12. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 1 Mortality. 81</li> <li>Analysis 4.2. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 1 Nortality. 81</li> <li>Analysis 4.3. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 1 Number of units of FPP transfused. 113</li> <li>Analysis 4.4. Comparison 4 30 minutes intermittent PTC v</li></ul>	Analysis 2.10. Comparison 2. Portal triad clamping: 'continuous' versus 'intermittent'. Outcome 10 Prothrombin activity	, -
Analysis 2.11. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 11 AST (aspartate transaminase) (IU/Itre).       81         Analysis 2.12. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 1 Mortality.       88         Analysis 3.2. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 1 Mortality.       89         Analysis 3.3. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 1 Mortality.       89         Analysis 3.4. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 4 Number rededing transfusion.       95         Analysis 3.5. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 6 Hompital structure.       99         Analysis 3.6. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 6 Hompital structure.       97         Analysis 3.0. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 1 Billinubin (incimonol/litre).       97         Analysis 3.10. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 1 Billinubin (incimonol/litre).       97         Analysis 3.11. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 11 Billinubin (incircomol/litre).       90         Analysis 3.12. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 12 ALT (alanine transaminase)       101/11/11/11         Analysis 3.11. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 12 ALT (alanine transaminase)       101/11/11         Analysis 4.12. Comparison 4 30 minutes intermittent PTC versus 15 mi	(percentage of normal).	78
transaminase) (IU/litre). 81 Analysis 2.12. Comparison 3 Inflow occlusion: selective' versus 'total', Outcome 1 Mortality. 88 Analysis 3.1. Comparison 3 Inflow occlusion: selective' versus 'total', Outcome 1 Mortality. 88 Analysis 3.3. Comparison 3 Inflow occlusion: selective' versus 'total', Outcome 2 Iver failure. 89 Analysis 3.4. Comparison 3 Inflow occlusion: selective' versus 'total', Outcome 4 Number needing transfusion. 95 Analysis 3.5. Comparison 3 Inflow occlusion: selective' versus 'total', Outcome 5 Number of units transfused. 95 Analysis 3.6. Comparison 3 Inflow occlusion: selective' versus 'total', Outcome 5 Number of units transfused. 95 Analysis 3.6. Comparison 3 Inflow occlusion: selective' versus 'total', Outcome 6 Hospital stay (fin days). 96 Analysis 3.6. Comparison 3 Inflow occlusion: selective' versus 'total', Outcome 7 Operating (mc (min)). 96 Analysis 3.8. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 7 Operating (mc (min)). 97 Analysis 3.10. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 10 Bilirubin (micromole/litre). 99 Analysis 3.10. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 11 AST (aspartate transaminase) (IU/litre). 102 Analysis 3.1.2. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 12 ALT (alanite transaminase) (IU/litre). 105 Analysis 4.3. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 2 Peri-operative mothidity. 109 Analysis 4.3. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 4 Number of units of FPP transfusion. 113 Analysis 4.4. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 5 Number of units of FPP transfused. 114 Analysis 4.5. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 7 Operating time. 115 Analysis 4.8. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 7 Operating time. 115 Analysis 4.10. Comparison 4 30	Analysis 2.11. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 11 AST (aspartate	, -
Analysis 2.12. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 1 Mortality.       85         Analysis 3.1. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 1 Mortality.       89         Analysis 3.1. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 2 Liver failure.       89         Analysis 3.4. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 4 Number needing transfusion.       95         Analysis 3.4. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 6 Houpiet as run of the optical optical optical optical optical optical', outcome 6 Houpiet as run optical.       95         Analysis 3.5. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 6 Houpiet as run optical optica	transaminase) (IU/litre)	81
transaminase) (IU/litre)	Analysis 2.12. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 12 ALT (alanine	
Analysis 3.1. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 1 Mortality.       88         Analysis 3.2. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 3 Peri-operative morbidity.       89         Analysis 3.3. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 4 Number needing transfusion.       95         Analysis 3.5. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 6 Hompital stay (in days).       96         Analysis 3.5. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 6 Hompital stay (in days).       96         Analysis 3.5. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 7 Operating time (min).       97         Analysis 3.1. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 9 Blood loss (ml).       98         Analysis 3.1. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 10 Bilirubin (micromole/lirre).       97         Analysis 3.1. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 10 Bilirubin (micromole/lirre).       92         Analysis 3.1. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 12 ALT (alarine transaminase) (U/U/lirre).       102         Analysis 4.1. Comparison 4 3 Inflow occlusion: 'selective' versus 'total', Outcome 12 ALT (alarine transaminase) (U/U/lirre).       103         Analysis 4.2. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 2 Number of units transfused.       114         Analysis 4.3. Comparison 4 30 minutes intermitte	transaminase) (IU/litre).	85
Analysis 3.2. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 2 Iver failure.       89         Analysis 3.4. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 4 Number rol unit transfuscion.       95         Analysis 3.5. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 7 Operating time (min).       96         Analysis 3.5. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 7 Operating time (min).       96         Analysis 3.6. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 7 Operating time (min).       96         Analysis 3.7. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 7 Operating time (min).       96         Analysis 3.10. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 7 Operating time (min).       97         Analysis 3.10. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 10 Bilirubin (micromole/litre).       98         Analysis 3.11. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 11 AST (aparate transminase) (IU/litre).       102         (IU/litre).       105       Analysis 4.1. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 2 Number of units transfusion.       113         Analysis 4.2. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 2 Number of units transfused.       114         Analysis 4.3. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 7 Operating time.       114	Analysis 3.1. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 1 Mortality	88
Analysis 3.3. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 4 Number needing transfusion.       89         Analysis 3.5. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 5 Number of units transfused.       95         Analysis 3.5. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 6 Hospital stay (in days).       96         Analysis 3.6. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 7 Operating time (min).       96         Analysis 3.8. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 7 Operating time (min).       97         Analysis 3.10. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 10 Bilirubin (micromole/litre).       97         Analysis 3.10. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 10 Bilirubin (micromole/litre).       98         Analysis 3.11. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 10 Bilirubin (micromole/litre).       102         Analysis 4.12. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 12 ALT (alanine transminase)       101         (IU/litre).       102       103       108         Analysis 4.1. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 2 Number of units of FPT transfused.       113         Analysis 4.2. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 4 Number of units of FPT transfused.       114         Analysis 4.5. Comparison 4 30 minutes intermittent PTC versus 15 minute	Analysis 3.2. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 2 Liver failure	89
Analysis 3:4. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 4 Number of units transfused.       95         Analysis 3:5. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 6 Hospital stay (in days).       96         Analysis 3:5. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 7 Operating time (ini).       96         Analysis 3:5. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 7 Operating time (ini).       97         Analysis 3:0. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 10 Bilirubin (micromole/lire).       99         Analysis 3:10. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 10 Bilirubin (micromole/lire).       99         Analysis 3:10. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 10 Bilirubin (micromole/lire).       99         Analysis 3:10. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 11 AST (apartate transminase) (IU/lire).       102         Analysis 4:1. Comparison 4 3 Inflow occlusion: 'selective' versus 'total', Outcome 12 ALI' (alanine transminase) (IU/lire).       103         Analysis 4:3. Comparison 4:30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 2 Number of units transfused.       113         Analysis 4:3. Comparison 4:30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 4 Number of units transfused.       114         Analysis 4:4. Comparison 4:30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 7 Number of units of FFP transfused.       114 <td>Analysis 3.3. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 3 Peri-operative morbidity.</td> <td>89</td>	Analysis 3.3. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 3 Peri-operative morbidity.	89
Analysis 3.5. Comparison 3 Inflow occlusion: selective' versus 'total', Outcome 6 Hospital stay (in days).       96         Analysis 3.5. Comparison 3 Inflow occlusion: selective' versus 'total', Outcome 7 Operating time (min).       96         Analysis 3.7. Comparison 3 Inflow occlusion: selective' versus 'total', Outcome 7 Operating time (min).       97         Analysis 3.9. Comparison 3 Inflow occlusion: selective' versus 'total', Outcome 10 Bilrubin (micromole/litre).       97         Analysis 3.10. Comparison 3 Inflow occlusion: selective' versus 'total', Outcome 10 Bilrubin (micromole/litre).       98         Analysis 3.12. Comparison 3 Inflow occlusion: selective' versus 'total', Outcome 10 Bilrubin (micromole/litre).       91         Analysis 3.12. Comparison 3 Inflow occlusion: selective' versus 'total', Outcome 10 Bilrubin (micromole/litre).       102         Analysis 4.1. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 1 Mortality.       105         Analysis 4.2. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 2 Number of units transfused.       114         Analysis 4.3. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 6 Number of units transfused.       114         Analysis 4.4. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 6 Number of units transfused.       114         Analysis 4.5. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 7 Operating time.       114         Analysi	Analysis 3.4. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 4 Number needing transfusion	95
Analysis 3.6. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 7 Operating time (min).       96         Analysis 3.8. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 7 Operating time (min).       97         Analysis 3.9. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 8 Hemodynamics change (10 min after release of clamping).       97         Analysis 3.10. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 19 Bilood loss (ml).       98         Analysis 3.10. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 10 Bilinubin (micromole/litre).       99         Analysis 3.11. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 11 AST (aspartate transaminase) (IU/litre).       102         Analysis 4.1. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 12 ALT (alanine transminase) (IU/litre).       103         Analysis 4.3. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 2 Number of units transfused.       113         Analysis 4.3. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 5 Number of units transfused.       114         Analysis 4.5. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 7 Number of units transfused.       114         Analysis 4.5. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 7 Number of units transfused.       114         Analysis 4.6. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 6 Hospit	Analysis 3.5. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 5 Number of units transfused	95
Analysis 3.7. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 7 Operating time (min).       96         Analysis 3.8. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 8 Hemodynamics change (10 min after release of clamping).       97         Analysis 3.9. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 10 Bilirubin (micromole/litre).       98         Analysis 3.10. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 11 AST (aspartate transminase) (UUlitre).       102         Analysis 3.11. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 12 ALT (alanine transminase) (UUlitre).       102         Analysis 4.1. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 2 Peri-operative morbidity.       109         Analysis 4.3. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 4 Number needing transfusion.       113         Analysis 4.3. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 4 Number of units transfused.       114         Analysis 4.5. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 7 Operating time.       114         Analysis 4.6. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 7 Operating time.       114         Analysis 4.7. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 7 Operating time.       115         Analysis 4.6. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outco	Analysis 3.6. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 6 Hospital stay (in days).	96
Analysis 3.8. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 8 Hemodynamics change (10 min after release of clamping).       97         Analysis 3.9. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 10 Bilirubin (micromole/litre).       98         Analysis 3.10. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 10 Bilirubin (micromole/litre).       99         Analysis 3.11. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 11 AST (spartate transaminase) (IU/litre).       102         Analysis 3.12. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 12 ALT (alanine transaminase) (IU/litre).       105         Analysis 4.1. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 1 Mortality.       108         Analysis 4.3. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 4 Number needing transfusion.       113         Analysis 4.4. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 6 Number of units transfused.       114         Analysis 4.5. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 6 Hospital stay.       115         Analysis 4.6. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 7 Operating trime.       115         Analysis 4.7. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 7 Operating trime.       116         Analysis 4.8. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome	Analysis 3.7. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 7 Operating time (min).	96
release of clamping).       97         Analysis 3.9. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 10 Bilirubin (micromole/litre).       98         Analysis 3.10. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 11 AST (aspartate transaminase) (IU/litre).       102         Analysis 3.11. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 11 AST (aspartate transaminase) (IU/litre).       102         Analysis 4.1. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 1 Mortality.       108         Analysis 4.3. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 2 Peri-operative morbidity.       109         Analysis 4.3. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 3 Number needing transfusion.       113         Analysis 4.3. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 5 Number of units of FPP transfused.       114         Analysis 4.6. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 6 Hospital stay.       115         Analysis 4.7. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 7 Operating time.       115         Analysis 4.8. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 8 Blood loss (ml).       114         Analysis 4.9. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 8 Blood loss (ml).       116         Analysis 4.10. Compar	Analysis 3.8. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 8 Hemodynamics change (10 min after	
Analysis 3.9. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 9 Blood loss (ml)	release of clamping)	97
Analysis 3.10. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 10 Bilirubin (micromole/litre).       99         Analysis 3.11. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 11 AST (agartate transaminase) (IU/litre).       102         Analysis 3.12. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 12 ALT (alanine transaminase) (IU/litre).       105         Analysis 4.1. Comparison 4 00 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 2 Peri-operative morbidity.       108         Analysis 4.2. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 3 Number needing transfusion.       113         Analysis 4.4. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 6 Number of units transfused.       114         Analysis 4.5. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 6 Hospital stay.       115         Analysis 4.6. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 6 Hospital stay.       115         Analysis 4.7. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 7 Operating time.       115         Analysis 4.9. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 8 Blood loss (ml).       116         Analysis 4.9. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 10 Prothrombin activity (percentage of normal).       117         Analysis 4.10. Comparison 4 30 minutes intermittent PTC versus 15 minut	Analysis 3.9. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 9 Blood loss (ml).	98
Analysis 3.11. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 11 AST (aspartate transaminase)       (IU/litre).         (IU/litre).       102         Analysis 3.12. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 12 ALT (alanine transaminase)       102         (IU/litre).       103         Analysis 4.1. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 2 Peri-operative morbidity.       108         Analysis 4.3. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 3 Number needing transfusion.       109         Analysis 4.3. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 4 Number of units transfused.       113         Analysis 4.4. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 6 Hospital stay.       114         Analysis 4.6. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 6 Hospital stay.       115         Analysis 4.7. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 7 Operating time.       115         Analysis 4.8. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 8 Blood loss (ml).       116         Analysis 4.9. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 9 Bilirubin (micromole/litre).       117         Analysis 4.10. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 1 Prothrombin activity (percentage of n	Analysis 3.10. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 10 Bilirubin (micromole/litre).	99
(IU/litre).       102         Analysis 3.12. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 12 ALT (alanine transaminase)       105         Analysis 4.1. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 2 Peri-operative morbidity.       108         Analysis 4.2. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 2 Number needing transfusion.       109         Analysis 4.3. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 3 Number needing transfused.       113         Analysis 4.4. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 4 Number of units transfused.       114         Analysis 4.5. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 6 Hospital stay.       114         Analysis 4.6. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 6 Hospital stay.       115         Analysis 4.7. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 7 Operating time.       115         Analysis 4.8. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 7 Deperating time.       116         Analysis 4.9. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 9 Bilirubin (micromole/litre).       117         Analysis 4.9. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 9 Bilirubin (micromole/litre).       118         Analysis 4.10.	Analysis 3.11. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 11 AST (aspartate transaminase)	
Analysis 3.12. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 12 ALT (alanine transaminase)       105         (IU/litre).       105         Analysis 4.1. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 2 Peri-operative       109         Analysis 4.2. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 3 Number       113         Analysis 4.3. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 4 Number of       113         Analysis 4.4. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 5 Number of       114         Analysis 4.5. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 6 Hospital       114         Analysis 4.6. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 6 Hospital       115         Analysis 4.7. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 7 Operating       115         malysis 4.8. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 8 Blood loss       116         (ml).       114       115         Analysis 4.10. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 9 Bilirubin       117         Analysis 4.11. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 1 AST       123         Analysis 4.11. Comparison 4 30 minutes intermittent PTC versus 15 minut	(IU/litre)	102
(IU/litre).       105         Analysis 4.1. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 2 Peri-operative morbidity.       108         Analysis 4.2. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 2 Peri-operative morbidity.       109         Analysis 4.3. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 3 Number needing transfusion.       113         Analysis 4.3. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 4 Number of units transfused.       114         Analysis 4.5. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 5 Number of units of FFP transfused.       114         Analysis 4.5. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 6 Hospital stay.       115         Analysis 4.7. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 7 Operating time.       115         Analysis 4.8. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 8 Blood loss (ml).       116         Analysis 4.10. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 9 Bilirubin (micromole/litre).       117         Analysis 4.10. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 11 AST (asparta transaminase) (IU/litre).       123         Analysis 5.1. Comparison 5 20 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 12 ALT (alanine transaminase) (IU/litre).	Analysis 3.12. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 12 ALT (alanine transaminase)	
Analysis 4.1. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 1 Mortality.       108         Analysis 4.2. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 3 Number       109         Analysis 4.3. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 3 Number       113         Analysis 4.4. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 4 Number of       114         Analysis 4.4. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 5 Number of       114         Analysis 4.5. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 6 Hospital       114         Analysis 4.6. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 6 Hospital       115         stay.       114       114         Analysis 4.7. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 6 Hospital       115         stay.       115       115         Analysis 4.8. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 8 Blood loss       115         Minutes 4.8. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 9 Bilirubin       116         Analysis 4.9. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 10 Prothrombin       117         Analysis 4.10. Comparison 4 30 minutes intermittent PTC vers	(IU/litre)	105
Analysis 4.2. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 2 Peri-operative       109         Analysis 4.3. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 3 Number       113         Analysis 4.4. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 4 Number of       114         Analysis 4.5. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 5 Number of       114         Analysis 4.6. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 6 Hospital       114         Analysis 4.6. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 6 Hospital       115         Analysis 4.7. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 7 Operating       115         Analysis 4.8. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 7 Operating       115         Analysis 4.8. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 8 Blood loss       116         Mil.       117       118         Analysis 4.9. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 10 Prothrombin       117         Analysis 4.10. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 10 Prothrombin       118         Analysis 4.11. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 12 ALT (alanine	Analysis 4.1. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 1 Mortality.	108
Analysis 4.3. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 3 Number       113         Analysis 4.4. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 4 Number of       114         Analysis 4.5. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 5 Number of       114         Analysis 4.5. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 5 Number of       114         Analysis 4.6. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 6 Hospital       115         stay.        115         Analysis 4.8. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 7 Operating       115         Analysis 4.8. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 8 Blood loss       116         (ml).            (micromole/litre).            Analysis 4.11. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 9 Bilirubin       117         Analysis 4.11. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 10 Prothrombin       121         Analysis 4.12. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 11 AST       123         Analysis 5.1. Comparison 5 20 minutes intermittent PTC versus 15 minutes intermittent PTC, O	Analysis 4.2. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 2 Peri-operative morbidity.	109
needing transfusion.       113         Analysis 4.4. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 4 Number of units transfused.       114         Analysis 4.5. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 5 Number of units of FFP transfused.       114         Analysis 4.6. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 6 Hospital stay.       114         Analysis 4.7. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 7 Operating time.       115         Analysis 4.8. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 7 Operating time.       115         Analysis 4.9. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 8 Blood loss (ml).       116         Analysis 4.9. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 9 Bilirubin (micromole/litre).       117         Analysis 4.10. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 10 Prothrombin activity (percentage of normal).       121         Analysis 4.11. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 11 AST (aspartate transaminase) (IU/litre).       123         Analysis 5.1. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 1 Bilirubin (micromole/litre).       130         Analysis 5.2. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, outcome 2 ALT (alanine transaminase	Analysis 4.3. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 3 Number	
Analysis 4.4. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 4 Number of units transfused.       114         Analysis 4.5. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 5 Number of units of FFP transfused.       114         Analysis 4.6. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 6 Hospital stay.       114         Analysis 4.7. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 7 Operating time.       115         Analysis 4.8. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 7 Operating time.       115         Analysis 4.8. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 8 Blood loss (ml).       115         Analysis 4.9. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 9 Bilirubin (micromole/litre).       117         Analysis 4.10. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 10 Prothrombin activity (percentage of normal).       121         Analysis 4.11. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 11 AST (aspartate transaminase) (IU/litre).       123         Analysis 5.1. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 1 Bilirubin (micromole/litre).       130         Analysis 5.2. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 2 ALT (alanine transaminase) (IU/litre).       130         Analysi	needing transfusion.	113
units transfused.       114         Analysis 4.5. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 5 Number of units of FFP transfused.       114         Analysis 4.6. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 6 Hospital stay.       114         Analysis 4.7. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 7 Operating time.       115         Analysis 4.8. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 7 Operating time.       115         Analysis 4.8. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 8 Blood loss (ml).       116         Analysis 4.9. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 9 Bilirubin (micromole/litre).       117         Analysis 4.10. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 10 Prothrombin activity (percentage of normal).       121         Analysis 4.11. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 11 AST (aspartate transaminase) (IU/litre).       123         Analysis 5.1. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 2 ALT (alanine transaminase) (IU/litre).       130         Analysis 6.1. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 2 ALT (alanine transaminase) (IU/litre).       131         Analysis 6.1. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermitt	Analysis 4.4. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 4 Number of	
Analysis 4.5. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 5 Number of units of FFP transfused.       114         Analysis 4.6. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 6 Hospital stay.       115         Analysis 4.7. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 7 Operating time.       115         Analysis 4.8. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 7 Operating time.       115         Analysis 4.8. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 8 Blood loss (ml).       116         Analysis 4.9. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 9 Bilirubin (micromole/litre).       117         Analysis 4.10. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 10 Prothrombin activity (percentage of normal).       121         Analysis 4.11. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 11 AST (aspartate transaminase) (IU/litre).       123         Analysis 5.1. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 1 Bilirubin (micromole/litre).       130         Analysis 5.1. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 2 ALT (alanine transaminase) (IU/litre).       131         Analysis 5.1. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, outcome 2 ALT (alanine transaminase) (IU/litre).       131	units transfused	114
units of FFP transfused.       114         Analysis 4.6. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 6 Hospital       115         Analysis 4.7. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 7 Operating       115         Analysis 4.7. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 7 Operating       115         Analysis 4.8. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 8 Blood loss       116         Analysis 4.9. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 9 Bilirubin       117         Analysis 4.10. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 10 Prothrombin       117         Analysis 4.11. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 11 AST       123         Analysis 4.12. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 1 AST       124         Analysis 5.1. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 2 ALT (alanine       130         Analysis 5.2. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, outcome 2 ALT (alanine       131         Analysis 6.1. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent       131         Analysis 6.1. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent       132<	Analysis 4.5. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 5 Number of	
Analysis 4.6. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 6 Hospital stay.       115         Analysis 4.7. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 7 Operating time.       115         Analysis 4.7. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 7 Operating time.       115         Analysis 4.8. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 8 Blood loss (ml).       116         Analysis 4.9. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 9 Bilirubin (micromole/litre).       117         Analysis 4.10. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 10 Prothrombin activity (percentage of normal).       117         Analysis 4.11. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 11 AST (aspartate transaminase) (IU/litre).       123         Analysis 5.1. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 1 Bilirubin (micromole/litre).       130         Analysis 5.2. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 2 ALT (alanine transaminase) (IU/litre).       131         Analysis 6.1. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion, Outcome 1 Mortality.       132	units of FFP transfused	114
stay.       115         Analysis 4.7. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 7 Operating time.       115         Analysis 4.8. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 8 Blood loss (ml).       116         Analysis 4.9. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 9 Bilirubin (micromole/litre).       116         Analysis 4.9. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 9 Bilirubin (micromole/litre).       117         Analysis 4.10. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 10 Prothrombin activity (percentage of normal).       121         Analysis 4.11. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 11 AST (aspartate transaminase) (IU/litre).       123         Analysis 5.1. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 1 Bilirubin (micromole/litre).       120         Analysis 5.2. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 2 ALT (alanine transaminase) (IU/litre).       131         Analysis 6.1. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, versus intermittent PTC, versus intermittent PTC, outcome 2 ALT (alanine transaminase) (IU/litre).       131         Analysis 6.1. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion, Outcome 1 Mortality.       132	Analysis 4.6. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 6 Hospital	
Analysis 4.7. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 7 Operating time.       115         Analysis 4.8. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 8 Blood loss (ml).       116         Analysis 4.9. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 9 Bilirubin (micromole/litre).       116         Analysis 4.9. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 9 Bilirubin (micromole/litre).       117         Analysis 4.10. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 10 Prothrombin activity (percentage of normal).       121         Analysis 4.11. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 11 AST (aspartate transaminase) (IU/litre).       123         Analysis 4.12. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 12 ALT (alanine transaminase) (IU/litre).       127         Analysis 5.1. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 2 ALT (alanine (micromole/litre).       130         Analysis 5.2. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 2 ALT (alanine transaminase) (IU/litre).       131         Analysis 6.1. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion, Outcome 1 Mortality.       132	stay	115
time.       115         Analysis 4.8. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 8 Blood loss       116         Analysis 4.9. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 9 Bilirubin       116         Analysis 4.9. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 9 Bilirubin       117         Analysis 4.10. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 10 Prothrombin       121         Analysis 4.11. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 11 AST       123         Analysis 4.12. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 12 ALT (alanine transaminase) (IU/litre).       127         Analysis 5.1. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 1 Bilirubin (micromole/litre).       130         Analysis 5.2. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 2 ALT (alanine transaminase) (IU/litre).       131         Analysis 6.1. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion, Outcome 1 Mortality.       132	Analysis 4.7. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 7 Operating	
Analysis 4.8. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 8 Blood loss       116         Analysis 4.9. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 9 Bilirubin       117         Analysis 4.10. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 10 Prothrombin       117         Analysis 4.10. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 10 Prothrombin       117         Analysis 4.11. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 11 AST       123         Analysis 4.12. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 12 ALT (alanine transaminase) (IU/litre).       127         Analysis 5.1. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 2 ALT (alanine (micromole/litre).       130         Analysis 5.2. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 2 ALT (alanine transaminase) (IU/litre).       131         Analysis 6.1. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion, Outcome 1 Mortality.       132	time	115
(ml).       116         Analysis 4.9. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 9 Bilirubin       117         Analysis 4.10. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 10 Prothrombin       117         Analysis 4.10. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 10 Prothrombin       121         Analysis 4.11. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 11 AST       123         Analysis 4.12. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 12 ALT (alanine transaminase) (IU/litre).       127         Analysis 5.1. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 1 Bilirubin (micromole/litre).       130         Analysis 5.2. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 2 ALT (alanine transaminase) (IU/litre).       131         Analysis 6.1. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion, Outcome 1 Mortality.       132	Analysis 4.8. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 8 Blood loss	
Analysis 4.9. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 9 Bilirubin (micromole/litre).       117         Analysis 4.10. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 10 Prothrombin activity (percentage of normal).       121         Analysis 4.11. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 11 AST (aspartate transaminase) (IU/litre).       123         Analysis 4.12. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 12 ALT (alanine transaminase) (IU/litre).       127         Analysis 5.1. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 1 Bilirubin (micromole/litre).       130         Analysis 5.2. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 2 ALT (alanine transaminase) (IU/litre).       131         Analysis 6.1. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion, Outcome 1 Mortality.       132	(ml)	116
(micromole/litre).       117         Analysis 4.10. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 10 Prothrombin activity (percentage of normal).       121         Analysis 4.11. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 11 AST (aspartate transaminase) (IU/litre).       123         Analysis 4.12. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 12 ALT (alanine transaminase) (IU/litre).       127         Analysis 5.1. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 1 Bilirubin (micromole/litre).       130         Analysis 5.2. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 2 ALT (alanine transaminase) (IU/litre).       131         Analysis 6.1. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion, Outcome 1 Mortality.       132	Analysis 4.9. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 9 Bilirubin	
Analysis 4.10. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 10 Prothrombin activity (percentage of normal).       121         Analysis 4.11. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 11 AST (aspartate transaminase) (IU/litre).       123         Analysis 4.12. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 12 ALT (alanine transaminase) (IU/litre).       123         Analysis 5.1. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 1 Bilirubin (micromole/litre).       130         Analysis 5.2. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 2 ALT (alanine transaminase) (IU/litre).       131         Analysis 6.1. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent       132	(micromole/litre)	117
activity (percentage of normal).       121         Analysis 4.11. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 11 AST       123         Analysis 4.12. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 12 ALT (alanine transaminase) (IU/litre).       123         Analysis 5.1. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 1 Bilirubin (micromole/litre).       120         Analysis 5.2. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 2 ALT (alanine transaminase) (IU/litre).       130         Analysis 6.1. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion, Outcome 1 Mortality.       131	Analysis 4.10. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 10 Prothrombin	
Analysis 4.11. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 11 AST       123         (aspartate transaminase) (IU/litre).       123         Analysis 4.12. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 12 ALT (alanine transaminase) (IU/litre).       127         Analysis 5.1. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 1 Bilirubin (micromole/litre).       130         Analysis 5.2. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 2 ALT (alanine transaminase) (IU/litre).       131         Analysis 6.1. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion, Outcome 1 Mortality.       132	activity (percentage of normal).	121
(aspartate transaminase) (IU/litre).       123         Analysis 4.12. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 12 ALT (alanine transaminase) (IU/litre).       127         Analysis 5.1. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 1 Bilirubin (micromole/litre).       130         Analysis 5.2. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 2 ALT (alanine transaminase) (IU/litre).       130         Analysis 5.1. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 2 ALT (alanine transaminase) (IU/litre).       130         Analysis 6.1. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion, Outcome 1 Mortality.       132	Analysis 4.11. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 11 AST	
Analysis 4.12. Comparison 4.30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 12 AL1 (alanine transaminase) (IU/litre).       127         Analysis 5.1. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 1 Bilirubin (micromole/litre).       130         Analysis 5.2. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 2 ALT (alanine transaminase) (IU/litre).       131         Analysis 6.1. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion, Outcome 1 Mortality.       132	(aspartate transaminase) (IU/litre).	123
transaminase) (IU/litre).       12/         Analysis 5.1. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 1 Bilirubin (micromole/litre).       130         Analysis 5.2. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 2 ALT (alanine transaminase) (IU/litre).       131         Analysis 6.1. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion, Outcome 1 Mortality.       132	Analysis 4.12. Comparison 4.30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 12 ALI (alanine	107
Analysis 5.1. Comparison 5.20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 1 Bilirubin         (micromole/litre).       130         Analysis 5.2. Comparison 5.20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 2 ALT (alanine transaminase) (IU/litre).       131         Analysis 6.1. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion, Outcome 1 Mortality.       132	transaminase) (IU/litre).	12/
(micromole/life).       150         Analysis 5.2. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 2 ALT (alanine transaminase) (IU/litre).       131         Analysis 6.1. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion, Outcome 1 Mortality.       132	Analysis 5.1. Comparison 5.20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 1 Bilirubin	120
Analysis 5.2. Comparison 5.20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 2 ALT (alamine transaminase) (IU/litre).       131         Analysis 6.1. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion, Outcome 1 Mortality.       132	(micromole/litre).	130
Analysis 6.1. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent       131         Occlusion, Outcome 1 Mortality.       132	transaminese) (IU/litre)	121
occlusion, Outcome 1 Mortality.       132	Analysis 6.1 Comparison 6 Ischaemic preconditioning followed by continuous acclusion (IPC) versus intermittent	1.71
	occlusion. Outcome 1 Mortality	132
· · · · · · · · · · · · · · · · · · ·		

Analysis 6.2. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent	100
occlusion, Outcome 2 Liver failure.	133
Analysis 6.3. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent	
occlusion, Outcome 3 Peri-operative morbidity.	133
Analysis 6.4. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent	
occlusion, Outcome 4 Number needing transfusion	136
Analysis 6.5. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent	
occlusion, Outcome 5 Number of units transfused	137
Analysis 6.6. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent	
occlusion, Outcome 6 Hospital stay (in days)	137
Analysis 6.7. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent	
occlusion, Outcome 7 ITU stay (in days)	138
Analysis 6.8. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent	
occlusion, Outcome 8 Operating time	138
Analysis 6.9. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent	
occlusion, Outcome 9 Blood loss (ml).	139
Analysis 6.10. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent	
occlusion, Outcome 10 Bilirubin (micromole/litre)	140
Analysis 6.11. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent	
occlusion, Outcome 11 Prothrombin activity (percentage of normal).	143
Analysis 6.12. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent	
occlusion, Outcome 12 AST (IU/L).	145
Analysis 6.13. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent	
occlusion, Outcome 13 ALT (IU/L).	148
APPENDICES	148
HISTORY	151
CONTRIBUTIONS OF AUTHORS	151
DECLARATIONS OF INTEREST	151
SOURCES OF SUPPORT	151
DIFFERENCES BETWEEN PROTOCOL AND REVIEW	152
NOTES	152

#### [Intervention Review]

# Methods of vascular occlusion for elective liver resections

Kurinchi Selvan Gurusamy<sup>1</sup>, Hemant Sheth<sup>1</sup>, Yogesh Kumar<sup>2</sup>, Dinesh Sharma<sup>1</sup>, Brian R Davidson<sup>1</sup>

<sup>1</sup>University Department of Surgery, Royal Free Hospital and University College School of Medicine, London, UK. <sup>2</sup>General Surgery, Leeds Teaching hospital, Leeds, UK

Contact address: Kurinchi Selvan Gurusamy, University Department of Surgery, Royal Free Hospital and University College School of Medicine, 9th Floor, Royal Free Hospital, Pond Street, London, NW3 2QG, UK. kurinchi2k@hotmail.com. (Editorial group: Cochrane Hepato-Biliary Group.)

Cochrane Database of Systematic Reviews, Issue 1, 2009 (Status in this issue: New) Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. DOI: 10.1002/14651858.CD007632 This version first published online: 21 January 2009 in Issue 1, 2009. Last assessed as up-to-date: 16 August 2007. (Help document - Dates and Statuses explained)

This record should be cited as: Gurusamy KS, Sheth H, Kumar Y, Sharma D, Davidson BR. Methods of vascular occlusion for elective liver resections. *Cochrane Database of Systematic Reviews* 2009, Issue 1. Art. No.: CD007632. DOI: 10.1002/14651858.CD007632.

# ABSTRACT

#### Background

Vascular occlusion is used to reduce blood loss during liver resection surgery. Various methods of vascular occlusion have been suggested.

#### Objectives

To compare the benefits and harms of different methods of vascular occlusion during elective liver resection.

#### Search strategy

We searched *The Cochrane Hepato-Biliary Group Controlled Trials Register*, the *Cochrane Central Register of Controlled Trials (CENTRAL)* in *The Cochrane Library, MEDLINE, EMBASE*, and *Science Citation Index Expanded* until August 2008.

#### Selection criteria

We included randomised clinical trials comparing different methods of vascular occlusion during elective liver resections (irrespective of language or publication status).

#### Data collection and analysis

Two authors independently assessed trials for inclusion and independently extracted the data. We calculated the risk ratio or mean difference with 95% confidence intervals using fixed-effect and random-effects models based on intention-to-treat or available data analysis.

#### Main results

Ten trials including 657 patients compared different methods of vascular occlusion. All trials were of high risk of bias. Only one or two trials were included under each comparison. There was no statistically significant differences in mortality, liver failure, or other morbidity between any of the comparisons.

Hepatic vascular occlusion does not decrease the blood transfusion requirements. It decreases the cardiac output and increases the systemic vascular resistance. In the comparison between continuous portal triad clamping and intermittent portal triad clamping, four of the five liver failures occurred in patients with chronic liver diseases undergoing the liver resections using continuous portal triad

clamping. In the comparison between selective inflow occlusion and portal triad clamping, all four patients with liver failure occurred in the selective inflow occlusion group. There was no difference in any of the other important outcomes in any of the comparisons.

#### Authors' conclusions

In elective liver resection, hepatic vascular occlusion cannot be recommended over portal triad clamping. Intermittent portal triad clamping seems to be better than continuous portal triad clamping at least in patients with chronic liver disease. There is no evidence to support selective inflow occlusion over portal triad clamping. The optimal method of intermittent portal triad clamping is not clear. There is no evidence for any difference between the ischaemic preconditioning followed by vascular occlusion and intermittent vascular occlusion for liver resection in patients with non-cirrhotic livers. Further randomised trials of low risk of bias are needed to determine the optimal technique of vascular occlusion.

# PLAIN LANGUAGE SUMMARY

#### Further trials are necessary to find the optimal method of vascular occlusion in liver resection

More than 1000 elective liver resections (planned operation) are performed annually in the United Kingdom alone. When liver resection is performed, the inflow of blood to the liver can be blocked (vascular occlusion), thereby potentially reducing the blood loss. When employed during liver resection, the vascular occlusion is generally achieved by occluding the hepatic artery and portal vein (blood vessels which supply the blood to the liver) either continuously or intermittently (when varying periods of occlusion and no occlusion are carried out in cycles till liver resection is complete). This is called portal triad clamping. However, there are many variations to this technique. These include hepatic vascular exclusion, where in addition to the occlusion of hepatic artery and portal vein, the veins draining blood from the liver are occluded with an intention of further decreasing the blood loss; selective inflow occlusion when only the vessels supplying the portion of the liver to be resected is occluded; and ischaemic preconditioning, where in order to prepare the liver for lack of blood flow, a vascular occlusion is performed briefly, after which the blood flow is re-established (reperfusion). This review is aimed at evaluating the different methods of vascular occlusion in liver resection.

Ten trials including 657 patients were included in this review. All were of high risk of bias (systematic error) and play of chance (random error). Only one or two trials were included under each comparison. There was no difference in mortality, liver failure, or post-operative complications between any of the comparisons. Hepatic vascular occlusion does not decrease the blood transfusion requirements. It decreases the cardiac output (amount of blood pumped by the heart in one second) and increases the systemic vascular resistance (resistance to the flow of blood in the vessels), which may have potential problems in patients with heart disorders.

Although there was no statistically significant difference in the incidence of liver failure between continuous portal triad clamping and intermittent portal triad clamping (5/60; 8.5% versus 0/61), most of them occurred in patients with chronic liver diseases undergoing the liver resections using continuous portal triad clamping.

There was no benefit in selective inflow occlusion compared to portal triad clamping. There was no statistically significant difference in the incidence of liver failure between the two groups (4/41; 9.8% versus 0/39), but all patients with liver failure occurred in the selective inflow occlusion group.

There were no significant differences in any of the important outcomes between the different methods of intermittent portal triad clamping or between ischaemic preconditioning followed by continuous vascular occlusion and intermittent vascular occlusion in noncirrhotic patients undergoing liver resections.

Further randomised trials of low risk of bias are needed to determine the optimal technique of vascular occlusion.

# BACKGROUND

#### **Description of the condition**

Elective liver resection is performed mainly for benign and malignant liver tumours (Belghiti 1993). The malignant tumours may arise primarily within the liver (hepatocellular carcinoma and cholangiocarcinoma) or be metastases from malignancies of other organs (Belghiti 1993). More than 1000 elective liver resections are performed annually in the United Kingdom alone (HES 2005). The liver is subdivided into eight Couinaud segments (Couinaud 1999), which can be removed either individually or by right hemihepatectomy (Couinaud segments 5 to 8), left hemi-hepatectomy (segments 2 to 4), right trisectionectomy (segments 4 to 8), or left trisectionectomy (segments 2 to 5 and 8 1) (Strasberg 2000). Although every liver resection is considered major surgery, only resection of three or more segments is considered a major liver resection (Belghiti 1993).

Blood loss during liver resection is one of the important factors affecting the peri-operative outcomes of patients (Shimada 1998; Yoshimura 2004; Ibrahim 2006). Various methods have been attempted to reduce the blood loss during liver resection. These include lowering the central venous pressure (Wang 2006), hypoventilation (Hasegawa 2002), and occluding the blood flow to the liver using a finger or an atraumatic clamp (Pringle manoeuvre) (Pringle 1908; Belghiti 1996).

#### **Description of the intervention**

Vascular occlusion can be total vascular exclusion (clamping of both inflow and outflow vessels) (Belghiti 1996) or portal triad clamping (clamping only the inflow tract) (Belghiti 1996; Belghiti 1999; Capussotti 2006). Outflow obstruction could be by occlusion of inferior vena cava (Belghiti 1996) or by occlusion of major hepatic veins (Azoulay 2006). The vascular occlusion could be complete (hepatic pedicle clamping) (Figueras 2005) or selective (only the vessels to the resected side are clamped) (Figueras 2005). The clamping could be continuous (Belghiti 1999; Capussotti 2006) or intermittent (Franco 1989; Elias 1991; Belghiti 1999; Capussotti 2006).

#### How the intervention might work

Outflow obstruction by occlusion of inferior vena cava or major hepatic veins can potentially result in a greater decrease in blood loss by decreasing the bleeding from the veins. For this, both the infrahepatic inferior vena cava and suprahepatic inferior vena cava or major hepatic veins have to be occluded. The selective vascular occlusion has been proposed so that only the blood supply to the hemi-liver that is to be resected can be cut-off without occlusion of the blood supply to the hemi-liver that is to be retained. The purpose is to reap the benefits of vascular occlusion (ie, decreasing the blood loss) without suffering the potential harms of vascular occlusion (ie, liver damage). Intermittent clamping has been proposed to increase the resection time under vascular occlusion without increasing the liver damage by briefly restoring blood supply to the liver before the next cycle of vascular occlusion.

#### Why it is important to do this review

The optimal method of vascular occlusion is not clear. This is an update of a part of a split Cochrane review (Gurusamy 2007).

### OBJECTIVES

To compare the benefits and harms of different methods of vascular occlusion during elective liver resections.

#### METHODS

#### Criteria for considering studies for this review

#### Types of studies

Only randomised clinical trials (irrespective of language, blinding, or publication status) were considered for this review. Quasirandomised studies (where the method of allocating participants to a treatment are not strictly random (eg, date of birth, hospital record number, alternation), cohort studies, and case-control studies were excluded.

#### **Types of participants**

Patients who were about to undergo elective liver resection surgery for benign or malignant liver tumour irrespective of whether the tumour was on a background of cirrhotic, steatotic, or normal liver.

#### **Types of interventions**

We included trials comparing one method of vascular occlusion versus another method of vascular occlusion.

Trials comparing vascular occlusion versus no vascular occlusion and those assessing a period of ischaemic pre-conditioning before vascular occlusion were excluded from this review and were considered in two other separate reviews (Gurusamy 2009a; Gurusamy 2009b).

Co-interventions were allowed provided that they are used equally in the intervention arms.

#### Types of outcome measures

#### **Primary outcomes**

- 1. Mortality.
  - i) Peri-operative.
  - ii) At maximal follow-up.
- 2. Liver failure.
- 3. Peri-operative morbidity.

Copyright  $\ensuremath{\textcircled{\text{\scriptsize C}}}$  2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Methods of vascular occlusion for elective liver resections (Review)

- 4. Transfusion requirements (whole blood or red cells).
- Secondary outcomes
  - 1. Hospital stay.
  - 2. Intensive therapy unit stay.
  - 3. Operating time.
  - Peri-operative haemodynamic variables (blood pressure, cardiac output, stroke volume, systemic vascular resistance).
  - 5. Operative blood loss.
    - i) Transection.
    - ii) Total operative blood loss.
  - 6. Markers of liver function (bilirubin, prothrombin time).
  - 7. Biochemical markers of liver injury (aspartate aminotransferase (AST), alanine aminotransferase (ALT)).

#### Search methods for identification of studies

We searched *The Cochrane Hepato-Biliary Group Controlled Trials Register*, the *Cochrane Central Register of Controlled Trials* (*CEN-TRAL*) in *The Cochrane Library, MEDLINE, EMBASE*, and *Science Citation Index Expanded* (Royle 2003) until August 2008. We have given the search strategies in Appendix 1 with the time span for the searches.

We also searched the references of the identified trials to identify further relevant trials.

### **Electronic searches**

We searched *The Cochrane Hepato-Biliary Group Controlled Tri*als Register (Gluud 2008), the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE, EMBASE, and Science Citation Index Expanded (Royle 2003) until August 2008. We have given the search strategies in Appendix 1 with the time span for the searches.

#### Searching other resources

We also searched the references of the identified trials to identify further relevant trials.

#### Data collection and analysis

We followed the instructions given in the *Cochrane Handbook for Systematic Reviews of Intervention* (Higgins 2008) and the *Cochrane Hepato-Biliary Group Module* (Gluud 2008). We imputed the standard deviation from P-values according to the instructions given in the *Cochrane Handbook for Systematic Reviews of Intervention* ( Higgins 2008) and used the median for the meta-analysis when mean was not available. If it was not possible to calculate the standard deviation from P-value or confidence intervals, we imputed the standard deviation as the highest standard deviation noted for that group under that outcome.

#### Selection of studies

KG and HS or YK identified the trials for inclusion, independent of each other. We have also listed the excluded trials with the reasons for the exclusion.

#### Data extraction and management

KG and HS or YK extracted the data for the review independently. In addition, the authors extracted the population characteristics (sex, age, percentage of major liver resections, and the presence of chronic liver disease) and the co-interventions used in each trial. We assessed the methodological quality of the trials independently, without masking of the trial names. We sought any unclear or missing information by contacting the authors of the individual trials. If there was any doubt whether the trials share the same patients - completely or partially (by identifying common authors and centres) - we contacted the authors of the trials whether the trial report had been duplicated.

We resolved any differences in opinion through discussion.

#### Assessment of risk of bias in included studies

Methodological quality was defined as the confidence that the design and the report of the randomised clinical trial would restrict bias in the comparison of the intervention (Moher 1998). According to empirical evidence (Schulz 1995; Moher 1998; Kjaergard 2001; Wood 2008), the methodological quality of the trials was assessed based on sequence generation, allocation concealment, blinding of participants, personnel, and outcome assessors, incomplete outcome data, selective outcome reporting, and other sources of bias. Quality components were classified as follows:

#### Sequence generation

- Low risk of bias (the methods used is either adequate (eg, computer generated random numbers, table of random numbers) or unlikely to introduce confounding).
- Uncertain risk of bias ( there is insufficient information to assess whether the method used is likely to introduce confounding).
- High risk of bias (the method used (eg, quasi-randomised trials) is improper and likely to introduce confounding).

#### Allocation concealment

- Low risk of bias (the method used (eg, central allocation) is unlikely to induce bias on the final observed effect).
- Uncertain risk of bias (there is insufficient information to assess whether the method used is likely to induce bias on the estimate of effect).
- High risk of bias (the method used (eg, open random allocation schedule) is likely to induce bias on the final observed effect).

#### Blinding of participants, personnel, and outcome assessors

It is difficult to blind the surgeons to the groups. Thus only blinding of patients and outcomes assessors were considered for assessing the risk of bias.

- Low risk of bias (blinding was performed adequately, or the outcome measurement is not likely to be influenced by lack of blinding).
- Uncertain risk of bias (there is insufficient information to assess whether the type of blinding used is likely to induce bias on the estimate of effect).
- High risk of bias (no blinding or incomplete blinding, and the outcome or the outcome measurement is likely to be influenced by lack of blinding).

#### Incomplete outcome data

- Low risk of bias (the underlying reasons for missingness are unlikely to make treatment effects departure from plausible values, or proper methods have been employed to handle missing data).
- Uncertain risk of bias (there is insufficient information to assess whether the missing data mechanism in combination with the method used to handle missing data is likely to induce bias on the estimate of effect).
- High risk of bias (the crude estimate of effects (eg, complete case estimate) will clearly be biased due to the underlying reasons for missingness, and the methods used to handle missing data are unsatisfactory).

#### Selective outcome reporting

- Low risk of bias (the trial protocol is available and all of the trial's pre-specified outcomes that are of interest in the review have been reported or similar).
- Uncertain risk of bias (there is insufficient information to assess whether the magnitude and direction of the observed effect is related to selective outcome reporting).
- High risk of bias (not all of the trial's pre-specified primary outcomes have been reported or similar).

#### Other bias

# **Baseline imbalance**

- Low risk of bias (there was no baseline imbalance in important characteristics).
- Uncertain risk of bias (the baseline characteristics were not reported).
- High risk of bias (there was an baseline imbalance due to chance or due to imbalanced exclusion after randomisation).

## Early stopping

• Low risk of bias (sample size calculation was reported and the trial was not stopped or the trial was stopped early by a formal stopping rule at a point where the likelihood of observing an extreme intervention effect due to chance was low).

- Uncertain risk of bias (sample size calculations were not reported and it is not clear whether the trial was stopped early or not).
- High risk of bias (the trial was stopped early due to an informal stopping rule or the trial was stopped early by a formal stopping rule at a point where the likelihood of observing an extreme intervention effect due to chance was high).

#### Academic bias

- Low risk of bias (the author of the trial has not conducted previous trials addressing the same interventions).
- Uncertain risk of bias (It is not clear if the author has conducted previous trials addressing the same interventions).
- High risk of bias (the author of the trial has conducted previous trials addressing the same interventions).

We considered trials which were classified as low risk of bias in sequence generation, allocation concealment, blinding, incomplete data, and selective outcome reporting as low bias-risk trials.

#### Measures of treatment effect

For dichotomous outcomes, we calculated the risk ratio with 95% confidence interval (CI). For continuous outcomes, we calculated mean difference (MD) with 95% CI. We planned to calculate standardised mean difference (SMD) in case we found the same outcome reported in different ways (eg, units of blood or volume of blood in ml; prothrombin time or prothrombin activity). However, we found no such outcomes. We also calculated the risk difference with 95% CI and planned to report the results if they were different from risk ratio. We identified no such results.

#### Unit of analysis issues

All the trials included in this review were with simple, parallel group design and the unit of analysis was each patient recruited into the trial.

#### Dealing with missing data

We performed the analysis on an 'intention-to-treat' basis (Newell 1992) whenever possible. Otherwise, we adopted the 'available data analysis'.

# Assessment of heterogeneity

Heterogeneity was explored by chi-squared test with significance set at P value 0.10, and the quantity of heterogeneity was measured by  $I^2$  (Higgins 2002). An  $I^2$  of > 30% was considered statistically significant heterogeneity.

#### Assessment of reporting biases

We used a funnel plot to explore bias (Egger 1997; Macaskill 2001). Asymmetry in funnel plot of trial size against treatment effect was used to assess bias. We could not perform linear regression approach described by Egger et al to determine the funnel

plot asymmetry because of the small number of trials included in the review (Egger 1997).

#### Data synthesis

We performed the meta-analyses according to the recommendations of The Cochrane Collaboration (Higgins 2008). We used the software package RevMan 5 provided by the Cochrane Collaboration (RevMan 2008). We used a random-effects model ( DerSimonian 1986) and a fixed-effect model (DeMets 1987). In case of discrepancy between the two models, we reported both results; otherwise we have reported only the results from the fixedeffect model.

#### Subgroup analysis and investigation of heterogeneity

We planned the following sub-group analysis.

- Low bias-risk trials compared to high bias-risk trials.
- Major compared to minor resections (if the remnant liver is smaller, liver function may be poorer).
- Cirrhotics compared to non-cirrhotic livers (if the remnant liver is cirrhotic, liver function may be poorer).

However, we did not perform any subgroup analysis because of the few trials included in each comparison.

#### Sensitivity analysis

In case we found 'zero-event' trials for statistically significant outcomes, we intended to perform a sensitivity analysis with and without empirical continuity correction factors as suggested by Sweeting 2004 et al. However, we did not find any such outcomes.

# RESULTS

#### **Description of studies**

See: Characteristics of included studies; Characteristics of excluded studies.

#### **Results of the search**

We identified a total of 1121 references through the electronic searches of *The Cochrane Hepato-Biliary Group Controlled Trials Register* and the *Cochrane Central Register of Controlled Trials (CEN-TRAL)* in *The Cochrane Library* (n = 134), *MEDLINE* (n = 425), *EMBASE* (n = 367), *Science Citation Index Expanded* (n = 185), and LILACS (n = 10). We have shown the flow of references in Figure 1. We excluded 304 duplicates and 798 clearly irrelevant references through reading abstracts. Nineteen references were retrieved for further assessment. Two references were identified through scanning reference lists of the identified randomised trials. Both were conference abstracts of published trials (Figueras 2005; Brooks 2007). Of the 21 references, we excluded nine because of the reasons listed under the table 'Characteristics of excluded studies'. In total, 12 publications describing 10 randomised trials fulfilled the inclusion criteria.





RCT = Randomised clinical trial

#### **Included studies**

All the ten randomised trials were completed trials and could provide data for the analyses. Details of the trials and the outcomes reported in individual trials are shown in the table 'Characteristics of included studies'. All the trials assessed the different methods of vascular occlusion in open liver resections. There were a total of five comparisons.

#### Hepatic vascular exclusion versus portal triad clamping

Two trials randomised 170 patients to hepatic vascular exclusion (n = 88) versus portal triad clamping (n = 82) (Belghiti 1996 (52 patients); Chen 2006 (118 patients)). The mean age of participants was 42.3 years. The proportions of females, major liver resections, and cirrhotic livers were 26.5%, 90.6%, and 69.4%. In one trial, hepatic vascular exclusion was performed by occluding the infrahepatic and suprahepatic inferior vena cava (Belghiti 1996). In the other trial, hepatic vascular exclusion was performed by occluding the infrahepatic inferior vena cava and by occluding the middle hepatic veins draining the section of liver to be resected (Chen 2006).

# Intermittent portal triad clamping versus continuous portal triad clamping

Two trials randomised 121 patients to continuous portal triad clamping (n = 60) versus intermittent portal triad clamping (n = 61) (Belghiti 1999 (86 patients); Capussotti 2003 (35 patients)). The mean age of participants was 54.4 years. The proportions of females, major liver resections and cirrhotic livers were 40.5%, 38.8%, and 49.6%.

#### Selective vascular occlusion versus portal triad clamping

Two trials randomised 138 patients to selective vascular occlusion (n = 71) versus portal triad clamping (n = 67) (Wu 2002 (58 patients); Figueras 2005 (80 patients)). Both trials used intermittent vascular occlusion. The mean age of participants was 59.1 years. The proportions of females was 22.5%. One trial included only minor liver resections (Figueras 2005). The proportion of major liver resections in the other trial was 34.5% (Wu 2002). One trial included only cirrhotic patients (Wu 2002). The proportion of cirrhotic patients was 48.8% in the other trial (Figueras 2005).

#### Different methods of intermittent portal triad clamping

Two trials assessed intermittent portal triad clamping with different clamping and unclamping periods. One trial randomised 108 patients to intermittent portal triad clamping of 30/5 (ie, 30 minutes clamping and 5 minutes unclamping) cycles (n = 48), and intermittent portal triad clamping of 15/5 cycles (n = 44) ( Esaki 2006). There were 16 post-randomisation drop-outs as no hepatectomy was performed in 8 patients; and 8 patients did not meet the inclusion criteria. The mean age of the participants was 62 years. The proportions of females and major liver resections were 30.4% and 19.6%. This trial included only non-cirrhotic patients. Another trial randomised 13 patients to intermittent portal triad clamping of 20/10 cycles (n = 4) and intermittent portal triad clamping of 10/5 cycles (n = 5) (Brooks 2007). There were 4 postrandomisation drop-outs (reasons not stated). The proportions of females and major liver resections were 33.3% and 77.8%. This trial also included only non-cirrhotic patients.

# Ischaemic pre-conditioning followed by continuous vascular occlusion versus intermittent vascular occlusion

Two trials randomised 127 patients to ischaemic pre-conditioning followed by continuous vascular occlusion (n = 63) versus intermittent vascular occlusion (n = 64) (Petrowsky 2006 (73 patients); Smyrniotis 2006 (54 patients)). The mean age of participants was 59.7 years. The proportions of females was 40.2%. Both trials included patients with non-cirrhotic livers undergoing major liver resections only. In one trial, portal triad clamping was used in both groups (Petrowsky 2006). In the other trial hepatic vascular exclusion (major hepatic veins method) was used in both groups (Smyrniotis 2006).

# **Excluded studies**

Nine studies were excluded. Three were quasi-randomised studies (Smyrniotis 2002; Smyrniotis 2003a; Smyrniotis 2003b). Four were not randomised clinical trials (Cheung 1996; Konigsrainer 2006; Man 2002; Sugimoto 2003). Two trials were out of this review's scope because of the reasons mentioned in the table 'Characteristics of excluded studies'.

#### **Risk of bias in included studies**

The risk of bias in the included trials is summarised in Figure 2 and Figure 3. All trials had some kind of methodological inadequacy and following the methodological components, we classified them as trials with high risk of bias.







Figure 3. Methodological quality summary: review authors' judgements about each methodological quality item for each included study.

#### Allocation

Seven trials (70%) had adequate sequence generation (Belghiti 1996; Belghiti 1999; Wu 2002; Capussotti 2003; Figueras 2005; Esaki 2006; Smyrniotis 2006). Seven trials (70%) had adequate allocation concealment (Belghiti 1996; Belghiti 1999; Wu 2002; Figueras 2005; Esaki 2006; Petrowsky 2006; Smyrniotis 2006). Thus, six trials (60%) had low risk of bias due to allocation (Belghiti 1996; Belghiti 1999; Wu 2002; Figueras 2005; Esaki 2006; Smyrniotis 2006).

#### Blinding

None of the trials reported any blinding.

#### Follow up and exclusions

Seven trials (70%) were free from bias due to incomplete outcome data (Belghiti 1999; Wu 2002; Capussotti 2003; Figueras 2005; Chen 2006; Petrowsky 2006; Smyrniotis 2006).

#### Selective reporting

Six trials (60%) reported the primary outcomes and hence were considered to be free from bias (Belghiti 1996; Belghiti 1999; Figueras 2005; Chen 2006; Petrowsky 2006; Brooks 2007).

#### Other potential sources of bias

There was no baseline imbalance in any of the trials. Four trials (40%) reported sample size calculations and the trialists recruited the intended number of participants (Figueras 2005; Esaki 2006; Petrowsky 2006;

#### **Effects of interventions**

#### Secondary outcomes

#### Hospital stay and Intensive therapy unit stay

There was no difference in the hospital stay between the two groups (mean difference -0.34; 95% CI -2.92 to 2.24). Intensive therapy unit stay was not reported in any of the trials included under this category (Analysis 3.6).

#### Table 1. Mortality and causes

#### **Operating time**

There was no difference in the operating time between the two groups (mean difference 8.69; 95% CI -10.12 to 27.50) (Analysis 3.7).

#### Peri-operative haemodynamic variables

There was no difference in the mean arterial pressure between the two groups (mean difference -2.70; 95% CI -8.88 to 3.48) (Analysis 3.8).

#### **Blood loss**

There was no significant difference in the transection blood loss (mean difference -241.00 ml; 95% CI -539.63 to 57.63) or total operative blood loss (mean difference -174.56 ml; 95% CI -742.06 to 392.95) between the groups (Analysis 3.9).

#### Enzyme markers of liver function

There was no statistically significant difference in the bilirubin level at any time between the two groups. The prothrombin activity was not reported in either trial included under this outcome ( Wu 2002; Figueras 2005) (Analysis 3.10).

#### Enzyme markers of liver injury

There was no difference in the AST or ALT levels on the first, third, and fifth post-operative days. The levels of AST and ALT were slightly lower in the selective group than portal triad clamping group on the seventh post-operative day (AST: mean difference - 20.00 IU/litre; 95% CI -36.45 to -3.55 and ALT: mean difference -20.00 IU/litre; 95% CI -30.30 to -9.70) (Analysis 3.11; Analysis 3.12).

# Different methods of intermittent portal triad clamping: 30 minutes versus 15 minutes

#### Primary outcomes

#### Mortality and morbidity

There was no mortality in either group. Liver failure was not reported in the only trial included in this review (Esaki 2006). There was no difference in any other morbidity between the two groups (Analysis 4.1; Analysis 4.2) (Table 1).

Study	Intervention	Causes	Control	Causes
HVE versus PTC				
Belghiti 1996	0	-	1	Renal failure
Chen 2006	0	-	1	Hepatic failure

Methods of vascular occlusion for elective liver resections (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

CONTINUOUS versus INTERMITTENT PTC				
Belghiti 1999	2	Liver failure (cirrhotic livers)	0	-
Capussotti 2003	2	1 - case of portal vein throm- bosis 1 - Bleeding from cut surface. (No details of whether low CVP was used).	0	-
PTC - SELECTIVE ver- sus TOTAL				
Figueras 2005	1	Liver insufficiency (in cir- rhotic liver)	0	-
Wu 2002	0	-	0	-
INTERMITTENT PTC - 30 minutes vs 15 minutes				
Esaki 2006	0	-	0	-
IPC versus INTERMIT- TENT vascular occlu- sion				
Petrowsky 2006	1	Intestinal ischaemia	0	-
Smyrniotis 2006	0	-	0	-

#### Table 1. Mortality and causes (Continued)

HVE = hepatic vascular exclusion

PTC = portal triad clamping

IPC = ischaemic pre-conditioning

#### Transfusion requirements

There was no difference in the number of patients requiring blood transfusion (risk ratio 0.92; 95% CI 0.24 to 3.45) or the mean number of red cells units transfused (mean difference 0.00 units; 95% CI -3.27 to 3.27) or fresh frozen plasma (mean difference 1.00 units; 95% CI -2.48 to 4.48) (Analysis 4.3; Analysis 1.5).

Secondary outcomes

There was no difference in the hospital stay between the two groups (mean difference 0.00 days; 95% CI -2.45 to 2.45). Intensive therapy unit stay was not reported (Analysis 4.6).

#### **Operating time**

It was lower in the 30 minutes group than the 15 minutes group (mean difference -52.00 minutes; 95% CI -101.91 to -2.09) (Analysis 4.7).

# Peri-operative haemodynamic variables

This outcome was not reported.

Hospital stay and Intensive therapy unit stay

Blood loss

Methods of vascular occlusion for elective liver resections (Review)

Copyright  $\textcircled{\sc 0}$  2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

There was no significant difference in the transection blood loss (mean difference -1.30 ml/cm<sup>2</sup>; 95% CI -2.85 to 0.25) or total operative blood loss (mean difference 39.00 ml; 95% CI -1.50 to 79.50) between the groups (Analysis 4.8).

#### Enzyme markers of liver function

There was no statistically significant difference in the bilirubin level or prothrombin activity at any time between the two groups (Analysis 4.9; Analysis 4.10).

#### Enzyme markers of liver injury

There was no difference in the AST or ALT levels at any time between the two groups (Analysis 4.11; Analysis 4.12).

# Different methods of intermittent portal triad clamping: 20 minutes versus 10 minutes

The only outcomes of interest reported in the only trial included under this category was bilirubin (Analysis 5.1) and alanine transaminase (Analysis 5.2) on the second post operative day. There was no difference between the two groups in these enzyme levels.

# Ischaemic pre-conditioning followed by continuous vascular occlusion versus intermittent vascular occlusion

#### **Primary outcomes**

#### Mortality and morbidity

There was no statistically significant difference in mortality (risk ratio 3.08; 95% CI 0.13 to 73.24), liver failure (risk ratio 0.21; 95% CI 0.01 to 4.14), or any other morbidity between the two groups (Analysis 6.1; Analysis 6.3) (Table 1).

#### Transfusion requirements

There was no difference in the number of patients requiring blood transfusion (risk ratio 0.84; 95% CI 0.40 to 1.78) or the mean number of units transfused (mean difference -0.69 units; 95% CI -1.55 to 0.17) (Analysis 6.4; Analysis 6.5).

#### Secondary outcomes

#### Hospital stay and Intensive therapy unit stay

There was no difference in the hospital stay (mean difference - 0.10 days; 95% CI -2.79 to 2.60) or intensive therapy unit stay (mean difference 1.26 days; 95% CI -0.66 to 3.18) between the two groups (Analysis 6.6; Analysis 6.7).

#### **Operating time**

There was no difference in the operating time between the two groups (mean difference -13.82 minutes; 95% CI -51.17 to 23.54) (Analysis 6.8).

#### Peri-operative haemodynamic variables

This outcome was not reported.

#### **Blood loss**

There was no significant difference in the transection blood loss (mean difference -104.00; 95% CI -228.46 to 20.46) between the groups. The total operative loss was lower in the IPC group (mean difference -164.73; 95% CI -271.83 to -57.64) (Analysis 6.9).

#### Enzyme markers of liver function

There was no statistically significant difference in the bilirubin level or prothrombin activity at any time between the two groups (Analysis 6.10; Analysis 6.11).

#### Enzyme markers of liver injury

There was no difference in the AST or ALT levels at any time between the groups (Analysis 6.12; Analysis 6.13).

#### Subgroup analysis

We did not perform subgroup analysis because all the trials were of high risk of bias and because of the few trials included in each comparison.

#### Variations in statistical analysis

Adopting the random-effects model or calculating the risk difference did not change the results.

#### **Bias exploration**

Because of the few trials included under each comparison, we did not explore bias.

# DISCUSSION

#### Summary of main results

In a review comparing vascular occlusion and no vascular occlusion in elective liver resections, we found that vascular occlusion is safe and reduces blood loss in liver resections (Gurusamy 2009a). In this review, we assessed the different methods of vascular occlusion. We found that hepatic vascular exclusion does not provide any additional benefit and could be potentially harmful in patients with cardiac disorders. We also found that continuous vascular

occlusion can be potentially harmful in patients with chronic liver diseases. There were no difference in any of the important outcomes in the other comparisons.

# Hepatic vascular exclusion versus portal triad clamping

The main reasons for occluding the outflow in addition to the inflow occlusion is to decrease the risk of retrograde bleeding from the hepatic veins and to decrease the risk of air embolism (Smyrniotis 2003a). However, patients can be subjected to haemo-dynamic changes resulting in haemodynamic intolerance. Also, retrograde blood perfusion through hepatic veins contributes to the hepatic viability and attenuates ischaemia/reperfusion injury (Smyrniotis 2003a).

The two trials included under this comparison used different methods to achieve the hepatic vascular occlusion. Both trials used portal triad clamping and clamping of the infrahepatic inferior vena cava. However, one trial achieved outflow occlusion by clamping the suprahepatic inferior vena cava (Belghiti 1996) and the other trial achieved outflow occlusion by clamping the hepatic veins draining the side that was resected (Chen 2006). The results from the trial that employed suprahepatic inferior vena cava occlusion generally favoured the portal triad clamping in many of the secondary outcomes while the trial that employed occlusion of the hepatic veins draining the side that was resected generally favoured the hepatic vascular exclusion group.

There was no difference in mortality, liver failure, other morbidity, or transfusion requirements between the two groups. There were two patients with air embolism in the portal triad clamping group detected only by intra-operative capnography and were not clinically significant. While the mean difference in the operating time was not statistically significant, individually both the trials demonstrated statistically significantly higher operating time in the hepatic vascular exclusion group than portal triad clamping group ( Belghiti 1996; Chen 2006). This is likely to be related to the time taken to achieve control of the outflow. There was a significant difference in the haemodynamic changes caused by hepatic vascular exclusion and portal triad clamping. The difference in change in cardiac index is more than one litre/min/m<sup>2</sup> (baseline value about 4 litres/min/m<sup>2</sup>) (Belghiti 1996). The difference in change in systemic vascular resistance is about 400 dynes.seconds/cm<sup>2</sup> (baseline value about 925 dynes.sec/cm<sup>2</sup>) (Belghiti 1996). This may be important in patients who suffer from cardiac conditions. However, it must be noted that only the trial that employed suprahepatic inferior vena cava clamping reported cardiac index and systemic vascular resistance.

The occasional difference noted in the enzymes representing liver function and liver damage was small and mostly clinically insignificant as there was no difference in these enzymes at other times, and there was no difference in the incidence of liver failure. These differences are likely to have arisen due to the inclusion of the trial that favoured the hepatic vascular exclusion group (Chen 2006) under these outcomes without the inclusion of the other trial, which favoured the portal triad clamping group (Belghiti 1996) because the latter did not report these outcomes.

The hospital stay was higher in the hepatic vascular exclusion group than portal triad clamping group. However, the trial favouring hepatic vascular exclusion group was not included in this outcome, and it is difficult to draw conclusions based on one trial. Because of the lack of significant benefit with the potential for harm in patients with cardiac disease, hepatic vascular exclusion cannot be recommended over portal triad clamping.

#### Portal triad clamping: continuous versus intermittent

While intermittent portal triad clamping enables prolonged operating time under vascular occlusion, there are concerns that it may induce a series of ischaemia/reperfusion injuries (Belghiti 1999). There are also concerns that intermittent portal triad clamping may increase intra-operative blood loss by restoring blood supply intermittently (Belghiti 1999). There was no statistically significant difference in any of the outcomes between the two groups. There were totally four deaths and four patients with liver failure in the trials included under this category. All the deaths and liver failure occurred in the continuous group. Two of these deaths were reported by Belghiti et al (Belghiti 1999) and the two patients had chronic liver disease and died of liver failure (bridging fibrosis or cirrhosis). The duration of ischaemia was 30 minutes and 33 minutes. Belghiti et al also reported another two patients with liver failure, who survived. Of these, one had chronic liver disease and another had 40% steatosis. Although the liver enzyme levels are not reported separately for patients with chronic liver disease in this report, the authors state that when only livers with chronic liver disease were included, the transaminase levels were significantly higher in the continuous portal triad clamping than in the intermittent portal triad clamping. When only livers with chronic liver disease were included for analysis, the serum bilirubin levels were also significantly higher in the continuous portal triad clamping than in the intermittent portal triad clamping. Thus, it appears that livers with chronic disease seem not to tolerate continuous vascular clamping as well as normal livers. It must be noted that the other trial, which included only cirrhotic livers did not find any significant difference in the liver enzymes or bilirubin.

Considering that intermittent portal triad clamping does not increase the total blood loss, the operating time, and the predisposition of the cirrhotic and steatotic livers to ischaemic injury, intermittent portal triad clamping seems to be better than continuous portal triad clamping at least in patients with chronic liver disease. Also considering that ultra-structural changes occur in livers exposed to ischaemia and reperfusion even after 30 minutes of continuous vascular occlusion (Wilasrusmee 2004), intermittent portal triad clamping allows the surgeon sufficient time to perform the resection under vascular control.

#### Inflow occlusion: total versus selective

The rationale behind occluding the blood supply to only the hemi-liver in which resection is to be carried out is that the other hemi-liver is spared of the effects of ischaemia/reperfusion injury (Figueras 2005).

There was no statistically significant difference in any of the outcomes. However, the only cases of hepatic insufficiency were in the selective inflow occlusion (4 patients, out of which 3 were temporary and the other patient died). In cirrhotic patients, there is no difference in the peak levels of the enzyme markers of liver injury or in morbidity. Thus, there is no evidence to support selective inflow occlusion over total inflow occlusion routinely.

# Different methods of intermittent portal triad clamping

#### 30 minutes versus 15 minutes

There was no significant difference in the morbidity, blood loss, transfusion requirements, liver function tests, or hospital stay between the groups. The operating time was lower in the 30-minutes group. Further trials are necessary to confirm this finding.

#### 20 minutes versus 10 minutes

There was no difference between the two groups in bilirubin or aspartate transaminase on the second post-operative day. This is a small trial with the outcomes reported in only nine patients. No inference can be drawn from the results.

# Ischaemic preconditioning followed by continuous vascular occlusion versus intermittent vascular occlusion

There was no difference in any of the outcomes other than total operative loss between the two groups. The difference was less than 200 ml which is unlikely to be of any clinical significance. It should be noted that neither trial included cirrhotic patients. There is no evidence for any difference between the techniques for liver resection in patients with non-cirrhotic livers.

#### Difficulty in the interpretation of the data

The main difficulty that we faced in this review is the heterogeneity in the patients included in the included trials. Some trials included major and minor liver resections and included normal and cirrhotic livers. Because of the few trials included under different comparisons, subgroup analysis could not be performed for many comparisons. It must also be noted that the outcomes, which include only one trial should be interpreted as level Ib evidence or level Ib- evidence rather than as level Ia or level Ia- evidence ( CEBM 2001).

#### Other limitations of the review

We were only able to find few trials on each relevant comparison and these trials included few participants and few outcome measures. This increases the risks of type I as well as type II errors (random errors).

Although a number of trials used adequate methodologies for randomisation, none of them employed blinding of participants or observers. Thus, all the trials included in this review were of high risk of bias (systematic errors).

There were no randomised clinical trials assessing the different methods of vascular occlusion in the laparoscopic liver resection. The haemodynamic changes during portal triad clamping in the laparoscopic liver resection is different from those during open elective liver resection (Decailliot 2005). So, this review is applicable only for open liver resection. Information on pre-operative chemotherapy was available only in two trials. Pre-operative chemotherapy causes steatohepatitis (Clavien 2007). These patients may have to be considered on par with those who have a background liver disease, and only the results applicable for patients with cirrhosis may be applicable in these patients.

We followed the Cochrane Handbook for this review. There were no language, publication status, or sample size restrictions. Thus, we minimised the bias due to selection of trials. However, we have used median for the meta-analysis when the mean was not available. We have also imputed the standard deviation from P-values according to the formulae stated in the Cochrane Handbook. If the trials stated a P-value < 0.05, we calculated the standard deviation using a P-value = 0.05. If standard deviation could not be calculated because the trial reports just state that there was no statistical significance without mentioning the exact P-value, we used the highest standard deviation among the other trials included in the outcome. This imputation of standard deviation may have introduced bias.

# AUTHORS' CONCLUSIONS

#### Implications for practice

This review is applicable only for open liver resection. Because of the lack of significant benefit with the potential for harm in patients with cardiac disease, hepatic vascular exclusion cannot be recommended over portal triad clamping. Intermittent portal triad clamping seems to be better than continuous portal triad clamping at least in patients with chronic liver disease. There is no evidence to support selective inflow occlusion over total inflow occlusion routinely. The optimal method of intermittent vascular occlusion is not clear. There is no evidence for any difference between the ischaemic preconditioning followed by vascular occlusion and intermittent vascular occlusion for liver resection in patients with non-cirrhotic livers.

#### Implications for research

Further trials are necessary to determine the safety, benefits, and harms of different methods of vascular occlusion in major and minor liver resections; in normal and cirrhotic livers; in open and laparoscopic liver resections; and in patients who underwent preoperative chemotherapy, and in those who did not undergo chemotherapy. Stratification based on these factors can be adopted for this purpose. These trials should be adequately powered to identify the benefits and harms of the different methods of vascular occlusion. These trials should include outcome measures related to safety, blood transfusion requirements, and cost measures such as operating time, intensive therapy unit stay, and hospital stay. This would require multicentric trials in most instances. The inclusion of cirrhotic patients or those with severe steatosis in these trials should be carefully considered if one of the arms is continuous vascular occlusion as the morbidity appears to be higher in these patients if subjected to continuous vascular occlusion.

Further trials are necessary to assess the advantages and disadvantages of remote ischaemic preconditioning.

Trials need to be conducted and reported according to the CON-SORT Statement (www.consort-statement.org).

### ACKNOWLEDGEMENTS

Mr Martyn Parker, Peterborough District Hospital, Peterborough who inspired the first author to write Cochrane Reviews.

The Cochrane Hepato-Biliary Group for their support.

Peer Reviewers: Keus F, The Netherlands; Clavien PA, Switzerland; Lodge JPA, UK; Mann C, UK.

Contact Editor: Abe Fingerhut, France.

#### REFERENCES

#### References to studies included in this review

Belghiti 1996 {published and unpublished data}

Belghiti J, Noun R, Zante E, Ballet T, Sauvanet A. Portal triad clamping or hepatic vascular exclusion for major liver resection. A controlled study. *Annals of Surgery* 1996;**224**(2):155–61.

Belghiti 1999 {published and unpublished data}

Belghiti J, Noun R, Malafosse R, Jagot P, Sauvanet A, Pierangeli F, et al.Continuous versus intermittent portal triad clamping for liver resection: a controlled study. *Annals of Surgery* 1999;**229**(3):369–75.

Brooks 2007 {published data only}

\* Brooks AJ, Hammond JS, Girling K, Beckingham IJ. The effect of hepatic vascular inflow occlusion on liver tissue pH, carbon dioxide, and oxygen partial pressures: defining the optimal clamp/release regime for intermittent portal clamping. *Journal of Surgical Research* 2007;**141**(2):247–51.

Hammond JS, Brooks A, Ahmed I, Lobo D, Girling K, Beckingham I. Hepatic tissue carbon dioxide and the pringle manoeuvre. *HPB* 2005;7(Supplement 1):21.

Capussotti 2003 {published data only}

Capussotti L, Nuzzo G, Polastri R, Giuliante F, Muratore A, Giovannini I. Continuous versus intermittent portal triad clamping during hepatectomy in cirrhosis. Results of a prospective, randomized clinical trial. *Hepato-Gastroenterology* 2003;**50**(52):1073–7.

**Chen 2006** {published data only}

Chen XP, Zhang ZW, Zhang BX, Chen YF, Huang ZY, Zhang WG, et

al.Modified technique of hepatic vascular exclusion: effect on blood loss during complex mesohepatectomy in hepatocellular carcinoma patients with cirrhosis. *Langenbecks Archives of Surgery* 2006;**391**(3): 209–15.

#### Esaki 2006 {published data only}

Esaki M, Sano T, Shimada K, Sakamoto Y, Takahashi Y, Wakai IC, et al.Randomized clinical trial of hepatectomy using intermittent pedicle occlusion with ischaemic intervals of 15 versus 30 minutes. *The British Journal of Surgery* 2006;**93**(8):944–51.

#### Figueras 2005 {published and unpublished data}

\* Figueras J, Llado L, Ruiz D, Ramos E, Busquets J, Rafecas A, et al.Complete versus selective portal triad clamping for minor liver resections: a prospective randomized trial. *Annals of Surgery* 2005; 241(4):582–90.

Llado L, Figueras J, Ruiz D, Ramos E, Torras J, Montserrat A, et al.Complete versus selective portal triad clamping for minor liver resections. A prospective randomized trial. *HPB* 2005;7(Supplement 1):21.

#### Petrowsky 2006 {published data only}

Petrowsky H, McCormack L, Trujillo M, Selzner M, Jochum W, Clavien PA. A prospective, randomized, controlled trial comparing intermittent portal triad clamping versus ischemic preconditioning with continuous clamping for major liver resection. *Annals of Surgery* 2006;**244**(6):921–30.

#### Smyrniotis 2006 {published data only}

Smyrniotis V, Theodoraki K, Arkadopoulos N, Fragulidis G, Condi-Pafiti A, Plemenou-Fragou M, et al.Ischemic preconditioning versus intermittent vascular occlusion in liver resections performed under selective vascular exclusion: a prospective randomized study. *American Journal of Surgery* 2006;**192**(5):669–74.

#### Wu 2002 {published and unpublished data}

Wu CC, Yeh DC, Ho WM, Yu CL, Cheng SB, Liu TJ, et al. Occlusion of hepatic blood inflow for complex central liver resections in cirrhotic patients: a randomized comparison of hemihepatic and total hepatic occlusion techniques. *Archives of Surgery* 2002;**137**(12): 1369–76.

#### References to studies excluded from this review

#### Cheung 1996 {published data only}

Cheung HK, Jawan B, Fung ST, Cheng KW, Wang CC, Lee JH. Comparison of hemodynamic changes during orthotopic liver transplantation between total clamping and partial clamping of the inferior vena cava. *Transplantation Proceedings* 1996;**28**(3):1721–2.

#### Figueras 2003 {published data only}

Figueras J, Lopez-Ben S, Llado L, Rafecas A, Torras J, Ramos E, et al.Hilar dissection versus the "glissonean" approach and stapling of the pedicle for major hepatectomies: a prospective, randomized trial. *Annals of Surgery* 2003;**238**(1):111–9.

#### Kato 2008 {published data only}

Kato M, Kubota K, Kita J, Shimoda M, Rokkaku K, Sawada T. Effect of infra-hepatic inferior vena cava clamping on bleeding during hepatic dissection: A prospective, randomized, controlled study. *World Journal of Surgery* 2008;**32**(6):1082–7.

#### Konigsrainer 2006 {published data only}

Konigsrainer I, Ladurner R, Steurer W, Konigsrainer A. Complete versus selective portal triad clamping for minor liver resections. *Annals of Surgery* 2006;**243**(1):137–8.

#### Man 2002 {published data only}

Man K, Liang TB, Lo CM, Liu CL, Ng IO, Yu WC, et al. Hepatic stress gene expression and ultrastructural features under intermittent Pringle manoeuvre. *Hepatobiliary & Pancreatic Diseases International* 2002;1(2):249–57.

#### Smyrniotis 2002 {published and unpublished data}

Smyrniotis VE, Kostopanagiotou GG, Gamaletsos EL, Vassiliou JG, Voros DC, Fotopoulos AC, et al. Total versus selective hepatic vascular exclusion in major liver resections. *American Journal of Surgery* 2002; **183**(2):173–8.

#### Smyrniotis 2003a {published and unpublished data}

Smyrniotis V, Kostopanagiotou G, Lolis E, Theodoraki K, Farantos C, Andreadou I, et al. Effects of hepatovenous back flow on ischemicreperfusion injuries in liver resections with the Pringle maneuver. *Journal of the American College of Surgeons* 2003;**197**(6):949–54.

#### Smyrniotis 2003b {published data only}

Smyrniotis VE, Kostopanagiotou GG, Contis JC, Farantos CI, Voros DC, Kannas DC, et al.Selective hepatic vascular exclusion versus Pringle maneuver in major liver resections: prospective study. *World Journal of Surgery* 2003;**27**(7):765–9.

#### Sugimoto 2003 {published data only}

Sugimoto H. Effects of the intermittent Pringle manoeuvre on hepatic gene expression and ultrastructure in a randomized clinical study. *The British Journal of Surgery* 2003;**90**(5):595.

#### Additional references

#### Azoulay 2006

Azoulay D, Lucidi V, Andreani P, Maggi U, Sebagh M, Ichai P, et al. Ischemic preconditioning for major liver resection under vascular exclusion of the liver preserving the caval flow: a randomized prospective study. *Journal of the American College of Surgeons* 2006; **202**(2):203–11.

#### Belghiti 1993

Belghiti J, Kabbej M, Sauvanet A, Vilgrain V, Panis Y, Fekete F. Drainage after elective hepatic resection. A randomized trial. *Annals of Surgery* 1993;**218**(6):748–53.

#### Capussotti 2006

Capussotti L, Muratore A, Ferrero A, Massucco P, Ribero D, Polastri R. Randomized clinical trial of liver resection with and without hepatic pedicle clamping. *The British Journal of Surgery* 2006;**93**(6): 685–9.

#### CEBM 2001

CEBM. Oxford Centre for Evidence-Based Medicine. Levels of Evidence. http://www.cebm.net/index.aspx?o=1025 2001.

#### Clavien 2007

Clavien PA, Petrowsky H, DeOliveira ML, Graf R. Strategies for safer liver surgery and partial liver transplantation. *New England Journal of Medicine* 2007;**356**(15):1545–59.

#### Couinaud 1999

Couinaud C. Liver anatomy: portal (and suprahepatic) or biliary segmentation. *Digestive Surgery* 1999;**16**(6):459–67.

Methods of vascular occlusion for elective liver resections (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

#### Decailliot 2005

Decailliot F, Streich B, Heurtematte Y, Duvaldestin P, Cherqui D, Stephan F. Hemodynamic effects of portal triad clamping with and without pneumoperitoneum: an echocardiographic study. *Anesthesia and Analgesia* 2005;**100**(3):617–22.

#### DeMets 1987

DeMets DL. Methods for combining randomized clinical trials: strengths and limitations. *Statistics in Medicine* 1987;**6**(3):341–50.

#### DerSimonian 1986

DerSimonian R, Laird N. Meta-analysis in clinical trials. *Controlled Clinical Trials* 1986;7(3):177–88.

#### Egger 1997

Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ (Clinical Research Ed.)* 1997;**315**(7109):629–34.

#### Elias 1991

Elias D, Desruennes E, Lasser P. Prolonged intermittent clamping of the portal triad during hepatectomy. *British Journal of Surgery* 1991; **78**(1):42–4.

#### Franco 1989

Franco D, Smadja C, Meakins JL, Wu A, Berthoux L, Grange D. Improved early results of elective hepatic resection for liver tumors. One hundred consecutive hepatectomies in cirrhotic and noncirrhotic patients. *Archives of Surgery* 1989;**124**(9):1033–7.

#### Gluud 2008

Gluud C, Nikolova D, Klingenberg SL, Whitfield K, Alexakis N, Als-Nielsen B, et al.Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2008, Issue 1. Art. No.: LIVER.

#### Gurusamy 2009a

Gurusamy K, Kumar Y, R Ramamoorthy, Sharma D, Davidson BR. Vascular occlusion for elective liver resections. *Cochrane Database of Systematic Reviews* 2009, Issue 1. [DOI: 10.1002/14651858.CD007530]

#### Gurusamy 2009b

Gurusamy K, Kumar Y, Pamecha V, Sharma D, Davidson BR. Ischaemic pre-conditioning for elective liver resections performed under vascular occlusion. *Cochrane Database of Systematic Reviews* 2009, Issue 1.[Art. No.: CD007629. DOI: 10.1002/14651858.CD007629]

#### Hasegawa 2002

Hasegawa K, Takayama T, Orii R, Sano K, Sugawara Y, Imamura H, et al.Effect of hypoventilation on bleeding during hepatic resection: a randomized controlled trial. *Archives of Surgery* 2002;**137**(3):311–5.

#### **HES 2005**

Hospital Episode Statistics. Main operations. 3 character: 2004-05. http:

//www.hesonline.nhs.uk/Ease/servlet/ContentServer?siteID=1937&categoryIDcategoryIDcategory2000;2(3):333-9. (accessed 17 April 2007).

#### Higgins 2002

Higgins JPT, Thompson SG. Quantifying heterogeneity in a metaanalysis. *Statistics in Medicine* 2002;**21**(11):1539–58. Higgins 2008

Higgins JPT, Green S (editors). *Cochrane Handbook for Systematic Reviews of Intervention 5.0.0 [updated February 2008]*. The Cochrane Colloboration, 2008. Available from www.cochrane–handbook.org.

#### Ibrahim 2006

Ibrahim S, Chen CL, Lin CC, Yang CH, Wang CC, Wang SH, et al. Intraoperative blood loss is a risk factor for complications in donors after living donor hepatectomy. *Liver Transplantation* 2006;**12**(6): 950–7.

#### Kjaergard 2001

Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in metaanalyses. *Annals of Internal Medicine* 2001;**135**(11):982–9.

#### Macaskill 2001

Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. *Statistics in Medicine* 2001;**20**(4): 641–54.

#### Moher 1998

Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al.Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. *Lancet* 1998;**352** (9128):609–13.

#### Newell 1992

Newell DJ. Intention-to-treat analysis: implications for quantitative and qualitative research. *International Journal of Epidemiology* 1992; **21**(5):837–41.

#### Pringle 1908

Pringle J. Notes on the arrest of hepatic hemorrhage due to trauma. Annals of Surgery 1908;48(4):541–9.

#### RevMan 2008

The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.

#### Royle 2003

Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. *International Journal of Technology Assessment in Health Care* 2003; **19**(4):591–603.

#### Schulz 1995

Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. *JAMA* 1995;**273**(5):408–12.

#### Shimada 1998

Shimada M, Takenaka K, Fujiwara Y, Gion T, Shirabe K, Yanaga K, et al.Risk factors linked to postoperative morbidity in patients with hepatocellular carcinoma. *The British Journal of Surgery* 1998;**85**(2): 195–8.

#### Strasberg 2000

Strasberg SM, Belghiti J, Clavien PA, Gadzijev E, Garden JO, Lau WY, et al. The Brisbane 2000 terminology of liver anatomy and re-ID=205. HPB Surgery 2000-2(3):333-9

#### Sweeting 2004

Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. *Statistics in Medicine* 2004;**23**(9):1351–75.

Methods of vascular occlusion for elective liver resections (Review)

Copyright  $\textcircled{\sc 0}$  2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

#### Wang 2006

Wang WD, Liang LJ, Huang XQ, Yin XY. Low central venous pressure reduces blood loss in hepatectomy. *World Journal of Gastroenterology* 2006;**12**(6):935–9.

#### Wilasrusmee 2004

Wilasrusmee C, Siritheptawee S, Kanchanapanjapon S, Sopon P, Vanichanon C, Limpthong W, et al. Ultrastructural changes in cirrhotic and noncirrhotic patients due to hepatectomy. *Journal of Hep-atobiliary Pancreatic Surgery* 2004;**11**(4):266–71.

#### Wood 2008

Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al.Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. *BMJ (Clinical research ed.)* 2008;**336**(7644): 601–5. [PUBMED: 18316340]

#### Yoshimura 2004

Yoshimura Y, Kubo S, Shirata K, Hirohashi K, Tanaka H, Shuto T, et al.Risk factors for postoperative delirium after liver resection for hepatocellular carcinoma. *World Journal of Surgery* 2004;**28**(10): 982–6.

#### References to other published versions of this review

#### Gurusamy 2007

Gurusamy KS, Kumar Y, Sharma D, Davidson BR. Methods of vascular occlusion for elective liver resections. *Cochrane Database of Systematic Reviews* 2007, Issue 4. [DOI: 10.1002/14651858.CD006409.pub2]

\* Indicates the major publication for the study

# CHARACTERISTICS OF STUDIES

#### Characteristics of included studies [ordered by study ID]

#### Belghiti 1996

Methods	Randomised clinical trial.
	Sequence generation: adequate.
	Allocation concealment: adequate.
	Blinding: inadequate.
	Free from 'incomplete outcome data' bias: inadequate.
	Free from 'selective outcome reporting': adequate.
	Free from 'baseline imbalance' bias: adequate.
	Free from 'early stopping' bias: unclear.
	Free from 'academic' bias: adequate.
	Free from 'source of funding' bias: unclear.

# Belghiti 1996 (Continued)

Participants	Country: France. Number randomised: 52 (4 from each group crossed over). Mean age: 46 years. Females: 31 (43.3%). Major liver resections: 52 (100%). Cirrhotic livers: 0 (0%). Parenchymal transection: clamp-crush, CUSA. Inclusion criteria: 1. Non-cirrhotic. 2. Major liver resections. Exclusion criteria: Involvement of hepatic veins or the vena cava (ie, narrowing of the vessel lumen by the tumour) or both by imaging.
Interventions	Participants were randomly assigned to two groups. Group 1: HVE (IVC) (n = 28). occlusion of IVC below and above liver. Group 2: continuous PTC (n = 24).
Outcomes	The outcomes reported were peri-operative mortality, morbidity, blood transfusion re- quirements, hospital stay, operating time, peri-operative haemodynamic variables, oper- ative blood loss, and liver function tests.
Notes	Reasons for post-randomisation drop-out: 4 in each group crossed over. These patients were included for mortality, morbidity, and hospital stay as this was reported in these patients. These patients were not included for any of the other outcomes including blood transfusion requirements Additional information was provided by authors in January 2007.

# Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	Adequate. Quote: "the random sequence was generated using a table num- ber randomization".
Allocation concealment?	Yes	Adequate. Quote: "the allocation concealment was performed using sealed envelops".
Blinding? All outcomes	No	Inadequate.

Belghiti 1996	(Continued)
---------------	-------------

Incomplete outcome data addressed? All outcomes	No	Inadequate. Quote: These eight patients who required crossing over to the other group were not considered for analysis of surgical compli- cations, hemodynamic response, blood loss, and liver and renal tolerance Comment: 4 in each group crossed over. These patients were included for mortality, morbidity, and hospital stay as this was reported in these patients. These patients were not included for any of the other outcomes
Free of selective reporting?	Yes	Adequate. Comment: All important outcomes were reported.
Free of baseline imbalance?	Yes	Adequate. Comment: Patients were well matched for important character- istics.
Free of early stopping bias?	Unclear	Unclear.
Free of academic bias?	Yes	Adequate. Comment: No previous published report of the same interven- tion by the author.

# Belghiti 1999

Methods	Randomised clinical trial.
	Allocation concealment: adequate
	Blinding: indequate
	Error from 'incomplete outcome date' biog adequate
	Free from incomplete outcome data bias: adequate.
	Free from selective outcome reporting : adequate.
	Free from 'baseline imbalance' bias: adequate.
	Free from 'early stopping' bias: unclear.
	Free from 'academic' bias: adequate.
	Free from 'source of funding' bias: unclear.
Participants	Country: France.
	Number randomised: 86.
	Mean age: 51 years.
	0
	Females: 41 (47.7%).
	Females: 41 (47.7%). Major liver resections: 39 (45.3%).
	Females: 41 (47.7%). Major liver resections: 39 (45.3%). Cirrhotic livers: 25 (29.1%).
	Females: 41 (47.7%). Major liver resections: 39 (45.3%). Cirrhotic livers: 25 (29.1%). Parenchymal transection: CUSA.
	Females: 41 (47.7%). Major liver resections: 39 (45.3%). Cirrhotic livers: 25 (29.1%). Parenchymal transection: CUSA. Inclusion criteria:
	Females: 41 (47.7%). Major liver resections: 39 (45.3%). Cirrhotic livers: 25 (29.1%). Parenchymal transection: CUSA. Inclusion criteria: Elective resections.

# Belghiti 1999 (Continued)

	<ol> <li>Exclusion criteria:         <ol> <li>Total vascular exclusion required because of involvement of the cavo-suprahepatic junction or the inferior vena cava.</li> <li>Simultaneous bilio-enteric anastomosis or associated gastrointestinal procedures.</li> </ol> </li> </ol>
Interventions	Participants were randomly assigned to two groups. Group 1: Continuous PTC (n = 42). Group 2: Intermittent PTC (n = 63). 15 minutes clamp; 5 minutes unclamp
Outcomes	The outcomes reported were peri-operative mortality, morbidity, blood transfusion re- quirements, hospital stay, blood loss, and liver function tests.
Notes	Additional information was provided by authors in January 2007.

Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	Adequate. Quote: "the random sequence was generated using a table num- ber randomization".
Allocation concealment?	Yes	Adequate. Quote: "the allocation concealment was performed using sealed envelops".
Blinding? All outcomes	No	Inadequate.
Incomplete outcome data addressed? All outcomes	Yes	Adequate. Comment: There were no post-randomisation drop-outs.
Free of selective reporting?	Yes	Adequate. Comment: All important outcomes were reported.
Free of baseline imbalance?	Yes	Adequate. Comment: Patients were well matched for important character- istics.
Free of early stopping bias?	Unclear	Unclear.

# Belghiti 1999 (Continued)

Free of academic bias?	Yes	Adequate. Comment: No previous published report of the same interven- tion by the author.
Brooks 2007		
Methods	Randomised clinical trial. Sequence generation: unclear. Allocation concealment: unclear. Blinding: inadequate. Free from 'incomplete outcome data' bias: inadequate. Free from 'selective outcome reporting': inadequate. Free from 'baseline imbalance' bias: adequate. Free from 'early stopping' bias: unclear. Free from 'academic' bias: adequate. Free from 'academic' bias: adequate. Free from 'source of funding' bias: unclear.	
Participants	Country: UK. Sample size: 13. Post-randomisation drop-out: 4. Revised sample size: 9. Females: 3 (33.3%). Mean age: 67.8 years. Major liver resections: 7 (77.8%). Cirrhotic patients: 0 (0%). Parenchymal transection: not stated. Inclusion criteria: Elective liver resection for colorectal metastases. Exclusion criteria: 1. Patients with American Society of Anesthesiologists > grade 2. 2. Preexisting parenchymal liver disease. 3. Non-metastatic disease.	
Interventions	The participants were randomly assigned to two groups. Group 1: intermittent PTC (n = 4). 20 minutes clamp;10 minutes unclamp. Group 2: intermittent PTC (n = 5). 10 minutes clamp; 5 minutes unclamp.	
Outcomes	The outcomes reported	d were liver function tests.
Notes	Reasons for post-rando Additional information received.	omisation drop-out: not stated. n was sought from authors in September 2008. No replies were

#### Brooks 2007 (Continued)

# Risk of bias

•		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	Unclear.
Allocation concealment?	Unclear	Unclear.
Blinding? All outcomes	No	Inadequate.
Incomplete outcome data addressed? All outcomes	No	Inadequate. Comment: The outcomes of only 9 patients were reported
Free of selective reporting?	Yes	Adequate. Comment: All important outcomes were reported.
Free of baseline imbalance?	Yes	Adequate. Comment: Patients were well matched for important character- istics.
Free of early stopping bias?	Unclear	Unclear.
Free of academic bias?	Yes	Adequate. Comment: No previous published report of the same interven- tion by the author.

# Capussotti 2003

Methods	Randomised clinical trial. Sequence generation: adequate. Allocation concealment: unclear. Blinding: inadequate. Free from 'incomplete outcome data' bias: adequate. Free from 'selective outcome reporting': inadequate. Free from 'baseline imbalance' bias: adequate. Free from 'early stopping' bias: unclear. Free from 'academic' bias: adequate. Free from 'academic' bias: adequate. Free from 'source of funding' bias: unclear.
Participants	Country: Italy. Number randomised: 35. Mean age: 52.8 years. Females: 8 (22.9%). Major liver resections: 8 (22.9%).

# Capussotti 2003 (Continued)

	Cirrhotic livers: 35 (100%). Parenchymal transection: clamp-crush. Inclusion criteria: 1. < 75 years. 2. HCC. 3. Cirrhotic. 4. Child A.
Interventions	Participants were randomly assigned to two groups. Group 1: Continuous PTC (Continuous) (n = 18). Group 2: Intermittent PTC (n = 17). 15 minutes clamp; 5 minutes unclamp
Outcomes	The outcomes reported were peri-operative mortality, blood transfusion requirements, operating time, blood loss, and liver function tests.
Notes	Additional information was sought from authors in September 2006 and September 2008. No replies were received.

# Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	Adequate. Quote: "randomization to the type of clamping was assigned by computer-generated random numbers".
Allocation concealment?	Unclear	Unclear.
Blinding? All outcomes	No	Inadequate.
Incomplete outcome data addressed? All outcomes	Yes	Adequate. Comment: There were no post-randomisation drop-outs.
Free of selective reporting?	No	Inadequate. Comment: Some important outcomes such as peri-operative morbidity were not reported.
Free of baseline imbalance?	Yes	Adequate. Comment: Patients were well matched for important character- istics.
Free of early stopping bias?	Unclear	Unclear.

# Capussotti 2003 (Continued)

Free of academic bias?	Yes	Adequate. Comment: No previous published report of the same interven- tion by the author.
Chen 2006		
Methods	Randomised clinical trial. Sequence generation: unclear. Allocation concealment: unclear. Blinding: inadequate. Free from 'incomplete outcome data' bias: adequate. Free from 'selective outcome reporting': adequate. Free from 'selective outcome reporting': adequate. Free from 'baseline imbalance' bias: adequate. Free from 'early stopping' bias: unclear. Free from 'academic' bias: adequate. Free from 'academic' bias: adequate.	
Participants	Country: China. Number randomised: 118. Mean age: 40.6 years. Females: 14 (11.9%). Major liver resections: 102 (86.4%). Cirrhotic livers: 118 (100%). Parenchymal transection: clamp-crush. Inclusion criteria: 1. Cirrhosis. 2. HCC. 3. Tumour > 5 cm in diameter. 4. Tumour located in the central portion of the liver. Exclusion criteria: 1. Direct invasion of the hepatic hilar plate. 2. Uncontrolled ascitas	
Interventions	Participants were rando Group 1: HVE (IVC) Occlusion of IVC belo liver to be resected. Group 2: PTC (n = 58	omly assigned to two groups. (n = 60). ww and occlusion of middle hepatic veins draining the section of t).
Outcomes	The outcomes reported quirements, operating function tests.	d were peri-operative mortality, morbidity, blood transfusion re- time, peri-operative haemodynamic variables, blood loss, and liver
Notes	Additional information No replies were receive	n was sought from authors in March 2007 and September 2008. ed.

# Chen 2006 (Continued)

# Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	Unclear.
Allocation concealment?	Unclear	Unclear.
Blinding? All outcomes	No	Inadequate.
Incomplete outcome data addressed? All outcomes	Yes	Adequate. Quote: "If abdominal exploration was negative for extrahepatic spread and liver resection was indicated, the patients were ran- domly allocated to either the CIO or the MTHVE groups". Comment: "This avoided post-randomisation drop-outs".
Free of selective reporting?	Yes	Adequate. Comment: All important outcomes were reported.
Free of baseline imbalance?	Yes	Adequate. Comment: Patients were well matched for important character- istics.
Free of early stopping bias?	Unclear	Unclear.
Free of academic bias?	Yes	Adequate. Comment: No previous published report of the same interven- tion by the author.

# Esaki 2006

Methods	Randomised clinical trial.		
	Sequence generation: adequate.		
	Allocation concealment: adequate.		
	Blinding: inadequate.		
	Free from 'incomplete outcome data' bias: inadequate.		
	Free from 'selective outcome reporting': inadequate.		
	Free from 'baseline imbalance' bias: adequate.		
	Free from 'early stopping' bias: adequate.		
	Free from 'academic' bias: adequate.		
	Free from 'source of funding' bias: unclear.		

Participants	Country: Japan. Number randomised: 92. Mean age: 62 years. Females: 28 (30.4%). Major liver resections: 18 (19.6%). Cirrhotic livers: 0 (0%). Parenchymal transection: clamp-crush. Inclusion criteria: 1. Elective hepatectomy. 2. < 75 years of age. 3. Adequate cardiopulmonary and renal function. Exclusion criteria: Preoperative diagnosis of HCC.
Interventions	Participants were randomly assigned to two groups. Group 1: Intermittent PTC (n = 48). 30 minutes clamp; 5 minutes unclamp. Group 2: Intermittent PTC (n = 44). 15 minutes clamp; 5 minutes unclamp.
Outcomes	The outcomes reported were peri-operative mortality, morbidity, blood transfusion re- quirements, hospital stay, operating time, operative blood loss, and liver function tests.
Notes	Reasons for post-randomisation drop-out: No hepatectomy 8 patients; not eligible 8 patients. Additional information was provided by authors in March 2007.

# Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	Adequate. Quote: "Block randomization, which was made with using per- sonal computer by data center not associated with surgeons or patients at all, was individually performed by telephone calls soon after confirmation of the inclusion criteria".
Allocation concealment?	Yes	Adequate. Quote: "Block randomization, which was made with using per- sonal computer by data center not associated with surgeons or patients at all, was individually performed by telephone calls soon after confirmation of the inclusion criteria".
Blinding? All outcomes	No	Inadequate.

#### Esaki 2006 (Continued)

Incomplete outcome data addressed? All outcomes	No	Inadequate. Quote: "After randomization, 11 patients were excluded from the SG and five from the PG". Comment: Post-randomisation drop-outs were related to the outcomes.
Free of selective reporting?	No	Inadequate. Comment: Some important outcomes like liver failure were not reported.
Free of baseline imbalance?	Yes	Adequate. Comment: Patients were well matched for important character- istics.
Free of early stopping bias?	Yes	Adequate. Comment: The trialists recruited the intended number of peo- ple.
Free of academic bias?	Yes	Adequate. Comment: No previous published report of the same interven- tion by the author.

# Figueras 2005

Methods	Randomised clinical trial. Sequence generation: adequate. Allocation concealment: adequate. Blinding: inadequate. Free from 'incomplete outcome data' bias: adequate. Free from 'selective outcome reporting': adequate. Free from 'baseline imbalance' bias: adequate. Free from 'early stopping' bias: adequate. Free from 'academic' bias: adequate. Free from 'academic' bias: adequate. Free from 'source of funding' bias: adequate.
Participants	Country: Spain. Number randomised: 80. Mean age: 61.8 years. Females: 21 (26.2%). Major liver resections: 0 (0%). Cirrhotic livers: 39 (48.8%). Parenchymal transection: clamp-crush, CUSA. Inclusion criteria: Minor hepatic resections only. Exclusion criteria: 1. Gastro-intestinal anastomosis.

# Figueras 2005 (Continued)

	2. Contralateral hepatic resection.
Interventions	Participants were randomly assigned to two groups. Group 1: Intermittent PTC (n = 39). 15 minutes clamp; 5 minutes unclamp. Group 2: Intermittent selective inflow occlusion (n=41). 15 minutes clamp; 5 minutes unclamp.
Outcomes	The outcomes reported were peri-operative mortality, morbidity, blood transfusion re- quirements, hospital stay, operating time, operative blood loss, and liver function tests.
Notes	AST and ALT were reported in graphs. There is discrepancy between the graph and the text. So, these details were not obtained from graph. Additional information related to randomisation was provided by authors in September 2006.

# Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	Adequate. Quote: "The distribution of the groups was performed at the beginning of the study with a random table with stratification of the patients for cirrhosis".
Allocation concealment?	Yes	Adequate. Quote: "Randomization was performed using sealed envelopes".
Blinding? All outcomes	No	Inadequate.
Incomplete outcome data addressed? All outcomes	Yes	Adequate. Quote: "Because intraoperative ultrasonography might reveal new tumoral nodules and, therefore, lead to changes in the tech- nique of surgical resection, potential study patients were not randomized until full hepatic exploration had been completed".
Free of selective reporting?	Yes	Adequate. Comment: All important outcomes were reported.
Free of baseline imbalance?	Yes	Adequate. Comment: Patients were well matched for important character- istics.

# Figueras 2005 (Continued)

Free of early stopping bias?	Yes	Adequate. Comment: The trialists recruited the intended number of peo- ple.
Free of academic bias?	Yes	Adequate. Comment: No previous published report of the same interven- tion by the author.

Petrowsky	2006
-----------	------

Methods	Randomised clinical trial. Sequence generation: unclear. Allocation concealment: adequate. Blinding: inadequate. Free from 'incomplete outcome data' bias: adequate. Free from 'selective outcome reporting': adequate. Free from 'baseline imbalance' bias: adequate. Free from 'early stopping' bias: adequate. Free from 'academic' bias: adequate. Free from 'academic' bias: adequate. Free from 'academic' bias: adequate.
Participants	Country: Switzerland Number randomised: 73. Median age: 57.7 years. Females: 35 (47.9%). Major liver resections: 73 (100%). Cirrhotic livers: 0 (0%). Parenchymal transection: clamp-crush technique. Inclusion criteria: 1. Major liver resection. 2. 30 minutes of ischaemia time. Exclusion criteria: 1. Living donors for liver transplantation. 2. Combined local ablation such as radiofrequency or cryoablation. 3. Need for total vascular hepatic exclusion. 4. Major concomitant extrahepatic procedure.
Interventions	Participants were randomly assigned to two groups. Group 1: Ischaemic preconditioning (n = 36). 10 minutes clamping followed by 10 minutes unclamp followed by continuous PTC. Group 2: Intermittent PTC (n = 37). 15 minutes clamp; 5 minutes unclamp.
Outcomes	The outcomes reported were peri-operative mortality, morbidity, blood transfusion re- quirements, hospital stay, ITU stay, operating time, blood loss, and liver function tests.

# Petrowsky 2006 (Continued)

Notes

Additional information related to randomisation was sought from the authors in March 2007 but the answers were not clear.

# Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	Unclear.
Allocation concealment?	Yes	Adequate. Quote: "sealed random envelope technique".
Blinding? All outcomes	No	Inadequate.
Incomplete outcome data addressed? All outcomes	Yes	Adequate. Comment: There were no post-randomisation drop-outs.
Free of selective reporting?	Yes	Adequate. Comment: All important outcomes were reported.
Free of baseline imbalance?	Yes	Adequate. Comment: Patients were well matched for important character- istics.
Free of early stopping bias?	Yes	Adequate. Comment: The trialists recruited the intended number of peo- ple.
Free of academic bias?	Yes	Adequate. Comment: No previous published report of the same interven- tion by the author.
Smyrniotis 2006

Methods	Randomised clinical trial. Sequence generation: adequate. Allocation concealment: adequate. Blinding: inadequate. Free from 'incomplete outcome data' bias: adequate. Free from 'selective outcome reporting': inadequate. Free from 'baseline imbalance' bias: adequate. Free from 'aearly stopping' bias: adequate. Free from 'academic' bias: adequate. Free from 'academic' bias: adequate. Free from 'academic' bias: adequate.			
Participants	Country: Greece. Number randomised: 54. Median age: 62.5 years. Females: 16 (29.6%). Major liver resections: 27 (50%). Cirrhotic livers: 0 (0%). Parenchymal transection: sharp transection. Inclusion criteria: Liver resection for liver malignancy. Exclusion criteria: 1. Cirrhosis. 2. Serious co-morbidity.			
Interventions	Participants were randomly assigned to two groups. Group 1: Ischaemic preconditioning (n = 27). 10 minutes clamping followed by 10 minutes unclamp followed by continuous HVE (major hepatic veins). Group 2: Intermittent HVE (major hepatic veins) (n = 27). 15 minutes clamp; 5 minutes unclamp.			
Outcomes	The outcomes reported were peri-operative mortality, morbidity, blood transfusion re- quirements, hospital stay, ITU stay, operating time, blood loss, and liver function tests.			
Notes	Additional information related to randomisation was provided by authors in March 2007.			
Risk of bias				
Item	Authors' judgement	Description		
Adequate sequence generation?	Yes Adequate. Quote: "In our studies we use computer-generated numbers".			

#### Smyrniotis 2006 (Continued)

Allocation concealment?	Yes	Adequate. Quote: "Randomization was performed by the sealed-envelope method".
Blinding? All outcomes	No	Inadequate.
Incomplete outcome data addressed? All outcomes	Yes	Adequate. Comment: There were no post-randomisation drop-outs.
Free of selective reporting?	No	Inadequate. Comment: Some important outcomes like liver failure were not reported.
Free of baseline imbalance?	Yes	Adequate. Comment: Patients were well matched for important character- istics.
Free of early stopping bias?	Yes	Adequate. Comment: The trialists recruited the intended number of peo- ple.
Free of academic bias?	Yes	Adequate. Comment: No previous published report of the same interven- tion by the author.

### Wu 2002

Methods	Randomised clinical trial. Sequence generation: adequate. Allocation concealment: adequate. Blinding: inadequate. Free from 'incomplete outcome data' bias: adequate. Free from 'selective outcome reporting': inadequate. Free from 'baseline imbalance' bias: adequate. Free from 'early stopping' bias: unclear. Free from 'academic' bias: adequate. Free from 'academic' bias: adequate. Free from 'source of funding' bias: adequate.
Participants	Country: Taiwan. Number randomised: 58. Mean age: 55.3 years Females: 10 (17.2%). Major liver resections: 20 (34.5%) Cirrhotic livers: 58 (100%) Parenchymal transection: clamp-crush

### Wu 2002 (Continued)

	<ol> <li>Inclusion criteria:         <ol> <li>Cirrhotic</li> <li>Tumour location - Central (4,5,8)</li> <li>Must have resection of segment 5.</li> </ol> </li> <li>Exclusion criteria:         <ol> <li>Previous bile operations</li> <li>Pre-operative therapy</li> <li>Patients needing total vascular exclusion</li> <li>Patients with poor liver function (Indocyanine green 15 min retention rate &gt; 50%, Bilirubin 4 mg/dl or prothrombin time &lt; 75% of control levels.</li> </ol> </li> </ol>
Interventions	Participants were randomly assigned to two groups. Group 1: Intermittent PTC (n = 28). 15 minutes clamp; 5 minutes declamp. Group 2: Intermittent selective inflow occlusion (n = 30). 30 minutes clamp; 5 minutes declamp.
Outcomes	The outcomes reported were peri-operative mortality, morbidity, blood transfusion re- quirements, hospital stay, operating time, blood loss, and liver function tests.
Notes	Additional information related to randomisation was provided by authors in November 2006.

### Risk of bias

Item	Authors' judgement	Description
Adequate sequence generation?	Yes	Adequate. Quote: "The random sequence was made by computerized ran- dom sequence at the beginning of the study".
Allocation concealment?	Yes	Adequate. Quote: "randomization was performed by opening a sealed en- velope".
Blinding? All outcomes	No	Inadequate.
Incomplete outcome data addressed? All outcomes	Yes	Adequate. Comment: There were no post-randomisation drop-outs.
Free of selective reporting?	No	Inadequate. Comment: Some important outcomes such as liver failure were not reported.

#### Wu 2002 (Continued)

Free of baseline imbalance?	Yes	Adequate. Comment: Patients were well matched for important character- istics.
Free of early stopping bias?	Unclear	Unclear.
Free of academic bias?	Yes	Adequate. Comment: No previous published report of the same interven- tion by the author.

ATP = adenosine tri phosphate.

CD18 = integrin on resting polymorphonuclear cells.

CUSA = cavitron ultrasound surgical aspirator.

e-nos = endothelial nitrogen oxide synthase.

ET-1 = endothelin -1.

HCC = hepatocellular carcinoma.

HVE = hepatic vascular exclusion.

IPC = ischaemic pre-conditioning.

ITU = intensive therapy unit.

IVC = inferior vena cava.

PTC = portal triad clamping.

#### Characteristics of excluded studies [ordered by study ID]

Cheung 1996	Not a randomised clinical trial.
Figueras 2003	Compares selective vascular occlusion by dividing the vessels separately at the hilum or by en bloc transection of the vessels by a surgical stapler.
Kato 2008	Only the infrahepatic IVC was clamped without clamping of suprahepatic inferior vena cava or major hepatic veins. So, this was not a trial assessing hepatic vascular exclusion.
Konigsrainer 2006	Letter to editor and not a randomised clinical trial.
Man 2002	Randomised selection of patients for electron microscopy but not randomisation of patients.
Smyrniotis 2002	Quasi-randomised (random sequence generated by hospital number).
Smyrniotis 2003a	Quasi-randomised (random sequence generated by hospital number).
Smyrniotis 2003b	Quasi-randomised (random sequence generated by hospital number).

(Continued)

Sugimoto 2003 Letter to editor and not a randomised clinical trial.

IVC = inferior vena cava.

### DATA AND ANALYSES

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mortality	2	170	Risk Ratio (M-H, Fixed, 95% CI)	0.30 [0.03, 2.86]
2 Liver failure	2	170	Risk Ratio (M-H, Fixed, 95% CI)	0.97 [0.14, 6.64]
3 Peri-operative morbidity	2		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
3.1 Re-operation	1	52	Risk Ratio (M-H, Fixed, 95% CI)	2.59 [0.11, 60.69]
3.2 Abdominal collections	2	170	Risk Ratio (M-H, Fixed, 95% CI)	2.03 [0.75, 5.49]
3.3 Wound infection	1	118	Risk Ratio (M-H, Fixed, 95% CI)	0.97 [0.06, 15.09]
3.4 Ascites	1	118	Risk Ratio (M-H, Fixed, 95% CI)	0.64 [0.19, 2.17]
3.5 Haematoma	1	52	Risk Ratio (M-H, Fixed, 95% CI)	1.71 [0.17, 17.76]
3.6 Pulmonary complications	2	170	Risk Ratio (M-H, Fixed, 95% CI)	1.46 [0.76, 2.82]
3.7 Air embolism	1	44	Risk Ratio (M-H, Fixed, 95% CI)	0.17 [0.01, 3.31]
4 Number needing transfusion	2	162	Risk Ratio (M-H, Random, 95% CI)	0.63 [0.13, 3.14]
5 Number of units transfused	1	44	Mean Difference (IV, Fixed, 95% CI)	-0.40 [-2.58, 1.78]
6 Hospital stay (days)	1	52	Mean Difference (IV, Fixed, 95% CI)	5.01 [0.06, 9.94]
7 Operating time (minutes)	2	162	Mean Difference (IV, Random, 95% CI)	27.95 [-24.66, 80.57]
8 Haemodynamic changes	2		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
8.1 Mean Arterial Pressure (MAP) mmHg	2	162	Mean Difference (IV, Fixed, 95% CI)	-3.29 [-8.15, 1.58]
8.2 Cardiac Index (L/ min/ sq. m)	1	44	Mean Difference (IV, Fixed, 95% CI)	-1.30 [-1.78, -0.82]
8.3 Systemic Vascular Resistance (SVR) dyne.s.cm^-5	1	44	Mean Difference (IV, Fixed, 95% CI)	752.01 [504.98, 999.02]
9 Blood loss (ml)	2		Mean Difference (IV, Random, 95% CI)	Subtotals only
9.1 Transection blood loss	1	118	Mean Difference (IV, Random, 95% CI)	-330.01 [-407.25, - 252.75]
9.2 Operative blood loss	2	162	Mean Difference (IV, Random, 95% CI)	-185.48 [-682.89, 311.92]
10 Bilirubin (micromole/litre)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
10.1 First post-operative day	1	118	Mean Difference (IV, Fixed, 95% CI)	-3.40 [-6.61, -0.19]
10.2 Third post-operative day	1	118	Mean Difference (IV, Fixed, 95% CI)	Not estimable
10.3 Fifth post-operative day	1	118	Mean Difference (IV, Fixed, 95% CI)	Not estimable
11 Prothrombin activity	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
(percentage of normal)				·
11.1 First post-operative day	1	44	Mean Difference (IV, Fixed, 95% CI)	5.01 [-2.79, 12.79]
11.2 Fifth post-operative day	1	40	Mean Difference (IV, Fixed, 95% CI)	5.01 [-4.61, 14.61]
12 AST (aspartate transaminase) (IU/litre)	2		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
12.1 First post-operative day	2	162	Mean Difference (IV, Fixed, 95% CI)	-2.65 [-80.08, 74.78]
12.2 Third post-operative day	1	118	Mean Difference (IV, Fixed, 95% CI)	-60.01 [-93.15, - 26.85]
12.3 Fifth post-operative day	2	162	Mean Difference (IV, Fixed, 95% CI)	-8.57 [-19.76, 2.61]

### Comparison 1. Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC)

Methods of vascular occlusion for elective liver resections (Review)

13 ALT (alanine transaminase)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
13.1 First post-operative day	1	118	Mean Difference (IV, Fixed, 95% CI)	-130.01 [-285.75,
13.2 Third post-operative day	1	118	Mean Difference (IV, Fixed, 95% CI)	23.75] -230.00 [-346.63, -
13.3 Fifth post-operative day	1	118	Mean Difference (IV, Fixed, 95% CI)	Not estimable

## Comparison 2. Portal triad clamping: 'continuous' versus 'intermittent'

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mortality	2	121	Risk Ratio (M-H, Fixed, 95% CI)	4.98 [0.60, 41.14]
2 Liver failure	2	121	Risk Ratio (M-H, Fixed, 95% CI)	6.05 [0.76, 48.20]
3 Peri-operative morbidity	1		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
3.1 Re-operation	1	86	Risk Ratio (M-H, Fixed, 95% CI)	5.23 [0.26, 105.89]
3.2 Abdominal collections	1	86	Risk Ratio (M-H, Fixed, 95% CI)	0.79 [0.19, 3.30]
3.3 Haematoma	1	86	Risk Ratio (M-H, Fixed, 95% CI)	1.05 [0.07, 16.21]
3.4 Pulmonary complications	1	86	Risk Ratio (M-H, Fixed, 95% CI)	1.05 [0.33, 3.36]
3.5 Biliary fistula	1	86	Risk Ratio (M-H, Fixed, 95% CI)	1.05 [0.07, 16.21]
3.6 Pancreatitis	1	86	Risk Ratio (M-H, Fixed, 95% CI)	0.35 [0.01, 8.33]
4 Number needing transfusion	2	121	Risk Ratio (M-H, Fixed, 95% CI)	0.91 [0.53, 1.58]
5 Number of units transfused	2	121	Mean Difference (IV, Fixed, 95% CI)	0.20 [-0.38, 0.79]
6 Hospital stay (in days)	1	86	Mean Difference (IV, Fixed, 95% CI)	-1.01 [-4.82, 2.82]
7 Operating time (in minutes)	1	35	Mean Difference (IV, Fixed, 95% CI)	-13.40 [-68.08, 41.28]
8 Blood loss	2		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
8.1 Transection	1	86	Mean Difference (IV, Fixed, 95% CI)	-248.00 [-387.14, - 112.86]
8.2 Operative	2	121	Mean Difference (IV, Fixed, 95% CI)	-58.49 [-321.68, 204.71]
9 Bilirubin (micromole/litre)	2		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
9.1 First post-operative day	2	121	Mean Difference (IV, Fixed, 95% CI)	1.23 [-7.18, 9.63]
9.2 Second post-operative day	1	86	Mean Difference (IV, Fixed, 95% CI)	2.01 [-7.10, 11.10]
9.3 Third post-operative day	1	35	Mean Difference (IV, Fixed, 95% CI)	8.06 [-17.06, 34.06]
9.4 Fifth post-operative day	1	86	Mean Difference (IV, Fixed, 95% CI)	10.01 [-4.27, 24.27]
9.5 Seventh post-operative	2	127	Mean Difference (IV, Fixed, 95% CI)	7.23 [-5.71, 20.17]
day				
10 Prothrombin activity (percentage of normal)	2		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
10.1 First post-operative day	2	121	Mean Difference (IV, Fixed, 95% CI)	0.41 [-4.80, 5.62]
10.2 Second post-operative	1	86	Mean Difference (IV, Fixed, 95% CI)	-1.01 [-7.76, 5.76]
10.3 Third post-operative day	1	35	Mean Difference (IV. Fixed, 95% CI)	-8.01 [-18.93, 2.93]
10.4 Fifth post-operative day	1	86	Mean Difference (IV, Fixed, 95% CI)	Not estimable
10.5 Seventh post-operative	2	121	Mean Difference (IV, Fixed, 95% CI)	-2.67 [-8.32, 2.98]
dav	-	121		2.07 [ 0.02, 2.90]
11 AST (aspartate transaminase) (IU/litre)	2		Mean Difference (IV, Fixed, 95% CI)	Subtotals only

11.1 First post-operative day	2	121	Mean Difference (IV, Fixed, 95% CI)	12.38 [-68.95, 93.72]
11.2 Second post-operative day	1	86	Mean Difference (IV, Fixed, 95% CI)	134.01 [-3.59, 271.59]
11.3 Third post-operative day	1	35	Mean Difference (IV, Fixed, 95% CI)	-40.01 [-260.94, 180.94]
11.4 Fifth post-operative day	1	86	Mean Difference (IV, Fixed, 95% CI)	8.01 [-12.62, 28.62]
11.5 Seventh post-operative day	2	121	Mean Difference (IV, Fixed, 95% CI)	3.01 [-6.91, 12.94]
12 ALT (alanine transaminase) (IU/litre)	2		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
12.1 First post-operative day	2	121	Mean Difference (IV, Fixed, 95% CI)	10.00 [-92.00, 113.99]
12.2 Second post-operative day	1	86	Mean Difference (IV, Fixed, 95% CI)	98.01 [-40.90, 236.90]
12.3 Third post-operative day	1	35	Mean Difference (IV, Fixed, 95% CI)	-40.01 [-256.48, 176.48]
12.4 Fifth post-operative day	1	86	Mean Difference (IV, Fixed, 95% CI)	16.01 [-42.82, 74.82]
12.5 Seventh post-operative day	2	121	Mean Difference (IV, Fixed, 95% CI)	2.81 [-32.76, 38.39]

## Comparison 3. Inflow occlusion: 'selective' versus 'total'

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mortality	2	138	Risk Ratio (M-H, Fixed, 95% CI)	2.86 [0.12, 68.10]
2 Liver failure	1	80	Risk Ratio (M-H, Fixed, 95% CI)	8.57 [0.48, 154.15]
3 Peri-operative morbidity	2		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
3.1 Re-operation	1	80	Risk Ratio (M-H, Fixed, 95% CI)	Not estimable
3.2 Abdominal collections	2	138	Risk Ratio (M-H, Fixed, 95% CI)	1.74 [0.51, 5.94]
3.3 Wound infection	1	58	Risk Ratio (M-H, Fixed, 95% CI)	4.68 [0.23, 93.37]
3.4 Pulmonary complications	2	138	Risk Ratio (M-H, Fixed, 95% CI)	0.71 [0.16, 3.07]
3.5 Cardiac failure	1	80	Risk Ratio (M-H, Fixed, 95% CI)	4.76 [0.24, 96.16]
3.6 Portal vein thrombosis	1	80	Risk Ratio (M-H, Fixed, 95% CI)	4.76 [0.24, 96.16]
3.7 Bile leak	2	138	Risk Ratio (M-H, Fixed, 95% CI)	0.94 [0.31, 2.83]
3.8 Ascites	2	138	Risk Ratio (M-H, Fixed, 95% CI)	1.42 [0.42, 4.80]
4 Number needing transfusion	2	138	Risk Ratio (M-H, Random, 95% CI)	0.70 [0.20, 2.50]
5 Number of units transfused	1	80	Mean Difference (IV, Fixed, 95% CI)	-0.02 [-0.44, 0.40]
6 Hospital stay (in days)	2	138	Mean Difference (IV, Random, 95% CI)	-0.34 [-2.92, 2.24]
7 Operating time (min)	2	138	Mean Difference (IV, Fixed, 95% CI)	8.69 [-10.12, 27.50]
8 Hemodynamics change (10 min after release of clamping)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
8.1 Mean Arterial Pressure mmHg	1	80	Mean Difference (IV, Fixed, 95% CI)	-2.70 [-8.88, 3.48]
9 Blood loss (ml)	2	196	Mean Difference (IV, Random, 95% CI)	-165.35 [-475.60, 144.91]

9.1 Transection	1	58	Mean Difference (IV, Random, 95% CI)	-241.01 [-539.63, 57.63]
9.2 Operative	2	138	Mean Difference (IV, Random, 95% CI)	-174.56 [-742.06, 392.95]
10 Bilirubin (micromole/litre)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
10.1 First post-operative day	1	58	Mean Difference (IV, Fixed, 95% CI)	0.60 [-15.50, 16.70]
10.2 Third post-operative day	1	58	Mean Difference (IV, Fixed, 95% CI)	-3.40 [-18.77, 11.97]
10.3 Fifth post-operative day	1	58	Mean Difference (IV, Fixed, 95% CI)	-5.30 [-24.43, 13.83]
10.4 Seventh post-operative day	1	58	Mean Difference (IV, Fixed, 95% CI)	-4.20 [-25.01, 16.61]
11 AST (aspartate transaminase) (IU/litre)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
11.1 First post-operative day	1	58	Mean Difference (IV, Fixed, 95% CI)	-130.01 [-531.92, 271.92]
11.2 Third post-operative day	1	58	Mean Difference (IV, Fixed, 95% CI)	10.01 [-207.61, 227.61]
11.3 Fifth post-operative day	1	58	Mean Difference (IV, Fixed, 95% CI)	-10.01 [-120.67, 100.67]
11.4 Seventh post-operative day	1	58	Mean Difference (IV, Fixed, 95% CI)	-20.01 [-36.45, - 3.55]
12 ALT (alanine transaminase) (IU/litre)	2		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
12.1 First post-operative day	2	138	Mean Difference (IV, Fixed, 95% CI)	41.95 [-57.52, 141.41]
12.2 Third post-operative day	1	58	Mean Difference (IV, Fixed, 95% CI)	-10.01 [-162.92, 142.92]
12.3 Fifth post-operative day	1	58	Mean Difference (IV, Fixed, 95% CI)	-40.00 [-136.58, 56.58]
12.4 Seventh post-operative day	1	58	Mean Difference (IV, Fixed, 95% CI)	-20.01 [-30.30, - 9.70]

## Comparison 4. 30 minutes intermittent PTC versus 15 minutes intermittent PTC

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mortality	1	92	Risk Ratio (M-H, Fixed, 95% CI)	Not estimable
2 Peri-operative morbidity	1		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
2.1 Wound infection	1	92	Risk Ratio (M-H, Fixed, 95% CI)	2.76 [0.30, 25.47]
2.2 Pulmonary complications	1	92	Risk Ratio (M-H, Fixed, 95% CI)	0.92 [0.13, 6.23]
2.3 Bile leak	1	92	Risk Ratio (M-H, Fixed, 95% CI)	0.52 [0.16, 1.67]
2.4 Cholangitis	1	92	Risk Ratio (M-H, Fixed, 95% CI)	4.59 [0.23, 93.09]
2.5 Pancreatic fistula	1	92	Risk Ratio (M-H, Fixed, 95% CI)	0.31 [0.01, 7.32]
2.6 Bowel obstruction	1	92	Risk Ratio (M-H, Fixed, 95% CI)	2.76 [0.12, 65.92]
3 Number needing transfusion	1	92	Risk Ratio (M-H, Fixed, 95% CI)	0.92 [0.24, 3.45]
4 Number of units transfused	1	92	Mean Difference (IV, Fixed, 95% CI)	Not estimable

5 Number of units of FFP transfused	1	92	Mean Difference (IV, Fixed, 95% CI)	1.01 [-2.48, 4.48]
6 Hospital stay	1	92	Mean Difference (IV, Fixed, 95% CI)	Not estimable
7 Operating time	1	92	Mean Difference (IV, Fixed, 95% CI)	-50.00 [-101.91, - 2.09]
8 Blood loss (ml)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
8.1 Transection (per sq cm)	1	92	Mean Difference (IV, Fixed, 95% CI)	-1.30 [-2.85, 0.25]
8.2 Operative	1	92	Mean Difference (IV, Fixed, 95% CI)	39.01 [-1.50, 79.50]
9 Bilirubin (micromole/litre)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
9.1 First post-operative day	1	92	Mean Difference (IV, Fixed, 95% CI)	0.80 [-8.08, 9.68]
9.2 Second post-operative day	1	92	Mean Difference (IV, Fixed, 95% CI)	0.90 [-7.98, 9.78]
9.3 Third post-operative day	1	92	Mean Difference (IV, Fixed, 95% CI)	1.70 [-1.33, 4.73]
9.4 Fifth post-operative day	1	92	Mean Difference (IV, Fixed, 95% CI)	1.70 [-1.65, 5.05]
9.5 Seventh post-operative day	1	92	Mean Difference (IV, Fixed, 95% CI)	1.80 [-0.53, 4.13]
10 Prothrombin activity (percentage of normal)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
10.1 First post-operative day	1	92	Mean Difference (IV, Fixed, 95% CI)	-4.80 [-11.59, 1.99]
10.2 Third post-operative day	1	92	Mean Difference (IV, Fixed, 95% CI)	2.70 [-5.73, 11.13]
10.3 Seventh post-operative day	1	92	Mean Difference (IV, Fixed, 95% CI)	0.60 [-7.83, 9.03]
11 AST (aspartate transaminase)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
(IU/litre)				,
11.1 First post-operative day	1	92	Mean Difference (IV, Fixed, 95% CI)	-37.00 [-169.90, 91.90]
11.2 Second post-operative day	1	92	Mean Difference (IV, Fixed, 95% CI)	-10.01 [-25.14, 5.14]
11.3 Third post-operative day	1	92	Mean Difference (IV, Fixed, 95% CI)	-4.01 [-13.41, 5.41]
11.4 Fifth post-operative day	1	92	Mean Difference (IV, Fixed, 95% CI)	Not estimable
11.5 Seventh post-operative	1	92	Mean Difference (IV, Fixed, 95% CI)	2.01 [-4.55, 8.55]
12 ALT (alanine transaminase) (IU/litre)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
12.1 First post-operative day	1	92	Mean Difference (IV, Fixed, 95% CI)	31.01 [-111.76, 173.76]
12.2 Second post-operative	1	92	Mean Difference (IV, Fixed, 95% CI)	24.01 [-118.76,
day				166.76]
12.3 Third post-operative day	1	92	Mean Difference (IV, Fixed, 95% CI)	15.01 [-59.45, 89.45]
12.4 Fifth post-operative day	1	92	Mean Difference (IV, Fixed, 95% CI)	11.01 [-59.36,
12.5 Seventh post-operative day	1	92	Mean Difference (IV, Fixed, 95% CI)	-4.01 [-55.54, 47.54]

Comparison 5. 20 minutes intermittent PIC versus 10 minutes intermittent
--

Outcome or subgroup title	No. of No. of studies participants		Statistical method	Effect size
1 Bilirubin (micromole/litre)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
1.1 Second post-operative day	1	9	Mean Difference (IV, Fixed, 95% CI)	34.04 [-15.46, 84.06]
2 ALT (alanine transaminase) (IU/ litre)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
2.1 Second post-operative day	1	9	Mean Difference (IV, Fixed, 95% CI)	486.10 [-464.52, 1438.32]

### Comparison 6. Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mortality	2	127	Risk Ratio (M-H, Fixed, 95% CI)	3.08 [0.13, 73.24]
2 Liver failure	1	73	Risk Ratio (M-H, Fixed, 95% CI)	0.21 [0.01, 4.14]
3 Peri-operative morbidity	2		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
3.1 Abdominal collections	1	73	Risk Ratio (M-H, Fixed, 95% CI)	1.37 [0.33, 5.70]
3.2 Wound infection	1	73	Risk Ratio (M-H, Fixed, 95% CI)	0.69 [0.12, 3.86]
3.3 Pulmonary complications	2	127	Risk Ratio (M-H, Fixed, 95% CI)	1.01 [0.44, 2.29]
3.4 Bile leak	2	127	Risk Ratio (M-H, Fixed, 95% CI)	1.42 [0.48, 4.25]
4 Number needing transfusion	1	73	Risk Ratio (M-H, Fixed, 95% CI)	0.84 [0.40, 1.78]
5 Number of units transfused	2	127	Mean Difference (IV, Fixed, 95% CI)	-0.69 [-1.55, 0.17]
6 Hospital stay (in days)	2	127	Mean Difference (IV, Random, 95% CI)	-0.10 [-2.79, 2.60]
7 ITU stay (in days)	2	127	Mean Difference (IV, Fixed, 95% CI)	1.26 [-0.66, 3.18]
8 Operating time	2	127	Mean Difference (IV, Random, 95% CI)	-13.82 [-51.17, 23.54]
9 Blood loss (ml)	2		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
9.1 Transection	1	73	Mean Difference (IV, Fixed, 95% CI)	-104.01 [-228.46, 20.46]
9.2 Operative	2	127	Mean Difference (IV, Fixed, 95% CI)	-164.73 [-271.83, - 57.64]
10 Bilirubin (micromole/litre)	2		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
10.1 First post-operative day	2	127	Mean Difference (IV, Fixed, 95% CI)	1.02 [-3.35, 5.38]
10.2 Third post-operative day	1	54	Mean Difference (IV, Fixed, 95% CI)	0.06 [-3.83, 4.83]
10.3 Sixth post-operative day	1	54	Mean Difference (IV, Fixed, 95% CI)	3.80 [-0.53, 8.13]
11 Prothrombin activity (percentage of normal)	2		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
11.1 First post-operative day	2	127	Mean Difference (IV, Fixed, 95% CI)	-1.05 [-4.18, 2.09]
11.2 Third post-operative day	1	54	Mean Difference (IV, Fixed, 95% CI)	-0.10 [-3.38, 3.18]
11.3 Sixth post-operative day	1	54	Mean Difference (IV, Fixed, 95% CI)	2.30 [-0.92, 5.52]
12 AST (IU/L)	2		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
12.1 First post-operative day	2	127	Mean Difference (IV, Fixed, 95% CI)	50.55 [-45.27, 146.38]

Methods of vascular occlusion for elective liver resections (Review)

12.2 Third post-operative day	1	54	Mean Difference (IV, Fixed, 95% CI)	66.01 [-17.42,
12.3 Sixth post-operative day	1	54	Mean Difference (IV Fixed 95% CI)	149.42] -1 01 [-5 94 3 94]
13 ALT (IU/L)	1	<i>J</i> 1	Mean Difference (IV, Fixed, 95% CI)	Subtotals only
13.1 First post-operative day	1	73	Mean Difference (IV, Fixed, 95% CI)	-108.01 [-277.07,
				61.07]

# Analysis I.I. Comparison I Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome I Mortality.

Review: Methods of vascular occlusion for elective liver resections

Comparison: I Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC)

Outcome: I Mortality

-

Study or subgroup	HVE	PTC	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% CI
Belghiti 1996	0/28	1/24		51.4 %	0.29 [ 0.01, 6.74 ]
Chen 2006	0/60	1/58		48.6 %	0.32 [ 0.01, 7.76 ]
Total (95% CI)	88	82	-	100.0 %	0.30 [ 0.03, 2.86 ]
Total events: 0 (HVE), 2 (P	TC)				
Heterogeneity: $Chi^2 = 0.00$	), df = 1 (P = 0.96); I	<sup>2</sup> =0.0%			
Test for overall effect: Z =	1.04 (P = 0.30)				

0.0010 0.1 1.0 10.0 1000.0 Favours HVE Favours PTC

# Analysis I.2. Comparison I Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 2 Liver failure.

Review: Methods of vascular occlusion for elective liver resections

Comparison: I Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC)

Outcome: 2 Liver failure

.

Study or subgroup	HVE	PTC	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% Cl
Belghiti 1996	0/28	0/24	•	0.0 %	0.0 [ 0.0, 0.0 ]
Chen 2006	2/60	2/58		100.0 %	0.97 [ 0.14, 6.64 ]
Total (95% CI)	88	82	-	100.0 %	0.97 [ 0.14, 6.64 ]
Total events: 2 (HVE), 2 (P	TC)				
Heterogeneity: $Chi^2 = 0.0$ ,	$df = 0 (P = 1.00); I^2$	=0.0%			
Test for overall effect: $Z = 0$	0.03 (P = 0.97)				
			0.0010 0.1 1.0 10.0 1000.0		
			Favours HVE Favours PTC		

## Analysis I.3. Comparison I Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 3 Peri-operative morbidity.

Review: Methods of vascular occlusion for elective liver resections

Comparison: I Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC)

Outcome: 3 Peri-operative morbidity

Study or subgroup	HVE	PTC	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% CI
I Re-operation					
Belghiti 1996	1/28	0/24		100.0 %	2.59 [ 0.11, 60.69 ]
Subtotal (95% CI)	28	24		100.0 %	2.59 [ 0.11, 60.69 ]
Total events: I (HVE), 0 (PTC)					
Heterogeneity: not applicable					
Test for overall effect: $Z = 0.59$ (F	P = 0.56)				
2 Abdominal collections					
Belghiti 1996	9/28	4/24	-	89.4 %	1.93 [ 0.68, 5.48 ]
Chen 2006	1/60	0/58		10.6 %	2.90 [ 0.12, 69.81 ]
Subtotal (95% CI)	88	82	•	100.0 %	2.03 [ 0.75, 5.49 ]
			0.0010 0.1 1.0 10.0 1000.0		
			Favours HVE Favours PTC		
					(Continued )

Methods of vascular occlusion for elective liver resections (Review)

Study or subgroup	HVE n/N	PTC n/N	Risk Ratio M-H.Fixed.95% Cl	Weight	( Continued) Risk Ratio M-H.Fixed,95% Cl
Total events: 10 (HVE), 4 (PTC) Heterogeneity: Chi <sup>2</sup> = 0.06, df = Test for overall effect: Z = 1.40 (	$(P = 0.81);  ^2 = (P = 0.16)$	=0.0%			
3 Wound infection Chen 2006	1/60	1/58		100.0 %	0.97 [ 0.06, 15.09 ]
Subtotal (95% CI) Total events: 1 (HVE), 1 (PTC) Heterogeneity: not applicable Test for overall effect: Z = 0.02 (	<b>60</b> (P = 0.98)	58	-	100.0 %	0.97 [ 0.06, 15.09 ]
4 Ascites	4//0	(150		100.0.%	
Subtotal (95% CI) Total events: 4 (HVE), 6 (PTC)	<b>60</b>	58	-	100.0 %	0.64 [ 0.19, 2.17 ]
Heterogeneity: not applicable Test for overall effect: $Z = 0.71$ ( 5 Haematoma	(P = 0.48)				
Belghiti 1996	2/28	1/24		100.0 %	1.71 [ 0.17, 17.76 ]
Subtotal (95% CI) Total events: 2 (HVE), I (PTC) Heterogeneity: not applicable Test for overall effect: Z = 0.45 ( 6 Pulmonary complications	<b>28</b> (P = 0.65)	24	-	100.0 %	1.71 [ 0.17, 17.76 ]
Belghiti 1996	8/28	4/24	-	34.6 %	1.71 [ 0.59, 4.99 ]
Chen 2006	11/60	8/58	-	65.4 %	1.33 [ 0.58, 3.07 ]
Subtotal (95% CI) Total events: 19 (HVE), 12 (PTC Heterogeneity: Chi <sup>2</sup> = 0.13, df = Test for overall effect: Z = 1.13 ( 7 Air embolism Belghiti 1996	<b>88</b> ) =   (P = 0.71);   <sup>2</sup> = (P = 0.26) 0/24	<b>82</b> =0.0%	• 	100.0 %	0.17[001.331.1
Subtotal (95% CI)	24	20		100.0 %	0.17 [0.01, 3.31]
Total events: 0 (HVE), 2 (PTC) Heterogeneity: not applicable Test for overall effect: $Z = 1.17$ (	(P = 0.24)	20		100.0 %	0.17 [ 0.01, 3.31 ]
			0.0010 0.1 1.0 10.0 1000.0 Favours HVE Favours PTC		

Comparison: I Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC)

Outcome: 3 Peri-operative morbidity



Comparison: I Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC)

Outcome: 3 Peri-operative morbidity



Comparison: I Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC)

Outcome: 3 Peri-operative morbidity



Comparison: I Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC)

Outcome: 3 Peri-operative morbidity



# Analysis I.4. Comparison I Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 4 Number needing transfusion.

Review: Methods of vaso	cular occlusion for el	lective liver resection	IS		
Comparison: I Hepatic	vascular exclusion (H	HVE) versus portal tr	riad clamping (PTC)		
Outcome: 4 Number ne	eeding transfusion				
Study or subgroup	H\/F	PTC	Rick Ratio	Weight	Risk Ratio
stady of subgroup	n/N	n/N	M-H,Random,95% Cl	, reight	M-H,Random,95% Cl
Belghiti 1996	16/24	10/20	-	51.1 %	1.33 [ 0.79, 2.25 ]
Chen 2006	8/60	27/58	-	48.9 %	0.29 [ 0.14, 0.58 ]
Total (95% CI)	84	78	•	100.0 %	0.63 [ 0.13, 3.14 ]
Total events: 24 (HVE), 37	(PTC)				
Heterogeneity: Tau <sup>2</sup> = 1.25	5; Chi <sup>2</sup> = 13.58, df =	= I (P = 0.00023); I <sup>2</sup>	=93%		
Test for overall effect: Z =	0.57 (P = 0.57)				
			0.0010 0.1 1.0 10.0 1000.0		
			Favours HVE Favours PTC		

#### Analysis I.5. Comparison I Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 5 Number of units transfused.

Review: Methods of vascular occlusion for elective liver resections

Comparison: I Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC)

Outcome: 5 Number of units transfused



### Analysis I.6. Comparison I Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 6 Hospital stay (days).

Review: Methods of vascular occlusion for elective liver resections

Comparison: I Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC)

Outcome: 6 Hospital stay (days)

Study or subgroup	HVE		PTC		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fixed,95% CI		IV,Fixed,95% CI
Belghiti 1996	28	21 (11)	24	16 (7)		100.0 %	5.00 [ 0.06, 9.94 ]
<b>Total (95% CI)</b> Heterogeneity: not app Test for overall effect: Z	<b>28</b> Dicable Z = 1.98 (P =	= 0.047)	24		•	100.0 %	5.00 [ 0.06, 9.94 ]
					<u> </u>		
					-20 -10 0 10 20		
					Favours HVE Favours PTC		
Methods of vascular of	occlusion f	or elective liver	resections	(Review)			51

# Analysis 1.7. Comparison I Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 7 Operating time (minutes).

Review: Methods of vascular occlusion for elective liver resections

Comparison: I Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC)

Outcome: 7 Operating time (minutes)

Study or subgroup	HVE		PTC			Me	ean Differenc	e	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)		IV,Ran	dom,95% Cl			IV,Random,95% CI
Belghiti 1996	24	366 (106)	20	301 (103)					34.4 %	65.00 [ 3.06, 126.94 ]
Chen 2006	60	33 (  .8)	58	124.5 (10.7)					65.6 %	8.50 [ 4.44, 12.56 ]
Total (95% CI)	84		78				•		100.0 %	27.95 [ -24.66, 80.57 ]
Heterogeneity: Tau $^2$ =	1094.67; C	$ni^2 = 3.18, df = 1$	(P = 0.07)	); I <sup>2</sup> =69%						
Test for overall effect: 2	Z = 1.04 (P	= 0.30)								
					-200	-100	0 100	200		
					Favo	urs HVE	Favours	РТС		

### Analysis I.8. Comparison I Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 8 Haemodynamic changes.

Review: Methods of vaso	cular occlu	ision for elective	liver resea	tions			
Comparison: I Hepatic	vascular ex	clusion (HVE) v	ersus por	tal triad clamping	(PTC)		
Outcome: 8 Haemodyna	amic chan	ges					
Study or subgroup	HVF		PTC.		Mean D	ifference Weight	Mean Difference
/ -·8·F	N	Mean(SD)	N	Mean(SD)	IV,Fixed,95	% Cl	IV,Fixed,95% Cl
I Mean Arterial Pressure (	MAP) mm	ηHg					
Belghiti 1996	24	93 (17)	20	102 (16)		24.8 %	-9.00 [ -18.77, 0.77 ]
Chen 2006	60	81.9 (17)	58	83.3 (14)		75.2 %	-1.40 [ -7.01, 4.21 ]
<b>Subtotal (95% CI)</b> Heterogeneity: Chi <sup>2</sup> = 1.75	<b>84</b> 5, df = 1 (I	P = 0.19); l <sup>2</sup> =43	<b>78</b>			100.0 %	-3.29 [ -8.15, 1.58 ]
lest for overall effect: $\angle =$	1.32 (P =	0.19)					
Belghiti 1996	24	2.5 (0.5)	20	3.8 (1)		100.0 %	-1.30 [ -1.78, -0.82 ]
<b>Subtotal (95% CI)</b> Heterogeneity: not applicat Test for overall effect: Z =	<b>24</b> ble 5.29 (P <	0.00001)	20			100.0 %	-1.30 [ -1.78, -0.82 ]
				-	000 -500 0	500  000	
					Favours HVE	Favours PTC	
							(Continued )

Methods of vascular occlusion for elective liver resections (Review)

Study or subgroup	HVE N	Mean(SD)	PTC N	Mean(SD)	Mea IV,Fixe	n Difference d,95% Cl	Weight	( Continued) Mean Difference IV,Fixed,95% Cl
3 Systemic Vascular Resistan Belghiti 1996	ce (SVR) o 24	dyne.s.cm^-5 1699 (555)	20	947 (247)			100.0 %	752.00 [ 504.98, 999.02 ]
<b>Subtotal (95% CI)</b> Heterogeneity: not applicabl Test for overall effect: Z = 5. Test for subgroup difference:	<b>24</b> 97 (P < 0 s: Chi <sup>2</sup> = 5	.00001) 36 36 df = 2 (P	<b>20</b>	=94%		•	100.0 %	752.00 [ 504.98, 999.02 ]
	, cn .	50.50, di 2 (i	0.00), 1	7170	<b>I</b> I			
					-1000 -500 Favours HVE	0 500 1000 Favours PTC		
Review: Methods of vascu	lar occlusi	ion for elective l	iver resecti	ons				
Comparison: I Hepatic va	scular exc	lusion (HVE) ve	rsus porta	l triad clampin	g (PTC)			
Outcome: 8 Haemodynar	nic change	es						
Study or subgroup	HVE N	Mean(SD)	PTC N	Mean(S	D) I	Mean Difference V,Fixed,95% Cl	e Weigh	nt Mean Difference IV,Fixed,95% Cl
I Mean Arterial Pressure (M Belghiti 1996	AP) mmH 24	Hg 93 (17)	20	102 (	16)		24.8	8 % -9.00 [ -18.77, 0.77 ]
Chen 2006	60	81.9 (17)	58	83.3 (	14)		75.2	2 % -1.40 [ -7.01, 4.21 ]
Subtotal (95% CI) Heterogeneity: $Chi^2 = 1.75$ , Test for overall effect: $Z = 1$ .	<b>84</b> df = 1 (P 32 (P = 0	= 0.19); l <sup>2</sup> =439	<b>78</b>				100.0	% -3.29 [ -8.15, 1.58 ]
					-1000 -500 Favours H	) 0 500 VE Favours I	1000 PTC	
Methods of vascular occlu Copyright © 2009 The Co	ision for chrane (	elective liver Collaboration	resectior . Publishe	us (Review) ed by John V	Viley & Sons, L	td.		53

Comparison: I Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC)

Outcome: 8 Haemodynamic changes

Study or subgroup	HVE N	Mean(SD)	PTC N	Mean(SD)	Mean Difference IV,Fixed,95% Cl	Weight	Mean Difference IV,Fixed,95% Cl
2 Cardiac Index (L/ min/ s	q. m)						
Belghiti 1996	24	2.5 (0.5)	20	3.8 (1)	•	100.0 %	-1.30 [ -1.78, -0.82 ]
Subtotal (95% CI)	24		20			100.0 %	-1.30 [ -1.78, -0.82 ]
Heterogeneity: not applica	ble	0.00001)					
lest for overall effect: Z –	5.29 (P <	0.00001)					
Review: Methods of vas Comparison: I Hepatic	cular occlu vascular e	usion for elective xclusion (HVE) \	. liver resect	tions al triad clamping ()	-1000 -500 0 500 1000 Favours HVE Favours PTC	)	
Outcome: 8 Haemodyn	namic chan	iges		1 0 (	,		
		-					
Study or subgroup	HVE	Maap(SD)	PTC	Maan(SD)	Mean Difference	Weight	Mean Difference
	IN	Filean(SD)	IN	Fileari(SD)	10,11xed,75% CI		TV,I IXEU,75% CI
3 Systemic Vascular Resista Belghiti 1996	ance (SVR 24	) dyne.s.cm^-5 1699 (555)	20	947 (247)		100.0 %	752.00 [ 504.98, 999.02 ]
Subtotal (95% CI)	24		20			0.0 % 752	2.00 [ 504.98, 999.02 ]
Heterogeneity: not applica	ble		20				
Test for overall effect: $Z =$	5.97 (P <	0.00001)					
				-10 F	00 -500 0 500 1000 iavours HVE Favours PTC		

### Analysis I.9. Comparison I Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 9 Blood loss (ml).

Review: Methods of vascular occlusion for elective liver resections

Comparison: I Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC)

Outcome: 9 Blood loss (ml)

	N	Mean(SD)	PTC N	Mean(SD)	Mean Difference IV,Random,95% Cl	Weight	Mean Difference IV,Random,95% Cl
I Transection blood loss							
Chen 2006	60	350 (110)	58	680 (280)	-	100.0 %	-330.00 [ -407.25, -252.75 ]
Subtotal (95% CI)	60		58		•	100.0 %	-330.00 [ -407.25, -252.75 ]
Heterogeneity: not applica	able						
lest for overall effect: $\angle =$ 2 Operative blood loss	8.37 (P ·	< 0.00001)					
Belghiti 1996	24	1195 (1105)	20	989 (1250)		2.7 %	206.00 [ -497.95, 909.95 ]
Chen 2006	60	420 (250)	58	770 (320)		97.3 %	-350.00 [ -453.84, -246.16 ]
Subtotal (95% CI)	84		78			100.0 %	-185.48 [ -682.89, 311.92 ]
Heterogeneity: Tau <sup>2</sup> = 886	663.89; C	2hi <sup>2</sup> = 2.35, df =	I (P = 0.	3);   <sup>2</sup> =57%			
Test for overall effect: Z =	0.73 (P =	= 0.46)					
					-1000 -500 0 500 10	00	
					Favours HVE Favours PTC		
Review: Methods of vas	scular occ	lusion for electiv	/e liver res	sections			
Review: Methods of vas	scular occ	lusion for electiv	ve liver res	sections	sing (PTC)		
Review: Methods of vas Comparison: I Hepatic	scular occ vascular	lusion for electiv	ve liver res I versus po	sections ortal triad clamp	ping (PTC)		
Review: Methods of vas Comparison: I Hepatic Outcome: 9 Blood loss	scular occ vascular (ml)	lusion for electiv	ve liver res I versus po	sections ortal triad clamp	bing (PTC)		
Review: Methods of vas Comparison: I Hepatic Outcome: 9 Blood loss Study or subgroup	vascular occ vascular (ml) HVE	lusion for electiv	ve liver res I versus po	sections ortal triad clamp	ning (PTC)	Weight	Mean Difference
Review: Methods of vas Comparison: I Hepatic Outcome: 9 Blood loss Study or subgroup	scular occ vascular (ml) HVE N	lusion for electiv exclusion (HVE) Mean(SD)	ve liver res I versus po PTC N	sections ortal triad clamp Mean(SD)	bing (PTC) Mean Difference IV,Random,95% Cl	Weight	Mean Difference IV,Random,95% Cl
Review: Methods of vas Comparison: I Hepatic Outcome: 9 Blood loss Study or subgroup	scular occ vascular (ml) HVE N	lusion for electiv exclusion (HVE) Mean(SD)	ve liver res versus po PTC N	sections ortal triad clamp Mean(SD)	oing (PTC) Mean Difference IV,Random,95% CI	Weight	Mean Difference IV,Random,95% Cl
Review: Methods of vas Comparison: I Hepatic Outcome: 9 Blood loss Study or subgroup I Transection blood loss Chen 2006	scular occ vascular (ml) HVE N 60	lusion for electiv exclusion (HVE) Mean(SD) 350 (110)	ve liver res versus po PTC N 58	sections ortal triad clamp Mean(SD) 680 (280)	bing (PTC) Mean Difference IV,Random,95% CI	Weight 100.0 %	Mean Difference IV,Random,95% CI -330.00 [ -407.25, -252.75 ]
Review: Methods of vas Comparison: I Hepatic Outcome: 9 Blood loss Study or subgroup I Transection blood loss Chen 2006 Subtotal (95% CI)	cular occ vascular (ml) HVE N 60 <b>60</b>	lusion for electiv exclusion (HVE) Mean(SD) 350 (110)	PTC N 58 58	sections ortal triad clamp Mean(SD) 680 (280)	Mean Difference IV;Random,95% CI	Weight 100.0 % <b>100.0 %</b>	Mean Difference IV,Random,95% CI -330.00 [ -407.25, -252.75 ] - <b>330.00 [ -407.25, -252.75</b> ]
Review: Methods of vas Comparison: I Hepatic Outcome: 9 Blood loss Study or subgroup I Transection blood loss Chen 2006 <b>Subtotal (95% CI)</b> Heterogeneity: not applica	scular occ vascular (ml) HVE N 60 <b>60</b> able	lusion for electiv exclusion (HVE) Mean(SD) 350 (110)	ve liver res versus po PTC N 58 <b>58</b>	sections ortal triad clamp Mean(SD) 680 (280)	bing (PTC) Mean Difference IV,Random,95% CI	Weight 100.0 % <b>100.0 %</b>	Mean Difference IV,Random,95% CI -330.00 [ -407.25, -252.75 ] -330.00 [ -407.25, -252.75 ]
Review: Methods of vas Comparison: I Hepatic Outcome: 9 Blood loss Study or subgroup I Transection blood loss Chen 2006 <b>Subtotal (95% CI)</b> Heterogeneity: not applica Test for overall effect: Z =	scular occ vascular (ml) HVE N 60 <b>60</b> able : 8.37 (P -	lusion for electiv exclusion (HVE) Mean(SD) 350 (110) < 0.00001)	PTC N 58 58	sections ortal triad clamp Mean(SD) 680 (280)	Mean Difference IV,Random,95% CI	Weight 100.0 % <b>100.0 %</b>	Mean Difference IV,Random,95% CI -330.00 [ -407.25, -252.75 ] -330.00 [ -407.25, -252.75 ]
Review: Methods of vas Comparison: I Hepatic Outcome: 9 Blood loss Study or subgroup I Transection blood loss Chen 2006 <b>Subtotal (95% CI)</b> Heterogeneity: not applica Test for overall effect: Z =	cular occ vascular (ml) HVE N 60 <b>60</b> able 8.37 (P •	lusion for electiv exclusion (HVE) Mean(SD) 350 (110) < 0.00001)	PTC N 58 58	sections ortal triad clamp Mean(SD) 680 (280)	Mean Difference IV,Random,95% CI	Weight 100.0 % <b>100.0 %</b>	Mean Difference IV,Random,95% CI -330.00 [ -407.25, -252.75 ] -330.00 [ -407.25, -252.75 ]
Review: Methods of vas Comparison: I Hepatic Outcome: 9 Blood loss Study or subgroup I Transection blood loss Chen 2006 <b>Subtotal (95% CI)</b> Heterogeneity: not applica Test for overall effect: Z =	scular occ vascular (ml) HVE N 60 <b>60</b> able s 8.37 (P -	lusion for electiv exclusion (HVE) Mean(SD) 350 (110) < 0.00001)	PTC N 58 58	sections ortal triad clamp Mean(SD) 680 (280)	Mean Difference IV,Random,95% CI	Weight 100.0 % <b>100.0 %</b>	Mean Difference IV,Random,95% CI -330.00 [ -407.25, -252.75 ] -330.00 [ -407.25, -252.75 ]
<ul> <li>Review: Methods of vas</li> <li>Comparison: I Hepatic</li> <li>Outcome: 9 Blood loss</li> <li>Study or subgroup</li> <li>I Transection blood loss</li> <li>Chen 2006</li> <li>Subtotal (95% CI)</li> <li>Heterogeneity: not applica</li> <li>Test for overall effect: Z =</li> </ul>	scular occ vascular (ml) HVE N 60 <b>60</b> able : 8.37 (P -	lusion for electiv exclusion (HVE) Mean(SD) 350 (110) < 0.00001)	PTC N 58 58	sections ortal triad clamp Mean(SD) 680 (280)	Mean Difference IV,Random,95% CI • • • • • • • • • • • • • • • • • • •	Weight 100.0 % <b>100.0 %</b>	Mean Difference IV,Random,95% CI -330.00 [ -407.25, -252.75 ] -330.00 [ -407.25, -252.75 ]
Review: Methods of vas Comparison: I Hepatic Outcome: 9 Blood loss Study or subgroup I Transection blood loss Chen 2006 <b>Subtotal (95% CI)</b> Heterogeneity: not applica Test for overall effect: Z =	cular occ vascular (ml) HVE N 60 60 able * 8.37 (P ·	lusion for electiv exclusion (HVE) Mean(SD) 350 (110) < 0.00001)	PTC N 58 <b>58</b>	sections ortal triad clamp Mean(SD) 680 (280)	Mean Difference IV,Random,95% CI • • • • • • • • • • • • • • • • • • •	Weight 100.0 % <b>100.0 %</b>	Mean Difference IV,Random,95% CI -330.00 [ -407.25, -252.75 ] -330.00 [ -407.25, -252.75 ]
Review: Methods of vas Comparison: I Hepatic Outcome: 9 Blood loss Study or subgroup I Transection blood loss Chen 2006 <b>Subtotal (95% CI)</b> Heterogeneity: not applica Test for overall effect: Z =	scular occ vascular (ml) HVE N 60 <b>60</b> able 8.37 (P -	lusion for electiv exclusion (HVE) Mean(SD) 350 (110) < 0.00001)	PTC N 58 58	sections ortal triad clamp Mean(SD) 680 (280)	Mean Difference IV,Random,95% CI	Weight 100.0 % <b>100.0 %</b>	Mean Difference IV,Random,95% CI -330.00 [ -407.25, -252.75 ] -330.00 [ -407.25, -252.75 ]

Comparison: I Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC)

Outcome: 9 Blood loss (ml)



#### Analysis 1.10. Comparison I Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 10 Bilirubin (micromole/litre).

Review: Methods of vasc	ular occlusi	ion for elective live	er resectio	ns				
Comparison: I Hepatic v	/ascular exc	lusion (HVE) vers	sus portal t	riad clamping (P <sup>-</sup>	ГС)			
Outcome: 10 Bilirubin (n	nicromole/l	itre)						
Study or subgroup	HVE		PTC		Mear	n Difference	Weight	Mean Difference
	N	Mean(SD)	N	Mean(SD)	IV,Fixed	1,95% Cl		IV,Fixed,95% CI
I First post-operative day								
Chen 2006	60	26 (8.9)	58	29.4 (8.9)			100.0 %	-3.40 [ -6.61, -0.19 ]
Subtotal (95% CI)	60		58				100.0 %	-3.40 [ -6.61, -0.19 ]
Heterogeneity: not applicab	ble							
Test for overall effect: $Z = 2$	2.07 (P = 0	.038)						
2 Third post-operative day								
Chen 2006	60	23.1 (6.5)	58	23.1 (5.8)		-	100.0 %	0.0 [ -2.22, 2.22 ]
Subtotal (95% CI)	60		58				100.0 %	0.0 [ -2.22, 2.22 ]
Heterogeneity: not applicab	ble							
Test for overall effect: $Z = 0$	0.0 (P = 1.0	))						
3 Fifth post-operative day								
Chen 2006	60	19 (6)	58	19 (6.2)		┣─	100.0 %	0.0 [ -2.20, 2.20 ]
					4 2 0	2 4		
					Favours HV/F	Eavours PTC		
					TavousTIVE	Tavodisi i C		(Continued )

Methods of vascular occlusion for elective liver resections (Review)

Study or subgroup	HVE N	Mean(SD)	PTC N	Mean(SD)	Mean Difference IV,Fixed,95% Cl	Weight	( Continued) Mean Difference IV,Fixed,95% CI
Subtotal (95% CI) Heterogeneity: not applicabl Test for overall effect: Z = 0 Test for subgroup difference	<b>60</b> e .0 (P = 1 s: Chi <sup>2</sup> =	0) 3.48, df = 2 (P =	<b>58</b> 0.18), 1 <sup>2</sup> =4	3%	-	100.0 %	0.0 [ -2.20, 2.20 ]
					-4 -2 0 2 4 Favours HVE Favours PTC		
Review: Methods of vascu Comparison: I Hepatic va Outcome: 10 Bilirubin (m	ılar occlu: ascular ex icromole.	sion for elective li cclusion (HVE) ver /litre)	ver resectior rsus portal t	ns riad clamping (P	TC)		
Study or subgroup	HVE N	Mean(SD)	PTC N	Mean(SD)	Mean Difference IV,Fixed,95% Cl	Weight	Mean Difference IV,Fixed,95% CI
<ul> <li>I First post-operative day Chen 2006</li> <li>Subtotal (95% CI)</li> <li>Heterogeneity: not applicable</li> <li>Test for overall effect: Z = 2</li> </ul>	60 <b>60</b> e .07 (P =	26 (8.9) 0.038)	58 <b>58</b>	29.4 (8.9)		100.0 % <b>100.0 %</b>	-3.40 [ -6.61, -0.19 ] - <b>3.40 [ -6.61, -0.19 ]</b>
					-4 -2 0 2 4 Favours HVE Favours PTC		

Comparison: I Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC)

Outcome: 10 Bilirubin (micromole/litre)

Study or subgroup	HVE N	Mean(SD)	PTC N	Mean(SD)	Mean Difference IV,Fixed,95% CI	Weight	Mean Difference IV,Fixed,95% Cl
2 Third post-operative day	(0)	22 4 4 5				100.0.0/	
Chen 2006	60	23.1 (6.5)	58	23.1 (5.8)		100.0 %	0.0 [ -2.22, 2.22 ]
Subtotal (95% CI)	60		58		•	100.0 %	0.0 [ -2.22, 2.22 ]
Heterogeneity: not applicabl	e 0 (P – 1 (	າ					
lest for overall effect. Z = 0	.0 (1 – 1.0	))					
					-4 -2 0 2 4		
					Favours HVE Favours PTC		
Review: Methods of vascu	ılar occlusi	ion for elective liv	ver resections				
Comparison: I Hepatic va	iscular exc	clusion (HVE) ver	rsus portal tria	ad clamping (PTC	)		
Outcome: 10 Bilinubin (m	icromole/l	itre)					
Study or subgroup	HVE		PTC		Mean Difference	Weight	Mean Difference
, , ,	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fixed,95% CI	0	IV,Fixed,95% CI
3 Fifth post-operative day							
Chen 2006	60	19 (6)	58	19 (6.2)		100.0 %	0.0 [ -2.20, 2.20 ]
Subtotal (95% CI)	60		58			100.0 %	00[-220 220]
Heterogeneity: not applicabl	e		)0			100.0 /0	0.0 [ -2.20, 2.20 ]
Test for overall effect: $Z = 0$	.0 (P = 1.0	))					
					-4 -2 0 2 4		
					Favours HVE Favours PTC		
					Favours HVE Favours PTC		
					Favours HVE Favours PTC		
					Favours HVE Favours PTC		
					Favours HVE Favours PTC		
					Favours HVE Favours PTC		
					Favours HVE Favours PTC		
					Favours HVE Favours PTC		

Methods of vascular occlusion for elective liver resections (Review)

Copyright @ 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

#### Analysis 1.11. Comparison I Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome II Prothrombin activity (percentage of normal).

Review: Methods of vascular occlusion for elective liver resections

Comparison: I Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC)

Outcome: II Prothrombin activity (percentage of normal)

Study or subgroup	HVE		PTC		Me	an Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fix	ed,95% Cl		IV,Fixed,95% CI
First post-operative day								
Belghiti 1996	24	-42 (12)	20	-47 (14)		<b>-</b>	100.0 %	5.00 [ -2.79, 12.79 ]
Subtotal (95% CI)	24		20			•	100.0 %	5.00 [ -2.79, 12.79 ]
Heterogeneity: not applicab	le							
Test for overall effect: $Z = I$	.26 (P = 0	.21)						
2 Fifth post-operative day								
Belghiti 1996	20	-63 (16)	20	-68 (15)			100.0 %	5.00 [ -4.61, 14.61 ]
Subtotal (95% CI)	20		20			•	100.0 %	5.00 [ -4.61, 14.61 ]
Heterogeneity: not applicab	le							
Test for overall effect: $Z = I$	.02 (P = 0	.31)						
Test for subgroup difference	es: $Chi^2 = 0$	0.0, df = 1 (P = 1.	00), l <sup>2</sup> =0.0	)%				
					-20 -10	0 10 20		
					Favours HVE	Favours PTC		

Review: Methods of vascular occlusion for elective liver resections

Comparison: I Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC)

Outcome: II Prothrombin activity (percentage of normal)

Study or subgroup	HVE		PTC		Mea	n Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fixe	ed,95% Cl		IV,Fixed,95% CI
I First post-operative day								
Belghiti 1996	24	-42 (12)	20	-47 (14)	-		100.0 %	5.00 [ -2.79, 12.79 ]
Subtotal (95% CI)	24		20			•	100.0 %	5.00 [ -2.79, 12.79 ]
Heterogeneity: not applicab	le							
Test for overall effect: $Z = I$	.26 (P = 0	0.21)						
					-20 -10	0 10 20		
					Favours HVE	Favours PTC		

Comparison: I Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC)

Outcome: II Prothrombin activity (percentage of normal)

Study or subgroup	HVE		PTC		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fixed,95% CI		IV,Fixed,95% CI
2 Fifth post-operative day Belghiti 1996	20	-63 (16)	20	-68 (15)		100.0 %	5.00 [ -4.61, 14.61 ]
Subtotal (95% CI)	20		20		-	100.0 %	5.00 [ -4.61, 14.61 ]
Heterogeneity: not applicab	ole						
Test for overall effect: Z =	I.02 (P =	0.31)					
					-20 -10 0 10 20	)	
					Favours HVE Favours PTC		

#### Analysis 1.12. Comparison I Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 12 AST (aspartate transaminase) (IU/litre).

Review: Methods of vascular occlusion for elective liver resections

Comparison: I Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC)

Outcome: 12 AST (aspartate transaminase) (IU/litre)

Study or subgroup	HVE		PTC		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fixed,95% CI		IV,Fixed,95% CI
I First post-operative day							
Belghiti 1996	24	352 (235)	20	268 (240)		30.1 %	84.00 [ -57.08, 225.08 ]
Chen 2006	60	530 (230)	58	570 (280)		69.9 %	-40.00 [ -132.63, 52.63 ]
Subtotal (95% CI)	84		78		-	100.0 %	-2.65 [ -80.08, 74.78 ]
Heterogeneity: $Chi^2 = 2.07$	7, df = 1 (F	$P = 0.15$ ; $I^2 = 525$	%				
Test for overall effect: Z =	0.07 (P =	0.95)					
2 Third post-operative day							
Chen 2006	60	280 (110)	58	340 (70)		100.0 %	-60.00 [ -93.15, -26.85 ]
Subtotal (95% CI)	60		58		•	100.0 %	-60.00 [ -93.15, -26.85 ]
Heterogeneity: not applical	ble						
Test for overall effect: Z =	3.55 (P =	0.00039)					
3 Fifth post-operative day							
Belghiti 1996	24	50 (23)	20	51 (21)	-	73.9 %	-1.00 [ -14.01, 12.01 ]
					-200 -100 0 100 200		
					Favours HVE Favours PTC		(Continued)

Methods of vascular occlusion for elective liver resections (Review)

Study or subgroup	HVE N	Mean(SD)	PTC N	Mean(SD)	Mean Difference IV,Fixed,95% Cl	Weight	( Continued) Mean Difference IV,Fixed,95% Cl
Chen 2006	60	80 (70)	58	110 (50)	-	26.1 %	-30.00 [ -51.89, -8.11 ]
Subtotal (95% CI) Heterogeneity: $Chi^2 = 4.98$ , Test for overall effect: $Z = 1$ Test for subgroup difference	<b>84</b> df = 1 (f .50 (P = es: $Chi^2$ =	P = 0.03); I <sup>2</sup> =80 0.13) • 8.38, df = 2 (P =	<b>78</b> % = 0.02), I <sup>2</sup> =	=76%	•	100.0 %	-8.57 [ -19.76, 2.61 ]
					-200 -100 0 100 200 Favours HVE Favours PTC	)	
Review: Methods of vasce Comparison: I Hepatic v Outcome: I2 AST (aspar	ular occlu ascular ex tate tran	sion for elective kclusion (HVE) ve saminase) (IU/litr	liver resecti ersus porta e)	ions I triad clamping	(PTC)		
Study or subgroup	HVE N	Mean(SD)	PTC N	Mean(SD)	Mean Difference IV,Fixed,95% Cl	Weight	Mean Difference IV,Fixed,95% Cl
I First post-operative day Belghiti 1996	24	352 (235)	20	268 (240)		30.1 %	84.00 [ -57.08, 225.08 ]
Chen 2006	60	530 (230)	58	570 (280)		69.9 %	-40.00 [ -132.63, 52.63 ]
Subtotal (95% CI) Heterogeneity: Chi <sup>2</sup> = 2.07, Test for overall effect: Z = 0	<b>84</b> . df = 1 (1 0.07 (P =	P = 0.15); l <sup>2</sup> =52 0.95)	78 %		-200 -100 0 100 2 Favours HVE Favours PTC	100.0 %	-2.65 [ -80.08, 74.78 ]

Comparison: I Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC)

Outcome: 12 AST (aspartate transaminase) (IU/litre)



#### Analysis 1.13. Comparison I Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC), Outcome 13 ALT (alanine transaminase) (IU/litre).

Review: Methods of vascular occlusion for elective liver resections

Comparison: I Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC)

Outcome: 13 ALT (alanine transaminase) (IU/litre)

Study or subgroup	HVE N	Mean(SD)	PTC N	Mean(SD)	Mean Difference IV,Fixed,95% CI	Weight	Mean Difference IV,Fixed,95% Cl
l First post-operative day Chen 2006	60	630 (400)	58	760 (460)		100.0 %	-130.00 [ -285.75, 25.75 ]
Subtotal (95% CI)	60		58		•	100.0 %	-130.00 [ -285.75, 25.75 ]
Heterogeneity: not applicat Test for overall effect: $Z =$	ble 1.64 (P =	0.10)					
2 Third post-operative day Chen 2006	60	480 (280)	58	710 (360)	-	100.0 %	-230.00 [ -346.63, -113.37 ]
Subtotal (95% CI) Heterogeneity: not applicat	60 ble		58		•	100.0 %	-230.00 [ -346.63, -113.37 ]
Test for overall effect: $Z =$ 3 Fifth post-operative day	3.87 (P =	0.00011)					
Chen 2006	60	350 (220)	58	350 (200)	-	100.0 %	0.0 [ -75.82, 75.82 ]
Subtotal (95% CI)	60		58		+	100.0 %	0.0 [ -75.82, 75.82 ]
Heterogeneity: not applicat Test for overall effect: Z =	ble 0.0 (P =	1.0)					
Test for subgroup difference	es: Chi <sup>2</sup> =	= 11.02, df = 2 (	(P = 0.00)	), I <sup>2</sup> =82%			
					-500 -250 0 250	500	
					Favours HVE Favours P	TC	

Comparison: I Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC)

Outcome: 13 ALT (alanine transaminase) (IU/litre)



Methods of vascular occlusion for elective liver resections (Review)

Comparison: I Hepatic vascular exclusion (HVE) versus portal triad clamping (PTC)

Outcome: 13 ALT (alanine transaminase) (IU/litre)

Study or subgroup	HVE		PTC		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fixed,95% CI		IV,Fixed,95% CI
3 Fifth post-operative day							
Chen 2006	60	350 (220)	58	350 (200)		100.0 %	0.0 [ -75.82, 75.82 ]
Subtotal (95% CI)	60		58		+	100.0 %	0.0 [ -75.82, 75.82 ]
Heterogeneity: not applicab	ole						
Test for overall effect: $Z = 0$	0.0 (P = 1	.0)					
						1	
					-500 -250 0 250 5	500	
					Favours HVE Favours PT	с	

#### Analysis 2.1. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome I Mortality.

Review: Methods of vascular occlusion for elective liver resections

Comparison: 2 Portal triad clamping: 'continuous' versus 'intermittent'

Outcome: I Mortality

-

-

Study or subgroup	Continuous	Intermittent	Risk Ratic	weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95%	CI	M-H,Fixed,95% Cl
Belghiti 1999	2/42	0/44		48.8 %	5.23 [ 0.26,   05.89 ]
Capussotti 2003	2/18	0/17		- 51.2 %	4.74 [ 0.24, 92.07 ]
Total (95% CI)	60	61	-	100.0 %	4.98 [ 0.60, 41.14 ]
Total events: 4 (Continuo	us), 0 (Intermittent)				
Heterogeneity: $Chi^2 = 0.0$	00, df = 1 (P = 0.96); $I^2$	=0.0%			
Test for overall effect: Z =	= 1.49 (P = 0.14)				
			0.0010 0.1 1.0 10.0	1000.0	
			Favours continuous Favours	s intermittent	

# Analysis 2.2. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 2 Liver failure.

Review: Methods of vascular occlusion for elective liver resections

Comparison: 2 Portal triad clamping: 'continuous' versus 'intermittent'

Outcome: 2 Liver failure

.

Study or subgroup	Continuous	Intermittent		Risk Ratio		Risk Ratio
	n/N	n/N		M-H,Fixed,95% CI		M-H,Fixed,95% CI
Belghiti 1999	4/42	0/44		-	48.8 %	9.42 [ 0.52, 169.76 ]
Capussotti 2003	1/18	0/17			51.2 %	2.84 [ 0.12, 65.34 ]
Total (95% CI)	60	61			100.0 %	6.05 [ 0.76, 48.20 ]
Total events: 5 (Continuo	us), 0 (Intermittent)					
Heterogeneity: $Chi^2 = 0.3$	$BI, df = I (P = 0.58); I^2$	=0.0%				
Test for overall effect: Z =	= 1.70 (P = 0.089)					
			0.0010	0.1 1.0 10.0	1000.0	

Favours continuous Favours intermittent

#### Analysis 2.3. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 3 Perioperative morbidity.

Review: Methods of vascular occlusion for elective liver resections

Comparison: 2 Portal triad clamping: 'continuous' versus 'intermittent'

Outcome: 3 Peri-operative morbidity

Study or subgroup	Continuous	Intermittent	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl	-	M-H,Fixed,95% CI
I Re-operation					
Belghiti 1999	2/42	0/44		100.0 %	5.23 [ 0.26, 105.89 ]
Subtotal (95% CI)	42	44		100.0 %	5.23 [ 0.26, 105.89 ]
Total events: 2 (Continuous),	0 (Intermittent)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 1.0$	8 (P = 0.28)				
2 Abdominal collections					
Belghiti 1999	3/42	4/44		100.0 %	0.79 [ 0.19, 3.30 ]
Subtotal (95% CI)	42	44	•	100.0 %	0.79 [ 0.19, 3.30 ]
Total events: 3 (Continuous), •	4 (Intermittent)				
Heterogeneity: not applicable					
		(	0.0010 0.1 1.0 10.0 100	0.0	
		Fa	vours continuous Favours interm	ittent	
					(Continued )

Methods of vascular occlusion for elective liver resections (Review)

Study or subgroup	Continuous	Intermittent	Risk Ratio	Weight	( Continued) Risk Ratio
Test for some U offert 7 = 0	n/IN	n/IN	M-H,FIXed,95% CI		M-H,Fixed,95% CI
lest for overall effect: $\angle - 0$ .	33 (P – 0.74)				
3 Haematoma Belghiti 1999	1/42	1/44	<b></b>	100.0 %	1.05 [ 0.07, 16.21 ]
Subtotal (95% CI)	42	44	-	100.0 %	1.05 [ 0.07. 16.21 ]
Total events:   (Continuous).	.   (Intermittent)			10000 /0	1005 [ 0107, 10121 ]
Heterogeneity: not applicable	e				
Test for overall effect: $Z = 0$ .	03 (P = 0.97)				
4 Pulmonary complications					
Belghiti 1999	5/42	5/44	-	100.0 %	1.05 [ 0.33, 3.36 ]
Subtotal (95% CI)	42	44	+	100.0 %	1.05 [ 0.33, 3.36 ]
Total events: 5 (Continuous),	, 5 (Intermittent)				
Heterogeneity: not applicable	e				
Test for overall effect: $Z = 0$ .	08 (P = 0.94)				
5 Biliary fistula					
Belghiti 1999	1/42	1/44		100.0 %	1.05 [ 0.07, 16.21 ]
Subtotal (95% CI)	42	44	-	100.0 %	1.05 [ 0.07, 16.21 ]
Total events:   (Continuous),	, I (Intermittent)				
Heterogeneity: not applicable	e				
Test for overall effect: $Z = 0$ .	03 (P = 0.97)				
6 Pancreatitis			_		
Belghiti 1999	0/42	1/44		100.0 %	0.35 [ 0.01, 8.33 ]
Subtotal (95% CI)	42	44		100.0 %	0.35 [ 0.01, 8.33 ]
Total events: 0 (Continuous),	, I (Intermittent)				
Heterogeneity: not applicable	5				
Test for overall effect: $Z = 0$ .	65 (P = 0.52)				

0.0010 0.1 1.0 10.0 1000.0

Favours continuous Favours intermittent

Comparison: 2 Portal triad clamping: 'continuous' versus 'intermittent'

Outcome: 3 Peri-operative morbidity

Study or subgroup	Continuous	Intermittent		Risk Ratio		Weight	Risk Ratio
	n/N	n/N	1	M-H,Fixed,95% C	1		M-H,Fixed,95% Cl
I Re-operation							
Belghiti 1999	2/42	0/44				100.0 %	5.23 [ 0.26, 105.89 ]
Subtotal (95% CI)	42	44				100.0 %	5.23 [ 0.26, 105.89 ]
Total events: 2 (Continuous)	), 0 (Intermittent)						
Heterogeneity: not applicabl	le						
Test for overall effect: $Z = I$	.08 (P = 0.28)						
			0.0010	0.1 1.0 10.0	1000.0		

Favours continuous Favours intermittent

Review: Methods of vascular occlusion for elective liver resections

Comparison: 2 Portal triad clamping: 'continuous' versus 'intermittent'

Outcome: 3 Peri-operative morbidity

-

Study or subgroup	Continuous n/N	Intermittent n/N	М-Н,	Risk Ratic	) Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
2 Abdominal collections							
Belghiti 1999	3/42	4/44	-	-		100.0 %	0.79 [ 0.19, 3.30 ]
Subtotal (95% CI)	42	44	-	•		100.0 %	0.79 [ 0.19, 3.30 ]
Total events: 3 (Continuous),	4 (Intermittent)						
Heterogeneity: not applicable	2						
Test for overall effect: $Z = 0.1$	33 (P = 0.74)						
					i		
			0.0010 0.1	1.0 10.0	1000.0		
			Favours continuous	Favours	s intermittent		
Comparison: 2 Portal triad clamping: 'continuous' versus 'intermittent'

Outcome: 3 Peri-operative morbidity

Study or subgroup	Continuous n/N	Intermittent n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
3 Haematoma					
Belghiti 1999	1/42	1/44		100.0 %	1.05 [ 0.07, 16.21 ]
Subtotal (95% CI)	42	44	-	100.0 %	1.05 [ 0.07, 16.21 ]
Total events:   (Continuous),	(Intermittent)				
Test for overall effect: $Z = 0.03$	(P = 0.97)				
			0.0010 0.1 1.0 10.0 1000.0		
Review: Methods of vascular	occlusion for elective	e liver resections			
Comparison: 2 Portal triad cl	lamping: 'continuous'	versus 'intermittent	,		
Outcome: 3 Peri-operative m	norbidity				
Study or subgroup	Continuous	Intermittent	Risk Ratio	Weight	Risk Ratio
, 3 ,	n/N	n/N	M-H,Fixed,95% Cl	Ũ	M-H,Fixed,95% Cl
4 Pulmonary complications					
Belghiti 1999	5/42	5/44		100.0 %	1.05 [ 0.33, 3.36 ]
Subtotal (95% CI)	42	44	+	100.0 %	1.05 [ 0.33, 3.36 ]
Total events: 5 (Continuous), 5 Heterogeneity: not applicable	(Intermittent)				
Test for overall effect: $Z = 0.08$	(P = 0.94)				
			0.0010 0.1 1.0 10.0 1000.0 Favours continuous Favours intermittent		

Comparison: 2 Portal triad clamping: 'continuous' versus 'intermittent'

Outcome: 3 Peri-operative morbidity

Study or subgroup	Continuous n/N	Intermittent n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
5 Biliary fistula					, ,
Belghiti 1999	1/42	1/44	<b></b>	100.0 %	1.05 [ 0.07, 16.21 ]
Subtotal (95% CI)	42	44	-	100.0 %	1.05 [ 0.07, 16.21 ]
Total events:   (Continuous),	(Intermittent)				
Heterogeneity: not applicable Test for overall effect: Z = 0.03	(P = 0.97)				
	()				
			0.0010 0.1 1.0 10.0 1000.0		
			Favours continuous Favours intermittent		
Review: Methods of vascular	occlusion for elective	liver resections			
Comparison: 2 Portal triad c	lamping: 'continuous'	versus 'intermittent'			
Outcome: 3 Peri-operative r	norbidity				
Study or subgroup	Continuous	Intermittent	Risk Ratio	Weight	Risk Ratio
(5	n/IN	n/in	IM-H,FIXed,75% CI		M-H,FIXed,95% CI
6 Pancreatitis Belghiti 1999	0/42	1/44	<b>_</b>	100.0 %	0.35 [ 0.0], 8.33 ]
Subtotal (95% CI)	42	44		100.0 %	0 35 [0 01 8 33]
Total events: 0 (Continuous), 1	(Intermittent)			10000 /0	0.05 [ 0.01; 0.055 ]
Heterogeneity: not applicable					
Test for overall effect: $Z = 0.65$	(P = 0.52)				
			0.0010 0.1 1.0 10.0 1000.0		
			Favours continuous Favours intermittent		

### Analysis 2.4. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 4 Number needing transfusion.

Review: Methods of vascular occlusion for elective liver resections

Comparison: 2 Portal triad clamping: 'continuous' versus 'intermittent'

Outcome: 4 Number needing transfusion

Study or subgroup	Continuous	Intermittent	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% CI		M-H,Fixed,95% CI
Belghiti 1999	12/42	14/44	+	72.7 %	0.90 [ 0.47, 1.71 ]
Capussotti 2003	5/18	5/17		27.3 %	0.94 [ 0.33, 2.69 ]
Total (95% CI)	60	61	+	100.0 %	0.91 [ 0.53, 1.58 ]
Total events: 17 (Continuc	ous), 19 (Intermittent)				
Heterogeneity: $Chi^2 = 0.0$	I, df = I (P = 0.94); $I^2$	=0.0%			
Test for overall effect: $Z =$	0.33 (P = 0.74)				

0.0050 0.1 1.0 10.0 200.0 Favours continuous Favours intermittent

### Analysis 2.5. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 5 Number of units transfused.

Review: Methods of vascular occlusion for elective liver resections

Comparison: 2 Portal triad clamping: 'continuous' versus 'intermittent'

Outcome: 5 Number of units transfused

Study or subgroup	Continuous		Intermittent		Mean Differen	ce Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fixed,95% CI		IV,Fixed,95% CI
Belghiti 1999	42	3 (2.57)	44	2.3 (2.57)		29.2 %	0.70 [ -0.39, 1.79 ]
Capussotti 2003	18	0.5 (1)	17	0.5 (1.1)		70.8 %	0.0 [ -0.70, 0.70 ]
<b>Total (95% CI)</b> Heterogeneity: Chi <sup>2</sup> = Test for overall effect:	<b>60</b> = 1.13, df = 1 (P = Z = 0.68 (P = 0.	= 0.29);   <sup>2</sup> =    % 50)	61		-	100.0 %	0.20 [ -0.38, 0.79 ]
				-2 Favours	-I O I continuous Favours	2 intermittent	

# Analysis 2.6. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 6 Hospital stay (in days).

Review: Methods of vascular occlusion for elective liver resections

Comparison: 2 Portal triad clamping: 'continuous' versus 'intermittent'

Outcome: 6 Hospital stay (in days)



## Analysis 2.7. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 7 Operating time (in minutes).

Review: Methods c	of vascular occlu	sion for elective	liver resections					
Comparison: 2 Por	tal triad clampir	ng: 'continuous' v	versus 'intermitt	ent'				
Outcome: 7 Opera	ating time (in m	inutes)						
Study or subgroup	Continuous		Intermittent		Mean D	Difference	Weight	Mean Difference
	N	Mean(SD)	N	Mean(SD)	IV,Fixed,9	5% Cl		IV,Fixed,95% CI
Capussotti 2003	18	228.3 (86.9)	17	241.7 (78.1)			100.0 %	-13.40 [ -68.08, 41.28 ]
Total (95% CI)	18		17		-		100.0 %	-13.40 [ -68.08, 41.28 ]
Heterogeneity: not ap	plicable							
Test for overall effect:	Z = 0.48 (P =	0.63)						
							1	
				-2	00 -100 0	100 20	00	
				Favou	rs continuous	Favours inter	mittent	

## Analysis 2.8. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 8 Blood loss.

Review: Methods of vascular occlusion for elective liver resections

Comparison: 2 Portal triad clamping: 'continuous' versus 'intermittent'

Outcome: 8 Blood loss

Study or subgroup	Continuous	In	termittent		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fixed,95% CI		IV,Fixed,95% CI
l Transection							
Belghiti 1999	42	280 (230)	44	530 (400)		100.0 %	-250.00 [ -387.14, -112.86 ]
Subtotal (95% CI)	42		44		•	100.0 %	-250.00 [ -387.14, -112.86 ]
Heterogeneity: not applic	able						
Test for overall effect: Z =	= 3.57 (P = 0.0	00035)					
2 Operative							
Belghiti 1999	42	1180 (800)	44	1290 (900)		53.6 %	-110.00 [ -469.52, 249.52 ]
Capussotti 2003	18	733 (522)	17	732 (635)	<b>e</b>	46.4 %	1.00 [ -385.35, 387.35 ]
Subtotal (95% CI)	60		61		-	100.0 %	-58.49 [ -321.68, 204.71 ]
Heterogeneity: $Chi^2 = 0$ .	17, df = 1 (P =	= 0.68); l <sup>2</sup> =0.0%					
Test for overall effect: Z =	= 0.44 (P = 0.6	56)					
Test for subgroup differer	nces: $Chi^2 = 1$ .	60, df = 1 (P = 0	0.21), I <sup>2</sup> =37	%			
				1		1	
				-500	-250 0 250 5	00	

Favours continuous Favours intermittent

	Review:	Methods of	vascular	occlusion <sup>·</sup>	for elective	liver resections
--	---------	------------	----------	------------------------	--------------	------------------

Comparison: 2 Portal triad clamping: 'continuous' versus 'intermittent'

Outcome: 8 Blood loss

-

Study or subgroup	Continuous		Intermittent		Mea	n Difference	e Weight	Mean Difference
	N	Mean(SD)	N	Mean(SD)	IV,Fixe	d,95% CI		IV,Fixed,95% CI
I Transection					_			
Belghiti 1999	42	280 (230)	44	530 (400)			100.0 %	-250.00 [ -387.14, -112.86 ]
Subtotal (95% CI)	42		44		•		100.0 %	-250.00 [ -387.14, -112.86 ]
Heterogeneity: not applic	able							
Test for overall effect: Z =	= 3.57 (P = 0.0	00035)						
				-500	-250 0	250	500	
				Favours co	ontinuous	Favours in	ntermittent	

Comparison: 2 Portal triad clamping: 'continuous' versus 'intermittent'

Outcome: 8 Blood loss

-

Study or subgroup	Continuous		Intermittent		Mea	an Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fixe	ed,95% CI		IV,Fixed,95% CI
2 Operative								
Belghiti 1999	42	1180 (800)	44	1290 (900)		<u> </u>	53.6 %	-110.00 [ -469.52, 249.52 ]
Capussotti 2003	18	733 (522)	17	732 (635)			46.4 %	1.00 [ -385.35, 387.35 ]
Subtotal (95% CI)	60		61				100.0 %	-58.49 [ -321.68, 204.71 ]
Heterogeneity: $Chi^2 = 0$ .	17, df = 1 (P =	= 0.68); l <sup>2</sup> =0.0	1%					
Test for overall effect: Z =	= 0.44 (P = 0.6	66)						
							1	
				-5	500 -250	0 250	500	

Favours continuous

Favours intermittent

# Analysis 2.9. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 9 Bilirubin (micromole/litre).

Review: Methods of vascular occlusion for elective liver resections

Comparison: 2 Portal triad clamping: 'continuous' versus 'intermittent'

Outcome: 9 Bilirubin (micromole/litre)

Study or subgroup	Continuous		Intermittent		Μ	ean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fi	xed,95% Cl		IV,Fixed,95% CI
I First post-operative day								
Belghiti 1999	42	29 (22)	44	28 (20)		<b>.</b>	89.2 %	1.00 [ -7.90, 9.90 ]
Capussotti 2003	18	30.8 (42)	17	27.7 (35)			10.8 %	3.10 [ -22.46, 28.66 ]
Subtotal (95% CI)	60		61			•	100.0 %	1.23 [ -7.18, 9.63 ]
Heterogeneity: $Chi^2 = 0.0$	02, df = 1 (P = 0	.88); I <sup>2</sup> =0.0%						
Test for overall effect: Z =	= 0.29 (P = 0.77)							
2 Second post-operative	day							
Belghiti 1999	42	28 (22)	44	26 (21)		- <b>#</b>	100.0 %	2.00 [ -7.10, 11.10 ]
Subtotal (95% CI)	42		44			+	100.0 %	2.00 [ -7.10, 11.10 ]
Heterogeneity: not applica	able							
Test for overall effect: Z =	= 0.43 (P = 0.67)							
3 Third post-operative da	у							
					i	-	i	
				-2	0 -10	0 10 2	20	
				Favour	s continuous	Favours inter	rmittent	
								(Continued)

Methods of vascular occlusion for elective liver resections (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

	Continuous N	Mean(SD)	Intermittent N	Mean(SD)	Mean Difference IV,Fixed,95% CI	Weight	( Continued) Mean Difference IV,Fixed,95% Cl
Capussotti 2003	18	35.9 (42)	17	27.4 (35)		100.0 %	8.50 [ -17.06, 34.06 ]
Subtotal (95% CI) Heterogeneity: not applica	18 able		17			100.0 %	8.50 [ -17.06, 34.06 ]
Test for overall effect: Z =	• 0.65 (P = 0.51)						
4 Fifth post-operative day							
Belghiti 1999	42	35 (42)	44	25 (22)		100.0 %	10.00 [ -4.27, 24.27 ]
Subtotal (95% CI)	42		44			100.0 %	10.00 [ -4.27, 24.27 ]
Heterogeneity: not applica	able						
est for overall effect: $Z =$	: 1.37 (P = 0.17)						
Belghiti 1999	uay 42	32 (38)	44	26 (35)		70.1 %	6.00 [ -9.46, 21,46 ]
	24	27.5 (42)	17	274 (25)		200%	
	24	57.5 (42)	17	27.4 (55)		27.7 /0	
Subtotal (95% CI)	<b>66</b>	70) 12 -0.000	61			100.0 %	7.23 [ -5.71, 20.17 ]
Heterogeneity: $Chi^2 = 0.0$	$\sigma$ , at = 1 (P = 0.) = 1 09 (P = 0.27)	/ø); ı∸ =0.0%					
est for subgroup differen	$ces: Chi^2 = 1.64.$	df = 4 (P = 0	.80), l <sup>2</sup> =0.0%				
0			,				
Review: Methods of vas Comparison: 2 Portal tr Dutcome: 9 Bilirubin (r	scular occlusion fo riad clamping: 'co nicromole/litre)	or elective live	r resections us 'intermittent'				
Study or subgroup	Continuous	M(CD)	Intermittent	M(CD)	Mean Difference	Weight	Mean Difference
Study or subgroup	Continuous N	Mean(SD)	Intermittent N	Mean(SD)	Mean Difference IV,Fixed,95% CI	Weight	Mean Difference IV,Fixed,95% Cl
First post-operative day	Continuous N	Mean(SD)	Intermittent N	Mean(SD)	Mean Difference IV,Fixed,95% CI	Weight	Mean Difference IV,Fixed,95% CI
First post-operative day Belghiti 1999	Continuous N 42	Mean(SD) 29 (22)	Intermittent N 44	Mean(SD) 28 (20)	Mean Difference IV,Fixed,95% CI	Weight 89.2 %	Mean Difference IV,Fixed,95% CI 5 I.00 [ -7.90, 9.90 ]
First post-operative day Belghiti 1999 Capussotti 2003	Continuous N 42 18	Mean(SD) 29 (22) 30.8 (42)	Intermittent N 44 I7	Mean(SD) 28 (20) 27.7 (35)	Mean Difference IV,Fixed,95% CI	Weight 89.2 % 10.8 %	Mean Difference IV,Fixed,95% Cl I.00 [ -7.90, 9.90 ] 3.10 [ -22.46, 28.66 ]
First post-operative day Belghiti 1999 Capussotti 2003	Continuous N 42 18 <b>60</b>	Mean(SD) 29 (22) 30.8 (42)	Intermittent N 44 17 <b>61</b>	Mean(SD) 28 (20) 27.7 (35)	Mean Difference IV,Fixed,95% CI	Weight 89.2 % 10.8 % <b>100.0 %</b>	Mean Difference IV,Fixed,95% Cl 3.10 [ -7.90, 9.90 ] 3.10 [ -22.46, 28.66 ] <b>1.23 [ -7.18, 9.63 ]</b>
First post-operative day Belghiti 1999 Capussotti 2003 Subtotal (95% CI) Ieterogeneity: Chi <sup>2</sup> = 0.0	Continuous N 42 18 <b>60</b> 12, df = 1 (P = 0.1	Mean(SD) 29 (22) 30.8 (42) 88); I <sup>2</sup> =0.0%	Intermittent N 44 I7 <b>61</b>	Mean(SD) 28 (20) 27.7 (35)	Mean Difference IV,Fixed,95% CI	Weight 89.2 % 10.8 % <b>100.0 %</b>	Mean Difference IV,Fixed,95% Cl I.00 [ -7.90, 9.90 ] 3.10 [ -22.46, 28.66 ] I.23 [ -7.18, 9.63 ]
First post-operative day Belghiti 1999 Capussotti 2003 Subtotal (95% CI) Heterogeneity: Chi <sup>2</sup> = 0.0 iest for overall effect: Z =	Continuous N 42 18 60 )2, df = 1 (P = 0.: : 0.29 (P = 0.77)	Mean(SD) 29 (22) 30.8 (42) 88); I <sup>2</sup> =0.0%	Intermittent N 44 17 <b>61</b>	Mean(SD) 28 (20) 27.7 (35)	Mean Difference IV,Fixed,95% CI	Weight 89.2 % 10.8 %	Mean Difference IV,Fixed,95% Cl 1.00 [ -7.90, 9.90 ] 3.10 [ -22.46, 28.66 ] 1.23 [ -7.18, 9.63 ]
Study or subgroup First post-operative day Belghiti 1999 Capussotti 2003 Subtotal (95% CI) Heterogeneity: Chi <sup>2</sup> = 0.0 Test for overall effect: Z =	Continuous N 42 18 60 12, df = 1 (P = 0.77) : 0.29 (P = 0.77)	Mean(SD) 29 (22) 30.8 (42) 88); I <sup>2</sup> =0.0%	Intermittent N 44 17 <b>61</b>	Mean(SD) 28 (20) 27.7 (35)	Mean Difference IV,Fixed,95% CI	Weight 89.2 % 10.8 %	Mean Difference IV,Fixed,95% Cl 1.00 [ -7.90, 9.90 ] 3.10 [ -22.46, 28.66 ] 1.23 [ -7.18, 9.63 ]
Study or subgroup First post-operative day Belghiti 1999 Capussotti 2003 Subtotal (95% CI) Heterogeneity: Chi <sup>2</sup> = 0.0 Fest for overall effect: Z =	Continuous N 42 18 <b>60</b> 12, df = 1 (P = 0.77) : 0.29 (P = 0.77)	Mean(SD) 29 (22) 30.8 (42) 88); I <sup>2</sup> =0.0%	Intermittent N 44 17 <b>61</b>	Mean(SD) 28 (20) 27.7 (35) -20	Mean Difference IV,Fixed,95% CI	Weight 89.2 % 10.8 % 100.0 %	Mean Difference IV,Fixed,95% CI I.00 [ -7.90, 9.90 ] 3.10 [ -22.46, 28.66 ] I.23 [ -7.18, 9.63 ]
Study or subgroup I First post-operative day Belghiti 1999 Capussotti 2003 Subtotal (95% CI) Heterogeneity: Chi <sup>2</sup> = 0.0 Fest for overall effect: Z =	Continuous N 42 18 60 )2, df = 1 (P = 0.: : 0.29 (P = 0.77)	Mean(SD) 29 (22) 30.8 (42) 88); I <sup>2</sup> =0.0%	Intermittent N 44 17 <b>61</b>	Mean(SD) 28 (20) 27.7 (35) -20 Favours	Mean Difference IV,Fixed,95% CI	Weight 89.2 % 10.8 % 100.0 %	Mean Difference IV,Fixed,95% Cl I.00 [ -7.90, 9.90 ] 3.10 [ -22.46, 28.66 ] I.23 [ -7.18, 9.63 ]
Study or subgroup I First post-operative day Belghiti 1999 Capussotti 2003 Subtotal (95% CI) Heterogeneity: Chi <sup>2</sup> = 0.0 Test for overall effect: Z =	Continuous N 42 18 60 12, df = 1 (P = 0.77) : 0.29 (P = 0.77)	Mean(SD) 29 (22) 30.8 (42) 88); I <sup>2</sup> =0.0%	Intermittent N 44 17 <b>61</b>	Mean(SD) 28 (20) 27.7 (35) -20 Favours	Mean Difference IV,Fixed,95% CI	Weight 89.2 % 10.8 % 100.0 % 20 ermittent	Mean Difference IV,Fixed,95% CI 3.10 [ -7.90, 9.90 ] 3.10 [ -22.46, 28.66 ] 1.23 [ -7.18, 9.63 ]
I First post-operative day Belghiti 1999 Capussotti 2003 Subtotal (95% CI) Heterogeneity: Chi <sup>2</sup> = 0.0 Test for overall effect: Z =	Continuous N 42 18 <b>60</b> 12, df = 1 (P = 0. : 0.29 (P = 0.77)	Mean(SD) 29 (22) 30.8 (42) 88); I <sup>2</sup> =0.0%	Intermittent N 44 17 <b>61</b>	Mean(SD) 28 (20) 27.7 (35) -20 Favours	Mean Difference IV,Fixed,95% CI	Weight 89.2 % 10.8 % 100.0 % 20 ermittent	Mean Difference IV,Fixed,95% Cl 3 I.00 [ -7.90, 9.90 ] 3 I.0 [ -22.46, 28.66 ] 4 <b>1.23 [ -7.18, 9.63 ]</b>
I First post-operative day Belghiti 1999 Capussotti 2003 Subtotal (95% CI) Heterogeneity: Chi <sup>2</sup> = 0.0 Test for overall effect: Z =	Continuous N 42 18 <b>60</b> )2, df = 1 (P = 0. : 0.29 (P = 0.77)	Mean(SD) 29 (22) 30.8 (42) 88); I <sup>2</sup> =0.0%	Intermittent N 44 17 <b>61</b>	Mean(SD) 28 (20) 27.7 (35) -20 Favours	Mean Difference IV,Fixed,95% CI	Weight 89.2 % 10.8 % 100.0 % 20 ermittent	Mean Difference IV,Fixed,95% Cl 3 I.00 [ -7.90, 9.90 ] 3 I.10 [ -22.46, 28.66 ] 1.23 [ -7.18, 9.63 ]
Study or subgroup I First post-operative day Belghiti 1999 Capussotti 2003 Subtotal (95% CI) -leterogeneity: Chi <sup>2</sup> = 0.0 Test for overall effect: Z =	Continuous N 42 18 <b>60</b> )2, df = 1 (P = 0. : 0.29 (P = 0.77)	Mean(SD) 29 (22) 30.8 (42) 88); I <sup>2</sup> =0.0%	Intermittent N 44 17 <b>61</b>	Mean(SD) 28 (20) 27.7 (35) -20 Favours	Mean Difference IV,Fixed,95% CI	Weight 89.2 % 10.8 % <b>100.0 %</b> 20 ermittent	Mean Difference IV,Fixed,95% Cl I.00 [ -7.90, 9.90 ] 3.10 [ -22.46, 28.66 ] I.23 [ -7.18, 9.63 ]
Study or subgroup I First post-operative day Belghiti 1999 Capussotti 2003 Subtotal (95% CI) -leterogeneity: Chi <sup>2</sup> = 0.0 Test for overall effect: Z = ethods of vascular occ and the subscripts of the su	Continuous N 42 18 60 )2, df = 1 (P = 0. : 0.29 (P = 0.77)	Mean(SD) 29 (22) 30.8 (42) 88); I <sup>2</sup> =0.0% :tive liver reasons in a second	Intermittent N 44 17 61 sections (Revie	Mean(SD) 28 (20) 27.7 (35) -20 Favours	Mean Difference IV,Fixed,95% Cl	Weight 89.2 % 10.8 % 100.0 %	Mean Difference IV,Fixed,95% Cl 3.100 [-7.90, 9.90 ] 3.10 [-22.46, 28.66 ] 1.23 [-7.18, 9.63 ]
Study or subgroup First post-operative day Belghiti 1999 Capussotti 2003 Subtotal (95% CI) -leterogeneity: Chi <sup>2</sup> = 0.0 Test for overall effect: Z = for overall effect: Z = ethods of vascular occopyright © 2009 The o	Continuous N 42 18 60 )2, df = 1 (P = 0. : 0.29 (P = 0.77) : 0.29 (P = 0.77)	Mean(SD) 29 (22) 30.8 (42) 88); I <sup>2</sup> =0.0%	Intermittent N 44 17 61 sections (Revie 'ublished by Jol	Mean(SD) 28 (20) 27.7 (35) -20 Favours ***) hn Wiley & Sons	Mean Difference IV,Fixed,95% CI	Weight 89.2 % 10.8 % 100.0 % 20 ermittent	Mean Difference IV,Fixed,95% Cl 3.10 [ -7.90, 9.90 ] 3.10 [ -22.46, 28.66 ] 4.1.23 [ -7.18, 9.63 ]
Study or subgroup First post-operative day Belghiti 1999 Capussotti 2003 Subtotal (95% CI) Heterogeneity: Chi <sup>2</sup> = 0.0 Fest for overall effect: Z = Est for overall effect: Z = ethods of vascular occ pyright © 2009 The o	Continuous N 42 18 60 )2, df = 1 (P = 0. : 0.29 (P = 0.77) : 0.29 (P = 0.77)	Mean(SD) 29 (22) 30.8 (42) 88); I <sup>2</sup> =0.0%	Intermittent N 44 17 61 sections (Revie 'ublished by Jol	Mean(SD) 28 (20) 27.7 (35) -20 Favours ***) hn Wiley & Sons	Mean Difference IV,Fixed,95% CI	Weight 89.2 % 10.8 % 100.0 %	Mean Difference IV,Fixed,95% CI 3.10 [ -7.90, 9.90 ] 3.10 [ -22.46, 28.66 ] 4.1.23 [ -7.18, 9.63 ]
First post-operative day Belghiti 1999 Capussotti 2003 Subtotal (95% CI) Heterogeneity: Chi <sup>2</sup> = 0.0 Test for overall effect: Z =	Continuous N 42 18 60 )2, df = 1 (P = 0. : 0.29 (P = 0.77) clusion for elect Cochrane Collis	Mean(SD) 29 (22) 30.8 (42) 88); I <sup>2</sup> =0.0%	Intermittent N 44 17 61 sections (Revie 'ublished by Jol	Mean(SD) 28 (20) 27.7 (35) -20 Favours Sw) hn Wiley & Sons	Mean Difference IV,Fixed,95% CI	Weight 89.2 % 10.8 % 100.0 %	Mean Difference IV,Fixed,95% Cl 3.10 [-7.90, 9.90 ] 3.10 [-22.46, 28.66 ] 4.23 [-7.18, 9.63 ]

Comparison: 2 Portal triad clamping: 'continuous' versus 'intermittent'

Outcome: 9 Bilirubin (micromole/litre)

Study or subgroup	Continuous N	Mean(SD)	Intermittent N	Mean(SD)	Mean Difference IV,Fixed,95% Cl	Weight	Mean Difference IV,Fixed,95% CI
2 Second post-operative da Belghiti 1999	ay 42	28 (22)	44	26 (21)	-	100.0 %	2.00 [ -7.10, 11.10 ]
<b>Subtotal (95% CI)</b> Heterogeneity: not applicab Test for overall effect: Z = 0	<b>42</b> ble 0.43 (P = 0.67)	)	44		•	100.0 %	2.00 [ -7.10, 11.10 ]
				-2	0 -10 0 10 2	D	
				Favour	s continuous Favours inter	mittent	
Review: Methods of vasc	ular occlusion	for elective liv	ver resections				
Comparison: 2 Portal tria	ad clamping: 'co	ontinuous' vei	rsus 'intermittent'				
Outcome: 9 Bilirubin (mi	icromole/litre)						
Study or subgroup	Continuous N	Mean(SD)	Intermittent N	Mean(SD)	Mean Difference IV,Fixed,95% CI	Weight	Mean Difference IV,Fixed,95% CI
3 Third post-operative day Capussotti 2003	18	35.9 (42)	17	27.4 (35)		100.0 %	8.50 [ -17.06, 34.06 ]
<b>Subtotal (95% CI)</b> Heterogeneity: not applicab Test for overall effect: Z = 0	<b>18</b> ble 0.65 (P = 0.51)	)	17			100.0 %	8.50 [ -17.06, 34.06 ]
				-20	-10 0 10 20		
				Favours	continuous Favours intern	nittent	

Comparison: 2 Portal triad clamping: 'continuous' versus 'intermittent'

Outcome: 9 Bilirubin (micromole/litre)

Study or subgroup	Continuous N	Mean(SD)	Intermittent N	Mean(SD)	Mean Difference IV,Fixed,95% Cl	Weight	Mean Difference IV,Fixed,95% Cl
4 Fifth post-operative day Belghiti 1999	42	35 (42)	44	25 (22)		100.0 %	10.00 [ -4.27, 24.27 ]
Subtotal (95% CI)	42		44		-	100.0 %	10.00 [ -4.27, 24.27 ]
Test for overall effect: $Z = 1$	.37 (P = 0.17	)					
				-20	-10 0 10 20	)	
				Favours	continuous Favours interr	nittent	
Review: Methods of vascu	ular occlusion	for elective live	er resections				
Comparison: 2 Portal tria	d clamping: 'c	ontinuous' ver	sus intermittent				
	cromole/litre)						
Study or subgroup	Continuous N	Mean(SD)	Intermittent N	Mean(SD)	Mean Difference IV,Fixed,95% Cl	Weight	Mean Difference IV,Fixed,95% CI
5 Seventh post-operative da	ay 42	32 (38)	44	26 (35)		70   %	600 [ 946 2146 ]
Capussotti 2003	24	37.5 (42)	17	27.4 (35)		29.9 %	10.10 [ -13.55, 33.75 ]
Subtotal (95% CI)	66		61		-	100.0 %	7.23 [ -5.71, 20.17 ]
Heterogeneity: $Chi^2 = 0.08$ ,	df = 1 (P = 0)	0.78); l <sup>2</sup> =0.0%					
lest for overall effect. Z = 1	.07 (1 - 0.27	)					
				-2 Eavour	0 -10 0 10 2 s continuous Eavours inter	20 rmittent	

### Analysis 2.10. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 10 Prothrombin activity (percentage of normal).

Review: Methods of vascular occlusion for elective liver resections

Comparison: 2 Portal triad clamping: 'continuous' versus 'intermittent'

Outcome: 10 Prothrombin activity (percentage of normal)

Study or subgroup	Continuous N	Mean(SD)	Intermittent N	Mean(SD)	Mean Difference IV,Fixed,95% CI	Weight	Mean Difference IV,Fixed,95% Cl
First post-operative day	,						
Belghiti 1999	42	-57 (13)	44	-59 (15)		77.3 %	2.00 [ -3.92, 7.92 ]
Capussotti 2003	18	-72 (17)	17	-67 (16)		22.7 %	-5.00 [ -15.93, 5.93 ]
Subtotal (95% CI)	60		61		-	100.0 %	0.41 [ -4.80, 5.62 ]
Heterogeneity: $Chi^2 = 1.2$	22, df = 1 (P = 0	.27); I <sup>2</sup> = I 8%					
Test for overall effect: Z =	= 0.15 (P = 0.88) dav						
Belghiti 1999	42	-60 (16)	44	-59 (16)		100.0 %	-1.00 [ -7.76, 5.76 ]
Subtotal (95% CI)	42		44		-	100.0 %	-1.00 [ -7.76, 5.76 ]
Heterogeneity: not applica	able						
Test for overall effect: Z =	= 0.29 (P = 0.77)						
Capussotti 2003	18	-76 (17)	17	-68 (16)		100.0 %	-8.00 [ -18.93, 2.93 ]
Subtotal (95% CI)	18		17			100.0 %	-8.00 [ -18.93, 2.93 ]
Heterogeneity: not applica	able						
Test for overall effect: Z = 4 Fifth post-operative day	= 1.43 (P = 0.15) ,						
Belghiti 1999	42	-77 (16)	44	-77 (16)		100.0 %	0.0 [ -6.76, 6.76 ]
Subtotal (95% CI)	42		44		-	100.0 %	0.0 [ -6.76, 6.76 ]
Heterogeneity: not applic	able						
Iest for overall effect: $\angle =$ 5 Seventh post-operative	= 0.0 (P = 1.0) dav						
Belghiti 1999	42	-76 (17)	44	-76 (14)		73.3 %	0.0 [ -6.60, 6.60 ]
Capussotti 2003	18	-78 (17)	17	-68 (16) -		26.7 %	-10.00 [ -20.93, 0.93 ]
Subtotal (95% CI)	60		61		-	100.0 %	-2.67 [ -8.32, 2.98 ]
Heterogeneity: $Chi^2 = 2.3$	36, df = 1 (P = 0	.12); I <sup>2</sup> =58%					
Test for overall effect: Z =	= 0.93 (P = 0.35) aces: Chi <sup>2</sup> = 2.23	df = 4 (P = 0)	(9) $l^2 = 0.0\%$				
	2.23		, 0.070				
				-20	-10 0 10 2	0	
				Favours o	continuous Favours inter	mittent	

Comparison: 2 Portal triad clamping: 'continuous' versus 'intermittent'

Outcome: 10 Prothrombin activity (percentage of normal)

Study or subgroup	Continuous N	Mean(SD)	Intermittent N	Mean(SD)	Mean Difference IV,Fixed,95% CI	Weight	Mean Difference IV,Fixed,95% Cl
L First post-operative day							
Belghiti 1999	42	-57 (13)	44	-59 (15)	<b></b>	77.3 %	2.00 [ -3.92, 7.92 ]
Capussotti 2003	18	-72 (17)	17	-67 (16)		22.7 %	-5.00 [ -15.93, 5.93 ]
Subtotal (95% CI)	60		61		-	100.0 %	0.41 [ -4.80, 5.62 ]
Heterogeneity: $Chi^2 = 1.22$ ,	, df = 1 (P = 0	.27); l <sup>2</sup> = l 8%	01			10010 /0	0.11 [ 1.00, 9.02 ]
Test for overall effect: $Z = 0$	0.15 (P = 0.88)						
				-20	) -10 0 10 24	0	
				Favours	continuous Pavours Inter	mittent	
Devision Matheada a forma		Coursello atticco llivo					
Review: Methods of Vasci	ular occlusion	for elective live	r resections				
Comparison: 2 Portal tria	ad clamping: 'co	ontinuous' vers	us 'intermittent'				
Outcome: 10 Prothromb	oin activity (per	centage of nor	mal)				
Study or subgroup	Continuous	Maap(SD)	Intermittent	Moon(SD)	Mean Difference	Weight	Mean Difference
	IN	riean(SD)	11	(SD)	IV,FIXEd,75% CI		IV,FIXEd,75% CI
2 Second post-operative da	19 12	(0,414)					
Belghiti 1999	// /					100.0.0/	
$\mathbf{C}_{\mathbf{n}} = \mathbf{L}_{\mathbf{n}} + \mathbf{L}_{\mathbf{n}} = $	72	-60 (16)	44	-59 (16)		100.0 %	-1.00 [ -7.76, 5.76 ]
Subtotal (95% CI)	42	-60 (16)	44 <b>44</b>	-59 (16)	-	100.0 % <b>100.0 %</b>	-1.00 [ -7.76, 5.76 ] -1.00 [ -7.76, 5.76 ]
Heterogeneity: not applicab Test for overall effect: Z = C	42 Ne 0.29 (P = 0.77)	-60 (16)	44 <b>44</b>	-59 (16)	-	100.0 %	-1.00 [ -7.76, 5.76 ] -1.00 [ -7.76, 5.76 ]
Heterogeneity: not applicab Test for overall effect: $Z = C$	<b>42</b> ble 0.29 (P = 0.77)	-60 (16)	44 <b>44</b>	-59 (16)		100.0 %	-1.00 [ -7.76, 5.76 ] -1.00 [ -7.76, 5.76 ]
Heterogeneity: not applicab Test for overall effect: Z = C	<b>42</b> ble 0.29 (P = 0.77)	-60 (16)	44 <b>44</b>	-59 (16)	-10 0 10 20	100.0 %	-1.00 [ -7.76, 5.76 ] -1.00 [ -7.76, 5.76 ]
Heterogeneity: not applicab Test for overall effect: Z = 0	<b>42</b> ble 0.29 (P = 0.77)	-60 (16)	44 44	-59 (16) -20 Favours o	-10 0 10 20 Favours intern	100.0 % 100.0 %	-1.00 [ -7.76, 5.76 ] -1.00 [ -7.76, 5.76 ]
Heterogeneity: not applicab Test for overall effect: Z = 0	42 42 0.29 (P = 0.77)	-60 (16)	44 <b>44</b>	-59 (16) -20 Favours o	-10 0 10 20 continuous Favours intern	100.0 % 100.0 %	-1.00 [ -7.76, 5.76 ] -1.00 [ -7.76, 5.76 ]
Heterogeneity: not applicab Test for overall effect: Z = C	42 de 0.29 (P = 0.77)	-60 (16)	44 44	-59 (16) -20 Favours o	-10 0 10 20 continuous Favours intern	100.0 % 100.0 %	-1.00 [ -7.76, 5.76 ] -1.00 [ -7.76, 5.76 ]
Heterogeneity: not applicab Test for overall effect: Z = 0	42 Ale 0.29 (P = 0.77)	-60 (16)	44 44	-59 (16) -20 Favours d	-10 0 10 20 continuous Favours intern	100.0 % 100.0 %	-1.00 [ -7.76, 5.76 ]
Heterogeneity: not applicab Test for overall effect: Z = 0	42 de 0.29 (P = 0.77)	-60 (16)	44 <b>44</b>	-59 (16) 	-10 0 10 20 continuous Favours intern	100.0 %	-1.00 [ -7.76, 5.76 ] -1.00 [ -7.76, 5.76 ]
Heterogeneity: not applicab Test for overall effect: Z = 0	42 de 0.29 (P = 0.77)	-60 (16)	44 44	-59 (16) -20 Favours (	-10 0 10 20 continuous Favours intern	100.0 %	-1.00 [ -7.76, 5.76 ] -1.00 [ -7.76, 5.76 ]
Heterogeneity: not applicab Test for overall effect: Z = 0	42 de 0.29 (P = 0.77)	-60 (16)	44 <b>44</b>	-59 (16) -20 Favours o	-10 0 10 20 continuous Favours intern	100.0 %	-1.00 [ -7.76, 5.76 ]

Comparison: 2 Portal triad clamping: 'continuous' versus 'intermittent'

Outcome: 10 Prothrombin activity (percentage of normal)



Methods of vascular occlusion for elective liver resections (Review)

Copyright  $\textcircled{\sc 0}$  2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Comparison: 2 Portal triad clamping: 'continuous' versus 'intermittent'

Outcome: 10 Prothrombin activity (percentage of normal)

Study or subgroup	Continuous		Intermittent			Mea	n Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)		IV,Fixe	d,95% Cl		IV,Fixed,95% CI
5 Seventh post-operative	day								
Belghiti 1999	42	-76 (17)	44	-76 (14)				73.3 %	0.0 [ -6.60, 6.60 ]
Capussotti 2003	18	-78 (17)	17	-68 (16)	_	-	-	26.7 %	-10.00 [ -20.93, 0.93 ]
Subtotal (95% CI)	60		61			-	-	100.0 %	-2.67 [ -8.32, 2.98 ]
Heterogeneity: $Chi^2 = 2$ .	36, df = 1 (P = 0	0.12); I <sup>2</sup> =58%							
Test for overall effect: Z =	= 0.93 (P = 0.35)	)							
							ı	1	
					-20	-10 (	) 10 2	20	
				Favo	ours cor	ntinuous	Favours inte	rmittent	

# Analysis 2.11. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 11 AST (aspartate transaminase) (IU/litre).

Review: Methods of vascular occlusion for elective liver resections

Comparison: 2 Portal triad clamping: 'continuous' versus 'intermittent'

Outcome: II AST (aspartate transaminase) (IU/litre)

Study or subgroup	Continuous		Intermittent		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fixed,95% CI		IV,Fixed,95% CI
I First post-operative day	/						
Belghiti 1999	42	294 (221)	44	264 (191)		86.4 %	30.00 [ -57.48,   7.48 ]
Capussotti 2003	18	240 (436)	17	340 (191)		13.6 %	-100.00 [ -320.94, 120.94 ]
Subtotal (95% CI)	60		61		+	100.0 %	12.38 [ -68.95, 93.72 ]
Heterogeneity: $Chi^2 = 1$ . Test for overall effect: Z =	I5, df = I (P = = 0.30 (P = 0.77	0.28); I <sup>2</sup> = I 3% 7)					
2 Second post-operative	day						
Belghiti 1999	42	301 (436)	44	167 (133)		100.0 %	34.00 [ -3.59, 27 .59 ]
Subtotal (95% CI)	42		44			100.0 %	134.00 [ -3.59, 271.59 ]
Test for overall effect: Z =	= 1.91 (P = 0.05	56)					
				-20	00 -100 0 100 2	00	
				Favour	s continuous Favours inte	rmittent	(Continued )

Study or subgroup	Continuous N	Mean(SD)	Intermittent N	Mean(SD)	Mean Difference IV,Fixed,95% CI	Weight	( Continued) Mean Difference IV,Fixed,95% Cl
3 Third post-operative day	10		17				
Capussotti 2003	10	110 (436)	17	150 (191)		100.0 %	-40.00 [ -260.94, 180.94 ]
Heterogeneity: not applica Test for overall effect: Z = 4 Fifth post-operative day	ble 0.35 (P = 0.72	2)	1/			100.0 % -4	0.00 [ -200.94, 180.94 ]
Belghiti 1999	42	70 (59)	44	62 (35)	-	100.0 %	8.00 [ -12.62, 28.62 ]
Subtotal (95% CI) Heterogeneity: not applica Test for overall effect: Z = 5 Seventh post-operative of	<b>42</b> ble 0.76 (P = 0.45 day	)	44		•	100.0 %	8.00 [ -12.62, 28.62 ]
Belghiti 1999	42	47 (23)	44	44 (24)		99.8 %	3.00 [ -6.93, 12.93 ]
Capussotti 2003	18	80 (436)	17	70 (191)		0.2 %	10.00 [ -210.94, 230.94 ]
Subtotal (95% CI) Heterogeneity: $Chi^2 = 0.0$	<b>60</b> D, df = 1 (P = 1	0.95); l <sup>2</sup> =0.09	<b>61</b>			100.0 %	3.01 [ -6.91, 12.94 ]
Test for overall effect: $Z =$	0.60 (P = 0.55	5)	2				
Review: Methods of vas Comparison: 2 Portal tr	cular occlusion iad clamping: 'c	for elective li	ver resections ersus 'intermitter	ıť			
Outcome: 11 AST (aspa	artate transami	inase) (IU/litre	2)				
Study or subgroup	Continuous N	Mean(SD)	Intermittent N	Mean(SD)	Mean Differenc IV,Fixed,95% Cl	e Weight	Mean Difference IV,Fixed,95% Cl
I First post-operative day Belghiti 1999	42	294 (221)	44	264 (191)	-	86.4 %	30.00 [ -57.48, 117.48 ]
Capussotti 2003	18	240 (436)	17	340 (191)		13.6 %	-100.00 [ -320.94, 120.94 ]
Subtotal (95% CI) Heterogeneity: $Chi^2 = 1.1$ Test for overall effect: Z =	<b>60</b> 5, df = 1 (P = 0.30 (P = 0.77	0.28);   <sup>2</sup> =  39 7)	<b>61</b>		•	100.0 %	12.38 [ -68.95, 93.72 ]
				-20 Favour	0 -100 0 100 s continuous Favours i	200 ntermittent	
Methods of vascular occ	lusion for ele	ective liver	resections (Re	eview)			82

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Comparison: 2 Portal triad clamping: 'continuous' versus 'intermittent'

Outcome: II AST (aspartate transaminase) (IU/litre)



Comparison: 2 Portal triad clamping: 'continuous' versus 'intermittent'

Outcome: II AST (aspartate transaminase) (IU/litre)

Study or subgroup	Continuous		Intermittent		Mean Differe	ence Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fixed,95% C	1	IV,Fixed,95% CI
4 Fifth post-operative day							
Belghiti 1999	42	70 (59)	44	62 (35)	-	100.0 %	8.00 [ -12.62, 28.62 ]
Subtotal (95% CI)	42		44		+	100.0 %	8.00 [ -12.62, 28.62 ]
Heterogeneity: not applicat	ole						
Test for overall effect: $Z = 0$	0.76 (P = 0.45	)					
				-2	00 -100 0 100	0 200	
				Favour	rs continuous Favou	urs intermittent	
Review: Methods of vaso	ular occlusion	for elective live	er resections				
Comparison: 2 Portal tri	ad clamping: 'c	ontinuous' vers	sus 'intermittent'				
Outcome: LLAST (aspa	rtate transami	nase) (IL J/litre)					
Study or subgroup	Continuous		Intermittent		Mean Differ	rence Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fixed,95% (	CI	IV,Fixed,95% CI
5 Seventh post-operative d	ay						
Belghiti 1999	42	47 (23)	44	44 (24)		99.8 %	3.00 [ -6.93, 12.93 ]
Capussotti 2003	18	80 (436)	17	70 (191)		- 0.2 %	10.00 [ -210.94, 230.94 ]
Subtotal (95% CI)	60		61		•	100.0 %	3.01 [ -6.91, 12.94 ]
Heterogeneity: $Chi^2 = 0.00$	), df = 1 (P = 0	0.95); l <sup>2</sup> =0.0%					
Test for overall effect: $Z = 0$	0.60 (P = 0.55	)					
				-	200 -100 0 10	00 200	
				Favoi	urs continuous Favo	ours intermittent	

# Analysis 2.12. Comparison 2 Portal triad clamping: 'continuous' versus 'intermittent', Outcome 12 ALT (alanine transaminase) (IU/litre).

Review: Methods of vascular occlusion for elective liver resections

Comparison: 2 Portal triad clamping: 'continuous' versus 'intermittent'

Outcome: 12 ALT (alanine transaminase) (IU/litre)

Study or subgroup	Continuous	h	ntermittent		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fixed,95% CI		IV,Fixed,95% CI
First post-operative day	,						
Belghiti 1999	42	358 (309)	44	321 (247)	-	76.9 %	37.00 [ -81.57, 155.57 ]
Capussotti 2003	18	180 (363)	17	260 (288)		23.1 %	-80.00 [ -296.48,   36.48 ]
Subtotal (95% CI)	60		61		+	100.0 %	10.00 [ -94.00, 113.99 ]
Heterogeneity: $Chi^2 = 0.8$	86, df = 1 (P =	0.35); I <sup>2</sup> =0.0%					
Test for overall effect: Z =	= 0.19 (P = 0.85	)					
2 Second post-operative	day						
Belghiti 1999	42	387 (363)	44	289 (288)		100.0 %	98.00 [ -40.90, 236.90 ]
Subtotal (95% CI)	42		44		•	100.0 %	98.00 [ -40.90, 236.90 ]
Heterogeneity: not applica	able						
Test for overall effect: Z =	= 1.38 (P = 0.17	)					
3 Third post-operative da	ly .						
Capussotti 2003	18	110 (363)	17	150 (288)		100.0 %	-40.00 [ -256.48,   76.48 ]
Subtotal (95% CI)	18		17		•	100.0 %	-40.00 [ -256.48, 176.48 ]
Heterogeneity: not application	able						
Test for overall effect: Z =	= 0.36 (P = 0.72	.)					
4 Fifth post-operative day	, 						
Belghiti 1999	42	157 (164)	44	141 (107)		100.0 %	6.00 [ -42.82, 74.82 ]
Subtotal (95% CI)	42		44		+	100.0 %	16.00 [ -42.82, 74.82 ]
Heterogeneity: not applic	able						
Test for overall effect: Z =	= 0.53 (P = 0.59	')					
5 Seventh post-operative	day						
Belghiti 1999	42	106 (97)	44	102 (71)	-	97.3 %	4.00 [ -32.07, 40.07 ]
Capussotti 2003	18	110 (363)	17	150 (288)		2.7 %	-40.00 [ -256.48, 176.48 ]
Subtotal (95% CI)	60		61		•	100.0 %	2.81 [ -32.76, 38.39 ]
Heterogeneity: $Chi^2 = 0.1$	5, df =   (P =	0.69); l <sup>2</sup> =0.0%					
Test for overall effect: Z =	= 0.15 (P = 0.88	5)					
Test for subgroup differen	nces: $Chi^2 = 1.9$	4, df = 4 (P = 0.	75), l <sup>2</sup> =0.0%				
				I		1	
				-1000	-500 Ó 500 IC	000	
				Favours c	ontinuous Favours inte	rmittent	

Methods of vascular occlusion for elective liver resections (Review) Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Comparison: 2 Portal triad clamping: 'continuous' versus 'intermittent'

Outcome: 12 ALT (alanine transaminase) (IU/litre)

	Continuous N	Mean(SD)	Intermittent N	Mean(SD)	Mean Difference IV,Fixed,95% Cl	Weight	Mean Difference IV,Fixed,95% Cl
l First post-operative day Belghiti 1999	42	358 (309)	44	321 (247)	-	76.9 %	37.00 [ -81.57, 155.57 ]
Capussotti 2003	18	180 (363)	17	260 (288)		23.1 %	-80.00 [ -296.48,   36.48 ]
<b>Subtotal (95% CI)</b> Heterogeneity: Chi <sup>2</sup> = 0.8 Test for overall effect: Z =	<b>60</b> 86, df = 1 (P = 0.19 (P = 0.8)	0.35); I <sup>2</sup> =0.0; 5)	<b>61</b>		•	100.0 %	10.00 [ -94.00, 113.99 ]
				- 1 000	) -500 0 500 10	00	
Review: Methods of vas	scular occlusion	n for elective li	ver resections	Favours o	continuous Favours inter	mittent	
Comparison: 2 Portal tr Outcome: 12 ALT (alar	riad clamping: ' nine transamina	continuous' ve use) (IU/litre)	ersus 'intermitter	ıt'			
Study or subgroup	Continuous N	Mean(SD)	Intermittent N	Mean(SD)	Mean Difference IV,Fixed,95% Cl	Weight	Mean Difference IV,Fixed,95% Cl
Study or subgroup 2 Second post-operative of Belghiti 1999	Continuous N day 42	Mean(SD) 387 (363)	Intermittent N 44	Mean(SD) 289 (288)	Mean Difference IV,Fixed,95% Cl	Weight	Mean Difference IV,Fixed,95% CI 98.00 [ -40.90, 236.90 ]
Study or subgroup 2 Second post-operative of Belghiti 1999 <b>Subtotal (95% CI)</b> Heterogeneity: not applica Test for overall effect: Z =	Continuous N 42 42 42 6 8 8 8 8 9 9 9.11	Mean(SD) 387 (363) 7)	Intermittent N 44 <b>44</b>	Mean(SD) 289 (288)	Mean Difference IV,Fixed,95% CI	Weight 100.0 % 100.0 %	Mean Difference IV,Fixed,95% Cl 98.00 [ -40.90, 236.90 ] <b>98.00 [ -40.90, 236.90 ]</b>

Comparison: 2 Portal triad clamping: 'continuous' versus 'intermittent'

Outcome: 12 ALT (alanine transaminase) (IU/litre)



Comparison: 2 Portal triad clamping: 'continuous' versus 'intermittent'

Outcome: 12 ALT (alanine transaminase) (IU/litre)

Study or subgroup	Continuous		Intermittent		Mea	an Differenc	e Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fixe	ed,95% CI		IV,Fixed,95% CI
5 Seventh post-operative	day							
Belghiti 1999	42	106 (97)	44	102 (71)	I	-	97.3 %	4.00 [ -32.07, 40.07 ]
Capussotti 2003	18	110 (363)	17	150 (288)	_	-	2.7 %	-40.00 [ -256.48, 176.48 ]
Subtotal (95% CI)	60		61			•	100.0 %	2.81 [ -32.76, 38.39 ]
Heterogeneity: $Chi^2 = 0.1$	5, df = 1 (P = 0	0.69); I <sup>2</sup> =0.09	%					
Test for overall effect: Z =	0.15 (P = 0.88	)						
				-	1000 -500	0 500	1000	
				Favo	urs continuous	Favours	intermittent	

### Analysis 3.1. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome I Mortality.

Review: Methods of vase	cular occlusion for ele	ctive liver resecti	ons		
Comparison: 3 Inflow of	cclusion: 'selective' ver	sus 'total'			
Outcome: I Mortality					
Study or subgroup	Selective n/N	Total n/N	Risk Ratio M-H,Fixed,95% C	Weight	Risk Ratio M-H,Fixed,95% Cl
Figueras 2005	1/41	0/39			2.86 [ 0.12, 68.10 ]
Wu 2002	0/30	0/28	•	0.0 %	0.0 [ 0.0, 0.0 ]
Total (95% CI) Total events:   (Selective), Heterogeneity: $Chi^2 = 0.0$ , Test for overall effect: Z =	<b>71</b> 0 (Total) df = 0 (P = 1.00); I <sup>2</sup> 0.65 (P = 0.52)	<b>67</b> =0.0%		- 100.0 %	2.86 [ 0.12, 68.10 ]
			0.01 0.1 1.0 10.0 Favours 'selective' Favours	100.0 'total'	

### Analysis 3.2. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 2 Liver failure.

Review: Methods of vascular occlusion for elective liver resections

Comparison: 3 Inflow occlusion: 'selective' versus 'total'

Outcome: 2 Liver failure

Study or subgroup	Selective	Total	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% Cl
Figueras 2005	4/41	0/39	+	100.0 %	8.57 [ 0.48, 154.15 ]
Total (95% CI)	41	39		100.0 %	8.57 [ 0.48, 154.15 ]
Total events: 4 (Selective),	0 (Total)				
Heterogeneity: not applica	able				
Test for overall effect: Z =	: 1.46 (P = 0.15)				
			0.0010 0.1 1.0 10.0 1000.0		
			Favours 'selective' Favours 'total'		

### Analysis 3.3. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 3 Peri-operative morbidity.

Review: Methods of vascular occlusion for elective liver resections

Comparison: 3 Inflow occlusion: 'selective' versus 'total'

Outcome: 3 Peri-operative morbidity

Study or subgroup	Selective	Total	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% Cl
I Re-operation					
Figueras 2005	0/41	0/39	•	0.0 %	0.0 [ 0.0, 0.0 ]
Subtotal (95% CI)	41	39		0.0 %	0.0 [ 0.0, 0.0 ]
Total events: 0 (Selective), 0 (	Total)				
Heterogeneity: not applicable					
Test for overall effect: Z = 0.0	(P < 0.00001)				
2 Abdominal collections					
Figueras 2005	/4	0/39		14.2 %	2.86 [ 0.12, 68.10 ]
Wu 2002	5/30	3/28		85.8 %	1.56 [ 0.41, 5.91 ]
Subtotal (95% CI)	71	67	-	100.0 %	1.74 [ 0.51, 5.94 ]
Total events: 6 (Selective), 3 (	Total)				
Heterogeneity: Chi <sup>2</sup> = 0.12, d	$f =   (P = 0.73);  ^2 = 0$	0.0%			
Test for overall effect: $Z = 0.8$	8 (P = 0.38)				
3 Wound infection					
			0.0010 0.1 1.0 10.0 1000.0		
			Favours 'selective' Favours 'total'		
					(Continued )

Methods of vascular occlusion for elective liver resections (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Selective	Total	Risk Ratio	Weight	( Continued) Risk Ratio
Wu 2002	2/30	0/28		100.0 %	4.68 [ 0.23, 93.37 ]
Subtatal (95% CI)	30	28		100.0.%	<b>4 68 [ 0 23 93 37 ]</b>
Total events: 2 (Selective), 0 (T	otal)	20		100.0 %	4.08 [ 0.23, 93.37 ]
Heterogeneity: not applicable	,				
Test for overall effect: $Z = 1.01$	(P = 0.31)				
4 Pulmonary complications		2/20		740.00	
Figueras 2005	1/41	3/39		/4.8 %	0.32 [ 0.03, 2.92 ]
Wu 2002	2/30	1/28		25.2 %	1.87 [ 0.18, 19.47 ]
Subtotal (95% CI)	71	67	•	100.0 %	0.71 [ 0.16, 3.07 ]
Total events: 3 (Selective), 4 (T	otal)	1.407			
Heterogeneity: $Chi^2 = 1.16$ , df Test for overall effect: $7 = 0.46$	P = 1 (P = 0.28); P = 0.28); P = 0.64)	14%			
5 Cardiac failure	(i = 0.0 i)				
Figueras 2005	2/41	0/39		100.0 %	4.76 [ 0.24, 96.16 ]
Subtotal (95% CI)	41	39		100.0 %	4.76 [ 0.24, 96.16 ]
Total events: 2 (Selective), 0 (T Heterogeneity: not applicable Test for overall effect: Z = 1.02 6 Portal vein thrombosis	ōtal) 2 (P = 0.31)				
Figueras 2005	2/41	0/39		100.0 %	4.76 [ 0.24, 96.16 ]
<b>Subtotal (95% CI)</b> Total events: 2 (Selective), 0 (T Heterogeneity: not applicable Test for overall effect: Z = 1.02 7 Bile leak	<b>41</b> Total) 2 (P = 0.31)	39		100.0 %	4.76 [ 0.24, 96.16 ]
Figueras 2005	0/41	1/39		27.1 %	0.32 [ 0.01, 7.57 ]
Wu 2002	5/30	4/28	+	72.9 %	1.17 [ 0.35, 3.91 ]
Subtotal (95% CI)	71	67	•	100.0 %	0.94 [ 0.31, 2.83 ]
Total events: 5 (Selective), 5 (T Heterogeneity: Chi <sup>2</sup> = 0.57, df Test for overall effect: Z = 0.12 8 Ascites Figueras 2005	Total) = I (P = 0.45); I <sup>2</sup> = 2 (P = 0.91) 4/41	0.0% 3/39	-	74.8 %	1.27 [ 0.30, 5.3   ]
VM/u 2002	2/30	1/28		25.2 %	87[018 1947]
	2/50	(720		100.0.0/	
Subtotal (95% CI) Total events: 6 (Selective), 4 (T Heterogeneity: $Chi^2 = 0.08$ , df Test for overall effect: $Z = 0.56$	7 <b>I</b> Total) $F = 1 (P = 0.78); 1^2 = 0.57$	<b>6</b> 7 0.0%		100.0 %	1.42 [ 0.42, 4.80 ]
			0.0010 0.1 1.0 10.0 1000.0 Favours 'selective' Favours 'total'		

Comparison: 3 Inflow occlusion: 'selective' versus 'total'

Outcome: 3 Peri-operative morbidity

Study or subgroup	Selective n/N	Total n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% CI
Re-operation					
Figueras 2005	0/41	0/39	•	0.0 %	0.0 [ 0.0, 0.0 ]
<b>Subtotal (95% CI)</b> Total events: 0 (Selective), 0 (Tota Heterogeneity: not applicable Test for overall effect: Z = 0.0 (P	<b>41</b> al) < 0.00001)	39		0.0 %	0.0 [ 0.0, 0.0 ]
				0	
Review: Methods of vascular o Comparison: 3 Inflow occlusio Outcome: 3 Peri-operative mo	cclusion for elective n: 'selective' versus ' prbidity	liver resections total'	Favours 'selective' Favours 'total'	U	
Study or subgroup	Selective n/N	Total n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
2 Abdominal collections					
Figueras 2005	/4	0/39		14.2 %	2.86 [ 0.12, 68.10 ]
Wu 2002	5/30	3/28	-	85.8 %	1.56 [ 0.41, 5.91 ]
Subtotal (95% CI) Total events: 6 (Selective), 3 (Tota Heterogeneity: $Chi^2 = 0.12$ , df = Test for overall effect: Z = 0.88 (F	<b>71</b> al)   (P = 0.73);   <sup>2</sup> =0. P = 0.38)	<b>67</b> 0% 0.	.0010 0.1 1.0 10.0 1000.0	100.0 %	1.74 [ 0.51, 5.94 ]
		Fa	avours 'selective' Favours 'total'		

Comparison: 3 Inflow occlusion: 'selective' versus 'total'

Outcome: 3 Peri-operative morbidity



Comparison: 3 Inflow occlusion: 'selective' versus 'total'

Outcome: 3 Peri-operative morbidity



Comparison: 3 Inflow occlusion: 'selective' versus 'total'

Outcome: 3 Peri-operative morbidity

Study or subgroup	Selective n/N	Total n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
7 Bile leak					
Figueras 2005	0/41	1/39		27.1 %	0.32 [ 0.01, 7.57 ]
Wu 2002	5/30	4/28		72.9 %	1.17 [ 0.35, 3.91 ]
Subtotal (95% CI)	71	67	+	100.0 %	0.94 [ 0.31, 2.83 ]
Total events: 5 (Selective), 5 (Heterogeneity: $Chi^2 = 0.57$ , c	(Total) df = $  (P = 0.45);  ^2 = 0$	).0%			
lest for overall effect: $\angle = 0$ .	12 (P = 0.91)				
			0.0010 0.1 1.0 10.0 1000.0 Favours 'selective' Favours 'total'		
Review: Methods of vascul	lar occlusion for elective	e liver resections			
Comparison: 3 Inflow occl	lusion: 'selective' versus	'total'			
Outcome: 3 Peri-operative	e morbidity				
	morbiary				
Study or subgroup	Selective	Total	Risk Ratio	Weight	
					Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		Risk Ratio M-H,Fixed,95% Cl
8 Ascites	n/N	n/N	M-H,Fixed,95% Cl		Risk Ratio M-H,Fixed,95% Cl
8 Ascites Figueras 2005	n/N 4/4 I	n/N 3/39	M-H,Fixed,95% Cl	74.8 %	Risk Ratio M-H,Fixed,95% Cl I.27 [ 0.30, 5.31 ]
8 Ascites Figueras 2005 Wu 2002	n/N 4/41 2/30	n/N 3/39 1/28	M-H,Fixed,95% Cl	74.8 % 25.2 %	Risk Ratio M-H,Fixed,95% Cl I .27 [ 0.30, 5.31 ] I .87 [ 0.18, 19.47 ]
8 Ascites Figueras 2005 Wu 2002 Subtotal (95% CI)	n/N 4/41 2/30 <b>71</b>	n/N 3/39 1/28 <b>67</b>	M-H,Fixed,95% Cl	74.8 % 25.2 % <b>100.0 %</b>	Risk Ratio M-H,Fixed,95% Cl 1.27 [ 0.30, 5.31 ] 1.87 [ 0.18, 19.47 ] <b>1.42 [ 0.42, 4.80 ]</b>
8 Ascites Figueras 2005 Wu 2002 <b>Subtotal (95% CI)</b> Total events: 6 (Selective), 4 ( Heterogeneity: Chi <sup>2</sup> = 0.08, 0 Test for overall effect: Z = 0.3	n/N 4/41 2/30 71 (Total) df = 1 (P = 0.78); $l^2 = 0$ 56 (P = 0.57)	n/N 3/39 1/28 <b>67</b> 0.0%	M-H,Fixed,95% Cl	74.8 % 25.2 % <b>100.0 %</b>	Risk Ratio M-H,Fixed,95% Cl 1.27 [ 0.30, 5.31 ] 1.87 [ 0.18, 19.47 ] <b>1.42 [ 0.42, 4.80 ]</b>
8 Ascites Figueras 2005 Wu 2002 <b>Subtotal (95% CI)</b> Total events: 6 (Selective), 4 ( Heterogeneity: Chi <sup>2</sup> = 0.08, Test for overall effect: Z = 0.9	n/N 4/41 2/30 <b>71</b> (Total) df = 1 (P = 0.78); $l^2 = 0$ 56 (P = 0.57)	n/N 3/39 1/28 <b>67</b>	M-H,Fixed,95% Cl	74.8 % 25.2 % 100.0 %	Risk Ratio M-H,Fixed,95% Cl I.27 [ 0.30, 5.31 ] I.87 [ 0.18, 19.47 ] <b>1.42 [ 0.42, 4.80 ]</b>
8 Ascites Figueras 2005 Wu 2002 <b>Subtotal (95% CI)</b> Total events: 6 (Selective), 4 ( Heterogeneity: Chi <sup>2</sup> = 0.08, 6 Test for overall effect: Z = 0.5	n/N 4/41 2/30 71 (Total) df = 1 (P = 0.78); $l^2 = 0$ 56 (P = 0.57)	n/N 3/39 1/28 <b>67</b>	M-H,Fixed,95% Cl	74.8 % 25.2 % 100.0 %	Risk Ratio M-H,Fixed,95% Cl 1.27 [ 0.30, 5.31 ] 1.87 [ 0.18, 19.47 ] <b>1.42 [ 0.42, 4.80 ]</b>

# Analysis 3.4. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 4 Number needing transfusion.

Review: Methods of vascular occlusion for elective liver resections

Comparison: 3 Inflow occlusion: 'selective' versus 'total'

Outcome: 4 Number needing transfusion

-

.

.

Study or subgroup	Selective	Total		Risk Ratio M-H,Random,95% Cl			Weight	Risk Ratio	
	n/N	n/N						M-H,Random,95% CI	
Figueras 2005	6/41	4/39			•		45.5 %	1.43 [ 0.44, 4.67 ]	
Wu 2002	5/30	12/28					54.5 %	0.39 [ 0.16, 0.96 ]	
Total (95% CI)	71	67		-	-		100.0 %	0.70 [ 0.20, 2.50 ]	
Total events: II (Selective),	I 6 (Total)								
Heterogeneity: $Tau^2 = 0.56$ ;	$Chi^2 = 2.91, df = 1$	$(P = 0.09); I^2 = 66$	%						
Test for overall effect: $Z = 0$ .	54 (P = 0.59)								
			0.01	0.1 1	.0 10.0	100.0			
			Favours	'selective'	Favours	'total'			

## Analysis 3.5. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 5 Number of units transfused.

Review: Methods of	vascular occlusi	ion for elective live	er resection	s				
Comparison: 3 Inflov	w occlusion: 'sel	lective' versus 'tota	al'					
Outcome: 5 Numbe	er of units transf	fused						
Study or subgroup	Selective N	Mean(SD)	Total N	Mean(SD)	Mear IV,Fixe	n Difference d,95% Cl	Weight	Mean Difference IV,Fixed,95% Cl
Figueras 2005	41	0.34 (0.9)	39	0.36 (1)			100.0 %	-0.02 [ -0.44, 0.40 ]
Total (95% CI) Heterogeneity: not app	41 blicable		39				100.0 %	-0.02 [ -0.44, 0.40 ]
Test for overall effect: 2	Z = 0.09 (P = 0)	1.93)						
				-0.	5 -0.25 0	0.25 0.5		
				Favou	rs 'selective'	Favours 'total'		

## Analysis 3.6. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 6 Hospital stay (in days).

Review: Methods of vascular occlusion for elective liver resections

Comparison: 3 Inflow occlusion: 'selective' versus 'total'

Outcome: 6 Hospital stay (in days)

Study or subgroup	Selective		Total			Me	an Diffe	erence		Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)		IV,Ranc	lom,95	% CI			IV,Random,95% CI
Figueras 2005	41	8.15 (3.8)	39	9.38 (4.9)			H			68.5 %	-1.23 [ -3.16, 0.70 ]
Wu 2002	30	16.4 (7.7)	28	14.8 (7.4)		_	-	_		31.5 %	1.60 [ -2.29, 5.49 ]
Total (95% CI)	71		67							100.0 %	-0.34 [ -2.92, 2.24 ]
Heterogeneity: Tau <sup>2</sup> =	1.55; $Chi^2 = 1.6$	63, df = 1 (P = 0.2	20); l <sup>2</sup> =399	%							
Test for overall effect:	Z = 0.26 (P = 0	.80)									
					-10	-5	0	5	10		

Favours 'selective'

Favours 'total'

Analysis 3.7. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 7 Operating time (min).

Review: Methods o	f vascular occlus	ion for elective liv	ver resectio	ns			
Comparison: 3 Inflo	ow occlusion: 'se	elective' versus 'to	taľ				
Outcome: 7 Opera	ting time (min)						
Study or subgroup	Selective		Total		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fixed,95% CI		IV,Fixed,95% CI
Figueras 2005	41	219 (45)	39	207 (48)	-	85.0 %	12.00 [ -8.41, 32.41 ]
Wu 2002	30	399 (85)	28	409 (102)		15.0 %	-10.00 [ -58.50, 38.50 ]
Total (95% CI)	71		67		-	100.0 %	8.69 [ -10.12, 27.50 ]
Heterogeneity: Chi <sup>2</sup> =	= 0.67, df = 1 (P	$= 0.41$ ); $ ^2 = 0.09$	6				
Test for overall effect:	Z = 0.91 (P = 0.01)	0.37)					
				-1	00 -50 0 50 100	)	
				Favo	urs 'selective' Favours 'total'		
Methods of vascular	occlusion for	elective liver r	esections	(Review)			96

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

## Analysis 3.8. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 8 Hemodynamics change (10 min after release of clamping).

Review: Methods of vascular occlusion for elective liver resections

Comparison: 3 Inflow occlusion: 'selective' versus 'total'

Outcome: 8 Hemodynamics change (10 min after release of clamping)



## Analysis 3.9. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 9 Blood loss (ml).

Review: Methods of vascular occlusion for elective liver resections

Comparison: 3 Inflow occlusion: 'selective' versus 'total'

Outcome: 9 Blood loss (ml)

Study or subgroup	Selective N	Mean(SD)	Total N	Mean(SD)	Mean D IV,Random,	95% Cl	Weight	Mean Difference IV,Random,95% CI
I Transection								
Wu 2002	30	1153 (562)	28	1394 (596)			36.1 %	-241.00 [ -539.63, 57.63 ]
Subtotal (95% CI)	30		28		-		36.1 %	-241.00 [ -539.63, 57.63 ]
Heterogeneity: not applic	able							
Test for overall effect: Z = 2 Operative	= 1.58 (P = 0.	11)						
Figueras 2005	41	735 (397)	39	671 (533)	-	-	43.7 %	64.00 [ -142.76, 270.76 ]
Wu 2002	30	1159 (1210)	28	1685 (900)			20.2 %	-526.00 [ -1072.45, 20.45 ]
Subtotal (95% CI)	71		67				63.9 %	-174.56 [ -742.06, 392.95 ]
Heterogeneity: $Tau^2 = 12$	9619.82; Chi <sup>2</sup>	<sup>2</sup> = 3.92, df = 1	(P = 0.05	); I <sup>2</sup> =74%				
Test for overall effect: Z =	= 0.60 (P = 0.	55)	07				100.0.0/	
Heterogeneity: $Tau^2 = 46$	21960: Chi <sup>2</sup>	= 5 54 df = 2 (l	<b>95</b> P = 0.06)	$ ^2 = 64\%$			100.0 %	-105.35 [ -4/5.60, 144.91 ]
Test for overall effect: Z =	= 1.04 (P = 0.	- 5.5 1, di - 2 (i 30)	- 0.00)	,1 -01/0				
				-   (	00 -500 0	500 1000		
				Favo	urs 'selective'	Favours 'total'		
Review: Methods of va	scular occlusio	on for elective liv	ver resect	ions				
Comparison: 3 Inflow of	occlusion: 'sele	ective' versus 'to	taľ					
Outcome: 9 Blood loss	(ml)							
Study or subgroup	Selective	Maap(SD)	Total	Moop(SD)	Mear	Difference	Weight	Mean Difference
	IN	riean(SD)	IN	riedn(SD)	IV,Nariuo	m,75% CI		IV,Random,73% CI
l Transection Wu 2002	30	1153 (562)	28	1394 (596)			36.1 %	-241.00 [ -539.63, 57.63 ]
Subtotal (05% CI)	30		26				36 1 %	2/1 00 [ 530 63 57 63 ]
Heterogeneity: not applic	able		20				30.1 %	-241.00 [ -339.03, 37.03 ]
Test for overall effect: Z =	= 1.58 (P = 0.	11)						
					1000 500 0	500 10	20	
				Fa	vours 'selective'	Favours 'tota		

Comparison: 3 Inflow occlusion: 'selective' versus 'total'

Outcome: 9 Blood loss (ml)

Study or subgroup	Selective		Total			Μ	ean Differe	nce	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)		IV,Rar	dom,95% (	CI		IV,Random,95% CI
2 Operative										
Figueras 2005	41	735 (397)	39	671 (533)					43.7 %	64.00 [ -142.76, 270.76 ]
Wu 2002	30	1159 (1210)	28	1685 (900)	•	-	_		20.2 %	-526.00 [ -1072.45, 20.45 ]
Subtotal (95% CI)	71		67						63.9 %	-174.56 [ -742.06, 392.95 ]
Heterogeneity: Tau <sup>2</sup> = 12	29619.82; Chi	<sup>2</sup> = 3.92, df = 1	(P = 0.05);	$ ^2 = 74\%$						
Test for overall effect: Z =	= 0.60 (P = 0	.55)								
					-1000	-500	0 500	100	0	

Favours 'selective'

Favours 'total'

## Analysis 3.10. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 10 Bilirubin (micromole/litre).

Review: Methods of vase	cular occlusion	for elective liver	resection	IS			
Comparison: 3 Inflow of	cclusion: 'selec	tive' versus 'total	,				
Outcome: 10 Bilirubin (r	micromole/litre	2)					
Study or subgroup	Selective		Total		Mean Differe	nce Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fixed,95% C		IV,Fixed,95% CI
I First post-operative day							
Wu 2002	30	35.9 (35.1)	28	35.3 (27.2)		100.0 %	0.60 [ -15.50, 16.70 ]
Subtotal (95% CI)	30		28			100.0 %	0.60 [ -15.50, 16.70 ]
Heterogeneity: not applical	ble						
Test for overall effect: Z =	0.07 (P = 0.94	ł)					
2 Third post-operative day							
Wu 2002	30	29.5 (21)	28	32.9 (36.2)		100.0 %	-3.40 [ -18.77, 11.97 ]
Subtotal (95% CI)	30		28			100.0 %	-3.40 [ -18.77, 11.97 ]
Heterogeneity: not applical	ble						
Test for overall effect: Z =	0.43 (P = 0.66	5)					
3 Fifth post-operative day							
Wu 2002	30	26.1 (21)	28	31.4 (47.5)		100.0 %	-5.30 [ -24.43, 13.83 ]
					-20 -10 0 10	20	
				E	avours 'selective' Eavou	rs 'total'	
							(Continued )

Methods of vascular occlusion for elective liver resections (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Selective N	Mean(SD)	Total N	Mean(SD)	Mean Difference IV,Fixed,95% Cl	Weight	( Continued) Mean Difference IV,Fixed,95% Cl
Subtotal (95% CI)	30		28			100.0 %	-5.30 [ -24.43, 13.83 ]
Heterogeneity: not applica	ble						
Test for overall effect: $Z =$	0.54 (P = 0.59	9)					
4 Seventh post-operative o	lay					100.0.0/	
VVu 2002	30	21.8 (24.6)	28	26 (50.9)		100.0 %	-4.20 [ -25.01, 16.61 ]
Subtotal (95% CI)	30		28			100.0 %	-4.20 [ -25.01, 16.61 ]
Heterogeneity: not applica	ble 0.40 (D = 0.44	2)					
Test for subgroup difference	0.40 (P - 0.6) res: Chi <sup>2</sup> = 0.7	7) 6 df = 3 (P = 0	97)   <sup>2</sup> =0	0%			
lest for subgroup difference	.03. 011 0.2	.0, 01 5 (1 0	.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	0,0			
					-20 -10 0 10 20		
				Fa	vours 'selective' Favours 'total'		
Review: Methods of vas	cular occlusior	n for elective live	r resection	S			
Comparison: 3 Inflow o	cclusion: 'selec	tive' versus 'tota	ľ				
Outcome: 10 Bilirubin (	micromole/litr	e)					
Study or subgroup	Selective		Total		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fixed,95% CI		IV,Fixed,95% CI
I First post-operative day							
Wu 2002	30	35.9 (35.1)	28	35.3 (27.2)		100.0 %	0.60 [ -15.50, 16.70 ]
Subtotal (95% CI)	30		28			100.0 %	0.60 [ -15.50, 16.70 ]
Heterogeneity: not applica	ble						
Test for overall effect: $Z =$	0.07 (P = 0.9)	4)					
				E.	-20 -10 0 10 20		

Comparison: 3 Inflow occlusion: 'selective' versus 'total'

Outcome: 10 Bilirubin (micromole/litre)

Study or subgroup	Selective N	Mean(SD)	Total N	Mean(SD)	Mean Difference IV,Fixed,95% Cl	Weight	Mean Difference IV,Fixed,95% CI
2 Third post-operative day							
Wu 2002	30	29.5 (21)	28	32.9 (36.2)		100.0 %	-3.40 [ -18.77, 11.97 ]
Subtotal (95% CI)	30		28			100.0 %	-3.40 [ -18.77, 11.97 ]
Heterogeneity: not applicab Test for overall effect: $Z = 0$	le 0.43 (P = 0.6	6)					
				-20 Emou	) -10 0 10 20		
Review: Methods of vasce Comparison: 3 Inflow occ	ular occlusio	n for elective liv	ver resection	s			
Outcome: 10 Bilirubin (m	nicromole/lit	re)					
Study or subgroup	Selective N	Mean(SD)	Total N	Mean(SD)	Mean Difference IV,Fixed,95% Cl	Weight	Mean Difference IV,Fixed,95% Cl
3 Fifth post-operative day	30	261 (21)	28	31 4 (47 5)		100.0 %	5 20 1 24 43 13 83 1
Subtotal (95% CI)	30	20.1 (21)	28 28	(כ. /ד) ד. וכ		100.0 %	-5.30 [ -24.43, 13.83 ]
Heterogeneity: not applicab Test for overall effect: Z = 0	le 0.54 (P = 0.5	9)					
				-20 Favou	) -10 0 10 20 rs 'selective' Favours 'total'		

Methods of vascular occlusion for elective liver resections (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Comparison: 3 Inflow occlusion: 'selective' versus 'total'

Outcome: 10 Bilirubin (micromole/litre)



# Analysis 3.11. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 11 AST (aspartate transaminase) (IU/litre).

Review: Methods of vas	cular occlusio	on for elective liv	ver resect	ions			
Comparison: 3 Inflow o	cclusion: 'sele	ctive' versus 'to	tal'				
Outcome: 11 AST (aspa	artate transar	ninase) (IU/litre)	)				
Study or subgroup	Selective		Total		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fixed,95% Cl		IV,Fixed,95% CI
I First post-operative day Wu 2002	30	290 (770)	28	420 (790)		100.0 %	-130.00 [ -531.92, 271.92 ]
Subtotal (95% CI)	30		28			100.0 %	-130.00 [ -531.92, 271.92 ]
Heterogeneity: not applica		- 2)					
lest for overall effect: $\angle =$	0.63 (P = 0.5)	53)					
2 Third post-operative day Wu 2002	30	190 (510)	28	180 (320)		100.0 %	10.00 [ -207.61, 227.61 ]
Subtotal (95% CI)	30		28			100.0 %	10.00 [ -207.61, 227.61 ]
Heterogeneity: not applica	ble						
Test for overall effect: Z =	0.09 (P = 0.9	93)					
3 Fifth post-operative day							
Wu 2002	30	80 (220)	28	90 (210)		100.0 %	-10.00 [-120.67, 100.67 ]
Subtotal (95% CI)	30		28		-	100.0 %	-10.00 [ -120.67, 100.67 ]
				- Fave	500 -250 0 250 50 ours 'selective' Favours 'tota	00	(Continued )

Methods of vascular occlusion for elective liver resections (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Selective N	Mean(SD)	Total N	Mean(SD)	Mean Difference IV,Fixed,95% Cl	Weight	( Continued) Mean Difference IV,Fixed,95% Cl
Heterogeneity: not application	able						
Test for overall effect: Z =	= 0.18 (P = 0.18)	86)					
4 Seventh post-operative Wu 2002	day 30	30 (20)	28	50 (40)		100.0 %	-20.00 [ -36.45, -3.55 ]
Subtotal (95% CI)	30		28		•	100.0 %	-20.00 [ -36.45, -3.55 ]
Heterogeneity: not applic	able						
Test for overall effect: Z =	= 2.38 (P = 0.	017)					
Test for subgroup differen	ices: $Chi^2 = 0$	0.39, df = 3 (P =	= 0.94), I <sup>2</sup>	=0.0%			
				50			
				-50 Eavou	u -250 0 250 500	)	
				14/04			
Review: Methods of va	scular occlusio	on for elective l	iver resect	tions			
Comparison: 3 Inflow	occlusion: 'sele	active' versus 'tr	otal'				
Companson. 5 millow c	Jeelusion. seit	ective versus to	Jtai				
Outcome: 11 AST (asp	oartate transa	minase) (IU/litre	e)				
Ctudy or subgroup	Soloctivo		Total		Maan Difference	\A/oight	Moon Difformero
study or subgroup	N	Mean(SD)	N	Mean(SD)	IV.Fixed.95% CI	vveignt	IV.Fixed.95% CI
Wu 2002	30	290 (770)	28	420 (790)		100.0 %	-130.00 [ -531.92, 271.92 ]
Subtatal (05% CI)	30	2,0 (,,0)	20	120 (770)		100.0.0%	130.00 [ 531.02 271.02 ]
Heterogeneity: not applic	<b>3U</b> able		20			100.0 %	-150.00 [ -551.92, 2/ 1.92 ]
Test for overall effect: Z =	= 0.63 (P = 0.	53)					
		,		1			
				-500	0 -250 0 250 500	)	
				Favour	rs 'selective' Favours 'total'		

Comparison: 3 Inflow occlusion: 'selective' versus 'total'

Outcome: II AST (aspartate transaminase) (IU/litre)


Comparison: 3 Inflow occlusion: 'selective' versus 'total'

Outcome: II AST (aspartate transaminase) (IU/litre)



# Analysis 3.12. Comparison 3 Inflow occlusion: 'selective' versus 'total', Outcome 12 ALT (alanine transaminase) (IU/litre).

Review: Methods of vascular occlusion for elective liver resections

Comparison: 3 Inflow occlusion: 'selective' versus 'total'

Outcome: 12 ALT (alanine transaminase) (IU/litre)

Study or subgroup	Selective		Total		Mean Difference	Weight	Mean Difference			
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fixed,95% CI		IV,Fixed,95% CI			
I First post-operative day										
Figueras 2005	41	402 (258)	39	372 (234)		85.1 %	30.00 [ -77.84, 137.84 ]			
Wu 2002	30	480 (510)	28	370 (490)		14.9 %	0.00 [ -   47.38, 367.38 ]			
Subtotal (95% CI)	71		67		-	100.0 %	41.95 [ -57.52, 141.41 ]			
Heterogeneity: $Chi^2 = 0.32$ , $df = 1$ (P = 0.57); $l^2 = 0.0\%$										
Test for overall effect: $Z =$	0.83 (P = 0.4	)								
2 Third post-operative day	/									
Wu 2002	30	320 (270)	28	330 (320)		100.0 %	-10.00 [ -162.92, 142.92 ]			
Subtotal (95% CI)	30		28			100.0 %	-10.00 [ -162.92, 142.92 ]			
Heterogeneity: not applica	ble									
Test for overall effect: $Z =$	0.13 (P = 0.9	D)								
3 Fifth post-operative day										
Wu 2002	30	150 (160)	28	190 (210)		100.0 %	-40.00 [ -136.58, 56.58 ]			
					200 100 0 100 20	0				
				- Four		יי יו				
				1 400			(Continued)			

Methods of vascular occlusion for elective liver resections (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	Selective N	Mean(SD)	Total N	Mean(SD)	Mean Difference IV.Fixed,95% Cl	Weight	( Continued) Mean Difference IV.Fixed,95% Cl
Subtotal (95% CI)	30		28		-	100.0 %	-40.00 [ -136.58, 56.58 ]
Heterogeneity: not applica	ble						
Test for overall effect: Z =	0.81 (P = 0.4	12)					
4 Seventh post-operative of	day						
Wu 2002	30	70 (20)	28	90 (20)		100.0 %	-20.00 [ -30.30, -9.70 ]
Subtotal (95% CI)	30		28		•	100.0 %	-20.00 [ -30.30, -9.70 ]
Heterogeneity: not applica	ble						
Test for overall effect: $Z =$	3.81 (P = 0.0	0014)					
Test for subgroup difference	tes: Chi <sup>2</sup> = 1.	66, df = 3 (P =	0.65), I <sup>2</sup> =	0.0%			
				-200	-100 0 100 200	)	
				Favours	'selective' Favours 'total'		
Review: Methods of vas	cular occlusio	n for elective liv	er resectio	ns			
Comparison: 3 Inflow o	cclusion: 'sele	ctive' versus 'tot	tal'				
Outcome: 12 ALT (alan	ine transamin	ase) (IU/litre)					
Study or subgroup	Selective	Marra (CD)	Total	Mara (CD)	Mean Difference	Weight	Mean Difference
	N	I*lean(SD)	IN	I™lean(SD)	IV,FIXed,95% CI		IV,FIXED,95% CI
I First post-operative day							
Figueras 2005	41	402 (258)	39	372 (234)	- <b>-</b>	85.1 %	30.00 [ -77.84, 137.84 ]
Wu 2002	30	480 (510)	28	370 (490)		14.9 %	0.00 [- 47.38, 367.38 ]
Subtotal (95% CI)	71		67		-	100.0 %	41.95 [ -57.52, 141.41 ]
Heterogeneity: $Chi^2 = 0.32$	2, df = 1 (P =	= 0.57); l <sup>2</sup> =0.0%	6				
Test for overall effect: Z =	0.83 (P = 0.4	ŧI)					
						ı	
				-20	0 -100 0 100 2	00	
				Favour	rs 'selective' Favours 'tota	al'	

Comparison: 3 Inflow occlusion: 'selective' versus 'total'

Outcome: 12 ALT (alanine transaminase) (IU/litre)



Methods of vascular occlusion for elective liver resections (Review)

 $\textbf{Copyright} @ \textbf{2009 The Cochrane Collaboration. Published by John Wiley \& Sons, Ltd. \\$ 

Comparison: 3 Inflow occlusion: 'selective' versus 'total'

Outcome: 12 ALT (alanine transaminase) (IU/litre)



### Analysis 4.1. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 1 Mortality.

Review: Methods of vas	cular occlusion for electiv	e liver resections			
Comparison: 4 30 minu	tes intermittent PTC vers	us 15 minutes interm	ittent PTC		
Outcome: I Mortality					
Study or subgroup	30 minutes n/N	15 minutes n/N	Risk f M-H,Fixed,9	Ratio Weight 95% Cl	Risk Ratio M-H,Fixed,95% CI
Esaki 2006	0/48	0/44	•	0.0 %	0.0 [ 0.0, 0.0 ]
<b>Total (95% CI)</b> Total events: 0 (30 minute: Heterogeneity: not applica Test for overall effect: Z =	<b>48</b> s), 0 (15 minutes) ble 0.0 (P < 0.00001)	44		0.0 %	0.0 [ 0.0, 0.0 ]
			0.01 0.1 1.0 Favours 30 minutes 1	10.0 100.0 Favours 15 minutes	

### Analysis 4.2. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 2 Peri-operative morbidity.

Review: Methods of vascular occlusion for elective liver resections

Comparison: 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC

Outcome: 2 Peri-operative morbidity

Study or subgroup	30 minutes n/N	15 minutes n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
I Wound infection					
Esaki 2006	3/48	1/44		100.0 %	2.75 [ 0.30, 25.47 ]
Subtotal (95% CI)	48	44	-	100.0 %	2.75 [ 0.30, 25.47 ]
Total events: 3 (30 minutes),	l (15 minutes)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 0.8$	89 (P = 0.37)				
2 Pulmonary complications					
Esaki 2006	2/48	2/44		100.0 %	0.92 [ 0.13, 6.23 ]
Subtotal (95% CI)	48	44	-	100.0 %	0.92 [ 0.13, 6.23 ]
Total events: 2 (30 minutes), 2	2 (15 minutes)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 0.0$	09 (P = 0.93)				
3 Bile leak					
Esaki 2006	4/48	7/44		100.0 %	0.52 [ 0.16, 1.67 ]
Subtotal (95% CI)	48	44	•	100.0 %	0.52 [ 0.16, 1.67 ]
Total events: 4 (30 minutes), 7	7 (15 minutes)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 1.0$	09 (P = 0.27)				
4 Cholangitis					
Esaki 2006	2/48	0/44		100.0 %	4.59 [ 0.23, 93.09 ]
Subtotal (95% CI)	48	44		100.0 %	4.59 [ 0.23, 93.09 ]
Total events: 2 (30 minutes), 0	0 (15 minutes)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 0.9$	99 (P = 0.32)				
5 Pancreatic fistula			_		
Esaki 2006	0/48	1/44		100.0 %	0.31 [ 0.01, 7.32 ]
Subtotal (95% CI)	48	44	-	100.0 %	0.31 [ 0.01, 7.32 ]
Total events: 0 (30 minutes),	l (15 minutes)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 0.7$	73 (P = 0.46)				
6 Bowel obstruction			_		
Esaki 2006	1/48	0/44		100.0 %	2.76 [ 0.12, 65.92 ]
Subtotal (95% CI)	48	44	-	100.0 %	2.76 [ 0.12, 65.92 ]
		-			
		C -	0.0010 0.1 1.0 10.0 1000.C		
		Fav	ours is minutes Favours 30 minut	85	

(Continued  $\dots$ )

Study or subgroup	30 minutes n/N	15 minutes n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	( Continued) Risk Ratio M-H,Fixed,95% Cl
Total events: 1 (30 minutes), 0 Heterogeneity: not applicable Test for overall effect: Z = 0.6	0 (15 minutes) 3 (P = 0.53)				
			0.0010 0.1 1.0 10.0 1000.0 Favours 15 minutes Favours 30 minutes		
Review: Methods of vascula Comparison: 4 30 minutes Outcome: 2 Peri-operative Study or subgroup	ar occlusion for elective intermittent PTC versu morbidity 30 minutes n/N	e liver resections us 15 minutes interr 15 minutes n/N	nittent PTC Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
I Wound infection Esaki 2006 Subtotal (95% CI)	3/48 <b>48</b>	1/44 <b>44</b>	-	100.0 % <b>100.0 %</b>	2.75 [ 0.30, 25.47 ] <b>2.75 [ 0.30, 25.47 ]</b>
Total events: 3 (30 minutes), Heterogeneity: not applicable Test for overall effect: Z = 0.8	I (15 minutes) 19 (P = 0.37)				
			0.0010 0.1 1.0 10.0 1000.0 Favours 15 minutes Favours 30 minutes		

Comparison: 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC

Outcome: 2 Peri-operative morbidity

Study or subgroup	30 minutes n/N	15 minutes n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl	
2 Pulmonary complications						
Esaki 2006	2/48	2/44		100.0 %	0.92 [ 0.13, 6.23 ]	
Subtotal (95% CI) Total events: 2 (30 minutes), 2 Heterogeneity: not applicable Test for overall effect: Z = 0.0	<b>48</b> 2 (15 minutes) 9 (P = 0.93)	44	•	100.0 %	0.92 [ 0.13, 6.23 ]	
			0.0010 0.1 1.0 10.0 1000.0 Favours 15 minutes Favours 30 minutes			
Review: Methods of vascula Comparison: 4 30 minutes Outcome: 2 Peri-operative Study or subgroup	ar occlusion for elective intermittent PTC vers morbidity 30 minutes n/N	e liver resections us 15 minutes interm 15 minutes n/N	iittent PTC Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl	
3 Bile leak						
Esaki 2006	4/48	7/44	-	100.0 %	0.52 [ 0.16, 1.67 ]	
<b>Subtotal (95% CI)</b> Total events: 4 (30 minutes), 7 Heterogeneity: not applicable Test for overall effect: Z = 1.0	<b>48</b> 7 (15 minutes) 9 (P = 0.27)	44		100.0 %	0.52 [ 0.16, 1.67 ]	
			0.0010 0.1 1.0 10.0 1000.0 Favours 15 minutes Favours 30 minutes			

Comparison: 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC

Outcome: 2 Peri-operative morbidity

Study or subgroup	30 minutes	15 minutes	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% Cl
4 Cholangitis					
Esaki 2006	2/48	0/44		100.0 %	4.59 [ 0.23, 93.09 ]
Subtotal (95% CI)	48	44		100.0 %	4.59 [ 0.23, 93.09 ]
Total events: 2 (30 minutes), 0	(15 minutes)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 0.99$	(P = 0.32)				
			0.0010 0.1 1.0 10.0 1000.0		
			Favours 15 minutes Favours 30 minutes		
Review: Methods of vascular	occlusion for elective	liver resections			
Comparison: 4 30 minutes in	ntermittent PTC versu	ıs 15 minutes interm	ittent PTC		
Outcome: 2 Peri-operative n	norbidity				
Study or subgroup	30 minutes	15 minutes	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% Cl
5 Panerpatic fictula					
Fsaki 2006	0/48	1/44		100.0 %	031[001 732]
	6,10			100.0 %	
Subtotal (95% CI)	48	44		100.0 %	0.31 [ 0.01, 7.32 ]
Iotal events: 0 (30 minutes), 1 (	(15 minutes)				
Heterogeneity: not applicable Test for overall effect: $7 = 0.73$	(P - 0.46)				
Test for overall effect. $\Sigma = 0.75$	(0 – 0.10)				
			Favours 15 minutes Favours 30 minutes		

Review: Methods of vascular occlusion for elective liver resections

Comparison: 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC

Outcome: 2 Peri-operative morbidity

Study or subgroup	30 minutes	15 minutes	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% CI
6 Bowel obstruction					
Esaki 2006	1/48	0/44		100.0 %	2.76 [ 0.12, 65.92 ]
Subtotal (95% CI)	48	44		100.0 %	2.76 [ 0.12, 65.92 ]
Total events:   (30 minutes),	0 (15 minutes)				
Heterogeneity: not applicable	e				
Test for overall effect: $Z = 0$ .	63 (P = 0.53)				
			0.0010 0.1 1.0 10.0	1000.0	

Favours 15 minutes Favours 30 minutes

### Analysis 4.3. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 3 Number needing transfusion.

Comparison: 4 30 minu	tes intermittent PTC ve	ersus 15 minutes int	ermittent PTC			
Outcome: 3 Number ne	eeding transfusion					
Study or subgroup	30 minutes n/N	15 minutes n/N	R M-H,Fix	lisk Ratio ed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
Esaki 2006	4/48	4/44		—	100.0 %	0.92 [ 0.24, 3.45 ]
Total (95% CI)	48	44			100.0 %	0.92 [ 0.24, 3.45 ]
Total events: 4 (30 minutes	s), 4 (15 minutes)					
Heterogeneity: not applica	ble					
Test for overall effect: $Z =$	0.13 (P = 0.90)					
				<u> </u>		
			0.01 0.1 1.	.0 10.0 100.0		
			Favours 30 minutes	Favours 15 minutes		

### Analysis 4.4. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 4 Number of units transfused.

Review: Methods of vascular occlusion for elective liver resections

Comparison: 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC

Outcome: 4 Number of units transfused



### Analysis 4.5. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 5 Number of units of FFP transfused.



### Analysis 4.6. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 6 Hospital stay.

Review: Methods of vascular occlusion for elective liver resections

Comparison: 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC

Outcome: 6 Hospital stay



### Analysis 4.7. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 7 Operating time.

Review: Methods of	of vascular occlus	sion for elective	liver resections					
Comparison: 4 30	minutes intermit	tent PTC versus	s 15 minutes in	termittent PTC				
Outcome: 7 Opera	ating time							
Study or subgroup	30 minutes		15 minutes		Mear	n Difference	Weight	Mean Difference
	N	Mean(SD)	N	Mean(SD)	IV,Fixed	1,95% CI		IV,Fixed,95% Cl
Esaki 2006	48	255 (122)	44	307 (122)			100.0 %	-52.00 [ -101.91, -2.09 ]
Total (95% CI)	48		44		-		100.0 %	-52.00 [ -101.91, -2.09 ]
Heterogeneity: not ap	oplicable							
Test for overall effect:	: Z = 2.04 (P =	0.041)						
				- I C	0 -50 0	50 IC	0	
				Favours	30 minutes	Favours 15 m	ninutes	
Methods of vascular	r occlusion for	elective liver	resections (	Review)				115
Copyright © 2009 T	he Cochrane	Collaboration	n. Published b	y John Wiley &	& Sons, Ltd.			

### Analysis 4.8. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 8 Blood loss (ml).

Review: Methods of vascular occlusion for elective liver resections

Comparison: 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC

Outcome: 8 Blood loss (ml)

Study or subgroup	30 minutes N	Mean(SD)	15 minutes N	Mean(SD)	Mean Differend IV,Fixed,95% Cl	ce Weight	Mean Difference IV.Fixed,95% Cl
		. ,		. ,			
Esski 2006	48	49 (38)	44	62 (38)		100.0 %	-1 30 [ -2 85 0 25 1
	(0	1.7 (5.0)		0.2 (5.0)	Ţ	100.0 %	1 20 [ 2 25 0 25 ]
Subtotal (95% CI)	48		44		1	100.0 %	-1.30 [ -2.85, 0.25 ]
Test for overall effect: $Z =$	1.64 (P = 0.10)						
2 Operative							
Esaki 2006	48	391 (99)	44	352 (99)			39.00 [ -1.50, 79.50 ]
Subtotal (95% CI)	48		44			- 100.0 %	39.00 [ -1.50, 79.50 ]
Heterogeneity: not applica	ble						
Test for overall effect: $Z =$	1.89 (P = 0.059	9)					
Test for subgroup difference	ces: $Chi^2 = 3.80$	, $df = 1$ (P = 0	.05), I <sup>2</sup> =74%				
				-	50 -25 0 25	50	
				Favou	rs 30 minutes Favours	15 minutes	
Review: Methods of vas	cular occlusion	for elective live	r resections				
Comparison: 4.30 minur	tes intermittent	PTC versus 1	minutes intern	oittent PTC			
Companson. 4 50 minu	tes intermitterit	TTC Versus T	Thindles intern				
Outcome: 8 Blood loss	(ml)						
Study or subgroup	30 minutes		15 minutes		Mean Differer	nce Weight	Mean Difference
	N	Mean(SD)	N	Mean(SD)	IV,Fixed,95% CI		IV,Fixed,95% CI
I Transection (per sq cm)							
Esaki 2006	48	4.9 (3.8)	44	6.2 (3.8)		100.0 %	-1.30 [ -2.85, 0.25 ]
Subtotal (95% CI)	48		44		•	100.0 %	-1.30 [ -2.85, 0.25 ]
Heterogeneity: not applica	ble						
Test for overall effect: $Z =$	1.64 (P = 0.10)						
						I	
				_	-50 -25 0 25	50	
				Favo	urs 30 minutes Favour	s 15 minutes	

Comparison: 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC

Outcome: 8 Blood loss (ml)



### Analysis 4.9. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 9 Bilirubin (micromole/litre).

Methods of vascular occ	lusion for elec	tive liver res	ections (Revie	ew)			117
				- 10 Favours	0 -5 0 30 minutes Fav	5 10 rours 15 minutes	(Continued )
Subtotal (95% CI)	48		44			100.0 %	1.70 [ -1.33, 4.73 ]
Esaki 2006	48	15.4 (7.4)	44	13.7 (7.4)	-	100.0 %	1.70 [ -1.33, 4.73 ]
Test for overall effect: $Z =$ 3 Third post-operative day	0.20 (P = 0.84)						
Subtotal (95% CI) Heterogeneity: not applica	<b>48</b> able		44			100.0 %	0.90 [ -7.98, 9.78 ]
2 Second post-operative c Esaki 2006	day 48	7.  (2 .7)	44	16.2 (21.7)		100.0 %	0.90 [ -7.98, 9.78 ]
Heterogeneity: not applica Test for overall effect: Z =	ble 0.18 (P = 0.86)						
Subtotal (95% CI)	48		44			100.0 %	0.80 [ -8.08, 9.68 ]
I First post-operative day Esaki 2006	48	18.8 (21.7)	44	18 (21.7)		100.0 %	0.80 [ -8.08, 9.68 ]
Study or subgroup	30 minutes N	Mean(SD)	15 minutes N	Mean(SD)	Mean Diffe IV,Fixed,95%	erence Weight Cl	Mean Difference IV,Fixed,95% CI
Outcome: 9 Bilirubin (n	nicromole/litre)						
Comparison: 4 30 minu	ites intermittent i	PIC versus 15	minutes intermi	ttent PTC			
C				Hand DTC			
Review: Methods of vas	cular occlusion fo	or elective liver	resections				

Study or subgroup	30 minutes N	Mean(SD)	15 minutes N	Mean(SD)	Mean Difference IV,Fixed,95% Cl	Weight	( Continued) Mean Difference IV,Fixed,95% Cl
Heterogeneity: not applica	ible						
Test for overall effect: Z =	I.IO (P = 0.27)						
4 Fifth post-operative day							
Esaki 2006	48	13.7 (8.2)	44	12 (8.2)		100.0 %	1.70 [ -1.65, 5.05 ]
Subtotal (95% CI)	48		44		-	100.0 %	1.70 [ -1.65, 5.05 ]
Heterogeneity: not applica	ible					10000 /0	1, 0 [ 103, 503 ]
Test for overall effect: Z =	0.99 (P = 0.32)						
5 Seventh post-operative	day						
Esaki 2006	, 48	13.7 (5.7)	44	11.9 (5.7)		100.0 %	1.80 [ -0.53, 4.13 ]
Subtatal (95% CI)	48		44		•	100.0 %	1 80 [ -0 53 4 13 ]
Heterogeneity: not applica	ible		11			100.0 /0	1.00 [ -0.95, 4.15 ]
Test for overall effect: $7 =$	5  (P = 0  3)						
Test for subgroup differen	res: $Chi^2 = 0.08$	. df = 4 (P = 1.	00), $ ^2 = 0.0\%$				
lest for subgroup different	0.00						
					5 0 5 10	)	
				Favours	30 minutes Envours 15 m	in tec	
				i avoui s		inutes	
Review: Methods of vas	cular occlusion f	or elective liver	resections				
Comparison: 4 30 minu	tes intermittent	PTC versus 15	minutes intermi	ttent PTC			
Outcome: 9 Bilirubin (n	nicromole/litre)						
,	,						
Study or subgroup	30 minutes		15 minutes		Maan Difference	\\/eight	Maan Difference
study or subgroup	SU minutes	Maan(CD)	15 minutes	Maan(SD)	V Fixed 95% Cl	vveigni	VEwad 95% CI
	IN	riean(SD)	IN	Mean(SD)	IV,FIXEU,75% CI		IV,FIXED,75% CI
I First post-operative day							
Esaki 2006							
	48	18.8 (21.7)	44	18 (21.7)		100.0 %	0.80 [ -8.08, 9.68 ]
Subtatal (95% CI)	48 <b>48</b>	18.8 (21.7)	44 <b>44</b>	18 (21.7)		100.0 %	0.80 [ -8.08, 9.68 ]
Subtotal (95% CI)	48 <b>48</b>	18.8 (21.7)	44 <b>44</b>	18 (21.7)		100.0 % 100.0 %	0.80 [ -8.08, 9.68 ] <b>0.80 [ -8.08, 9.68 ]</b>
Subtotal (95% CI) Heterogeneity: not applica	48 <b>48</b> Ible	18.8 (21.7)	44 <b>44</b>	18 (21.7)		100.0 % <b>100.0 %</b>	0.80 [ -8.08, 9.68 ] <b>0.80 [ -8.08, 9.68 ]</b>
Subtotal (95% CI) Heterogeneity: not applica Test for overall effect: Z =	48 <b>48</b> o.18 (P = 0.86)	18.8 (21.7)	44 <b>44</b>	18 (21.7)		100.0 %	0.80 [ -8.08, 9.68 ] 0.80 [ -8.08, 9.68 ]
<b>Subtotal (95% CI)</b> Heterogeneity: not applica Test for overall effect: Z =	48 <b>48</b> o.18 (P = 0.86)	18.8 (21.7)	44 <b>44</b>	I8 (21.7)		100.0 %	0.80 [ -8.08, 9.68 ] 0.80 [ -8.08, 9.68 ]
<b>Subtotal (95% CI)</b> Heterogeneity: not applica Test for overall effect: Z =	48 <b>48</b> 0.18 (P = 0.86)	18.8 (21.7)	44 <b>44</b>	18 (21.7) -10	-5 0 5 10	100.0 % 100.0 %	0.80 [ -8.08, 9.68 ] 0.80 [ -8.08, 9.68 ]
Subtotal (95% CI) Heterogeneity: not applica Test for overall effect: Z =	48 48 0.18 (P = 0.86)	18.8 (21.7)	44 <b>44</b>	18 (21.7) -10 Favours	-5 0 5 10 30 minutes Favours 15 mi	100.0 % 100.0 %	0.80 [ -8.08, 9.68 ] 0.80 [ -8.08, 9.68 ]
Subtotal (95% CI) Heterogeneity: not applica Test for overall effect: Z =	48 <b>48</b> 0.18 (P = 0.86)	18.8 (21.7)	44 <b>44</b>	18 (21.7) -10 Favours :	-5 0 5 10 30 minutes Favours 15 mi	100.0 % 100.0 %	0.80 [ -8.08, 9.68 ] 0.80 [ -8.08, 9.68 ]
Subtotal (95% CI) Heterogeneity: not applica Test for overall effect: Z =	48 <b>48</b> 0.18 (P = 0.86)	18.8 (21.7)	44 <b>44</b>	18 (21.7) -10 Favours :	-5 0 5 10 30 minutes Favours 15 mi	100.0 % 100.0 %	0.80 [ -8.08, 9.68 ] 0.80 [ -8.08, 9.68 ]
Subtotal (95% CI) Heterogeneity: not applica Test for overall effect: Z =	48 <b>48</b> 0.18 (P = 0.86)	18.8 (21.7)	44 <b>44</b>	18 (21.7) -10 Favours :	-5 0 5 10 30 minutes Favours 15 mi	100.0 %	0.80 [ -8.08, 9.68 ] 0.80 [ -8.08, 9.68 ]
Subtotal (95% CI) Heterogeneity: not applica Test for overall effect: Z =	48 <b>48</b> 0.18 (P = 0.86)	18.8 (21.7)	44 <b>44</b>	18 (21.7) -10 Favours :	-5 0 5 10 30 minutes Favours 15 mi	100.0 %	0.80 [ -8.08, 9.68 ] 0.80 [ -8.08, 9.68 ]
Subtotal (95% CI) Heterogeneity: not applica Test for overall effect: Z =	48 <b>48</b> 0.18 (P = 0.86)	18.8 (21.7)	44 <b>44</b>	18 (21.7) -10 Favours :	-5 0 5 10 30 minutes Favours 15 mi	100.0 %	0.80 [ -8.08, 9.68 ] 0.80 [ -8.08, 9.68 ]
Subtotal (95% CI) Heterogeneity: not applica Test for overall effect: Z =	48 <b>48</b> 0.18 (P = 0.86)	18.8 (21.7)	44 <b>44</b>	18 (21.7) -10 Favours :	-5 0 5 10 30 minutes Favours 15 mi	100.0 %	0.80 [ -8.08, 9.68 ] 0.80 [ -8.08, 9.68 ]

Comparison: 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC

Outcome: 9 Bilirubin (micromole/litre)

Study or subgroup	30 minutes		15 minutes		Mean Difference	Weight	Mean Difference
	N	Mean(SD)	N	Mean(SD)	IV,Fixed,95% CI		IV,Fixed,95% CI
2 Second post-operative d Esaki 2006	ay 48	17.1 (21.7)	44	16.2 (21.7)		100.0 %	0.90 [ -7.98, 9.78 ]
Subtatal (95% CI)	48		44	· · ·		100 0 %	0.00 [.7.08.0.78]
Heterogeneity: not applical	<b>HO</b>		TT			100.0 /0	0.90 [ -/.90, 9./0 ]
Test for overall effect: Z =	0.20 (P = 0.84)						
	, ,						
				- I C	-5 0 5 10		
				Favours	30 minutes Favours 15 mi	nutes	
Review: Methods of vase	cular occlusion	for elective live	r resections				
Comparison: 4 30 minut	es intermittent	PTC versus 15	minutes intermi	ttent PTC			
Outcome: 9 Bilinubin (m	icromole/litre)						
	icromole/litre)						
Study or subgroup	30 minutes		15 minutes		Mean Difference	Weight	Mean Difference
stady of sabgroup	N	Mean(SD)	N	Mean(SD)	IV,Fixed,95% CI	, roight	IV,Fixed,95% CI
		( )		( )			<u> </u>
3 Third post-operative day Esaki 2006	48	154 (74)	44	137 (74)		100.0 %	70 [ -  33 473 ]
$\mathbf{C} = 1 + 1 + 0 \mathbf{C} 0 \mathbf{C} \mathbf{I}$	(0	1011 (711)				100.0 0/	
Subtotal (95% CI)	<b>48</b>		44			100.0 %	1./0 [ -1.33, 4./3 ]
Test for overall effect: $7 =$	0 (P = 0.27)						
	1.10 (1 0.27)						
				-10	-5 0 5 10		
				-10 Favours	-5 0 5 10 30 minutes Favours 15 mi	nutes	
				-10 Favours	-5 0 5 10 30 minutes Favours 15 mi	nutes	
				-10 Favours	-5 0 5 10 30 minutes Favours 15 mi	nutes	
				-10 Favours	-5 0 5 10 30 minutes Favours 15 mi	nutes	
				-10 Favours	-5 0 5 10 30 minutes Favours I5 mi	nutes	
				-10 Favours	-5 0 5 10 30 minutes Favours I5 mi	nutes	
				-10 Favours	-5 0 5 10 30 minutes Favours 15 mi	nutes	
				- 10 Favours	-5 0 5 10 30 minutes Favours 15 mi	nutes	
				- 10 Favours	-5 0 5 10 30 minutes Favours I5 mi	nutes	

Comparison: 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC

Outcome: 9 Bilirubin (micromole/litre)

Study or subgroup	30 minutes N	Mean(SD)	15 minutes N	Mean(SD)	Mean Difference IV,Fixed,95% Cl	Weight	Mean Difference IV,Fixed,95% Cl
4 Fifth post-operative day Esaki 2006	48	13.7 (8.2)	44	12 (8.2)		100.0 %	1.70 [ -1.65, 5.05 ]
Subtotal (95% CI)	48		44		-	100.0 %	1.70 [ -1.65, 5.05 ]
Heterogeneity: not applical	ble						
Test for overall effect: Z =	0.99 (P = 0.32)						
				-10	-5 0 5 10		
				Favours	30 minutes Favours 15 mi	nutes	
Review: Methods of vase	cular occlusion f	or elective live	r resections				
Comparison: 4 30 minut	tes intermittent	PTC versus 15	minutes interm	ittent PTC			
Outserver 9 Bilinubin (m	i ene ne e le /litue)						
	iici oi iiole/iiti e)						
Study or subgroup	30 minutes		15 minutes		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fixed,95% CI		IV,Fixed,95% CI
5 Seventh post-operative of	day						
Esaki 2006	48	13.7 (5.7)	44	11.9 (5.7)	+	100.0 %	1.80 [ -0.53, 4.13 ]
Subtotal (95% CI)	48		44		-	100.0 %	1.80 [ -0.53, 4.13 ]
Heterogeneity: not applical	ble						
lest for overall effect: Z –	1.51 (P – 0.13)						
				-10	-5 0 5 10		
				Favours	30 minutes Favours 15 mi	nutes	

# Analysis 4.10. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 10 Prothrombin activity (percentage of normal).

Review: Methods of vascular occlusion for elective liver resections

Comparison: 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC

Outcome: 10 Prothrombin activity (percentage of normal)

Study or subgroup	30 minutes		15 minutes		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fixed,95% CI		IV,Fixed,95% CI
First post-operative day	40		4.4				400 5 11 50 100 3
ESAKI 2006	70	-63.7 (16.6)	44	-37.1 (10.0)	-	100.0 %	-4.00 [ -11.37, 1.77 ]
Subtotal (95% CI)	48		44	-		100.0 %	-4.80 [ -11.59, 1.99 ]
Heterogeneity: not applic	able						
Test for overall effect: Z =	= 1.39 (P = 0.17)						
2 Third post-operative da	ay 10	72.0 (20.4)		744 (20.4)		-	
Esaki 2006	48	-73.9 (20.6)	44	-/6.6 (20.6)		100.0 %	2.70 [ -5.73, 11.13 ]
Subtotal (95% CI)	48		44			100.0 %	2.70 [ -5.73, 11.13 ]
Heterogeneity: not applic	able						
Test for overall effect: Z =	= 0.63 (P = 0.53)						
3 Seventh post-operative	e day						
Esaki 2006	48	-62.6 (20.6)	44	-63.2 (20.6)		100.0 %	0.60 [ -7.83, 9.03 ]
Subtotal (95% CI)	48		44			100.0 %	0.60 [ -7.83, 9.03 ]
Heterogeneity: not applic	able						
Test for overall effect: Z =	= 0.14 (P = 0.89)						
Test for subgroup differer	nces: $Chi^2 = 2.08$ ,	df = 2 (P = 0.3)	5), I <sup>2</sup> =4%				
				1			
				-1	0 -5 0 5	10	
				Favours	30 minutes Favours 15	minutes	

Comparison: 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC

Outcome: 10 Prothrombin activity (percentage of normal)



Comparison: 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC

Outcome: 10 Prothrombin activity (percentage of normal)



# Analysis 4.11. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 11 AST (aspartate transaminase) (IU/litre).

Review: Methods of vascular occlusion for elective liver resections

Comparison: 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC

Outcome: II AST (aspartate transaminase) (IU/litre)

Study or subgroup	30 minutes		15 minutes		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fixed,95% CI		IV,Fixed,95% CI
I First post-operative day							
Esaki 2006	48	235 (320)	44	274 (320)		100.0 %	-39.00 [ -169.90, 91.90 ]
Subtotal (95% CI)	48		44			100.0 %	-39.00 [ -169.90, 91.90 ]
Heterogeneity: not applic	able						
Test for overall effect: Z =	= 0.58 (P = 0.56	)					
2 Second post-operative	day						
Esaki 2006	48	150 (37)	44	160 (37)		100.0 %	-10.00 [ -25.14, 5.14 ]
Subtotal (95% CI)	48		44		•	100.0 %	-10.00 [ -25.14, 5.14 ]
Heterogeneity: not applic	able						
Test for overall effect: Z =	= 1.29 (P = 0.20	)					
3 Third post-operative da	у						
Esaki 2006	48	76 (23)	44	80 (23)	-	100.0 %	-4.00 [ -13.41, 5.41 ]
Subtotal (95% CI)	48		44		•	100.0 %	-4.00 [ -13.41, 5.41 ]
				-20	00 -100 0 100	200	
				Favours	s 30 minutes Favours 15	minutes	
							(Continued )

Methods of vascular occlusion for elective liver resections (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	30 minutes N	Mean(SD)	15 minutes N	Mean(SD)	Mean Difference IV,Fixed,95% Cl	Weight	( Continued) Mean Difference IV.Fixed,95% Cl
Heterogeneity: not applic	able				,,		,,
Test for overall effect: Z :	= 0.83 (P = 0.40	))					
4 Fifth post-operative day	,	,					
Esaki 2006	48	48 (23)	44	48 (23)		100.0 %	0.0 [ -9.41, 9.41 ]
Subtotal (95% CI)	48		44		+	100.0 %	0.0 [ -9.41, 9.41 ]
Heterogeneity: not applic	able						
Test for overall effect: Z =	= 0.0 (P = 1.0)						
5 Seventh post-operative	day						
Esaki 2006	48	39 (16)	44	37 (16)	-	100.0 %	2.00 [ -4.55, 8.55 ]
Subtotal (95% CI)	48		44		•	100.0 %	2.00 [ -4.55, 8.55 ]
Heterogeneity: not applic	able						
Test for overall effect: Z =	= 0.60 (P = 0.5	5)					
Test for subgroup differen	nces: Chi <sup>2</sup> = 2.9	2, df = 4 (P =	0.57), l <sup>2</sup> =0.0%	Ś			
						I	
				-200	-100 0 100 2	200	
				Favours	30 minutes Favours 15	minutes	
Review: Methods of va	scular occlusior	for elective liv	er resections				
Comparison: 4 30 min	utes intermitter	nt PTC versus I	5 minutes inte	rmittent PTC			
		·····					
Outcome: TTAST (as	oar late transam	inase) (iO/iitre)					
Study or subgroup	30 minutes		15 minutes		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fixed,95% Cl		IV,Fixed,95% CI
First post-operative day	/						
Esaki 2006	48	235 (320)	44	274 (320)		100.0 %	-39.00 [ -169.90, 91.90 ]
		()					
Subtotal (95% CI)	48		44			100.0 %	-39.00 [ -169.90, 91.90 ]
Heterogeneity: not applic	able						
Test for overall effect: Z =	= 0.58 (P = 0.56	ó)					
				1		1	
				-200	-100 0 100 2	00	
				Favours 3	0 minutes Favours 15 r	ninutes	

Comparison: 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC

Outcome: II AST (aspartate transaminase) (IU/litre)



Comparison: 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC

Outcome: II AST (aspartate transaminase) (IU/litre)

Study or subgroup	30 minutes N	Mean(SD)	15 minutes N	Mean(SD)	Mean Difference IV,Fixed,95% CI	Weight	Mean Difference IV,Fixed,95% CI
4 Fifth post-operative day	48	48 (23)	44	48 (23)	+	100.0 %	00[-94  94 ]
Subtatal (05% CI)	49	10 (23)	6.6	10 (23)	Ţ	100.0.04	
Heterogeneity: not applicable	40 ble		44			100.0 %	0.0 [ -9.41, 9.41 ]
Test for overall effect: $Z = 0$	0.0 (P = 1.0)						
				-20 Eavours	00 -100 0 100 20	0	
						in acco	
Review: Methods of vasc	ular occlusion f	for elective liver	- resections				
Comparison: 4 30 minut	es intermittent	PTC versus 15	minutes intermi	ttent PTC			
Outcome: LLAST (aspa	rtate transamin	ase) (IU/litre)					
outcome. This of (aspa							
Study or subgroup	30 minutes N	Mean(SD)	15 minutes N	Mean(SD)	Mean Difference IV,Fixed,95% CI	Weight	Mean Difference IV,Fixed,95% CI
5 Seventh post-operative d	ay						
Esaki 2006	48	39 (16)	44	37 (16)	-	100.0 %	2.00 [ -4.55, 8.55 ]
Subtotal (95% CI)	48		44		•	100.0 %	2.00 [ -4.55, 8.55 ]
Heterogeneity: not applicat	ole						
lest for overall effect: $\angle = 0$	0.60 (P = 0.55)						
				-200	-100 0 100 200		
				Favours 2	30 minutes Favours 15 mir	nutes	

# Analysis 4.12. Comparison 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC, Outcome 12 ALT (alanine transaminase) (IU/litre).

Review: Methods of vascular occlusion for elective liver resections

Comparison: 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC

Outcome: 12 ALT (alanine transaminase) (IU/litre)

Study or subgroup	30 minutes		15 minutes		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fixed,95% CI		IV,Fixed,95% CI
First post-operative day	,						
Esaki 2006	48	255 (349)	44	224 (349)		- 100.0 %	31.00 [-111.76, 173.76 ]
Subtotal (95% CI)	48		44			100.0 %	31.00 [ -111.76, 173.76 ]
Heterogeneity: not applic	able						
Test for overall effect: Z =	= 0.43 (P = 0.67	7)					
2 Second post-operative	day						
Esaki 2006	48	203 (349)	44	179 (349)		100.0 %	24.00 [ -118.76, 166.76 ]
Subtotal (95% CI)	48		44			100.0 %	24.00 [ -118.76, 166.76 ]
Heterogeneity: not applic	able						
Test for overall effect: Z =	= 0.33 (P = 0.74	4)					
3 Third post-operative da	ıy						
Esaki 2006	48	130 (182)	44	115 (182)		100.0 %	5.00 [ -59.45, 89.45 ]
Subtotal (95% CI)	48		44			100.0 %	15.00 [ -59.45, 89.45 ]
Heterogeneity: not applic	able						
Test for overall effect: Z =	= 0.39 (P = 0.69	9)					
4 Fifth post-operative day	,				$\perp$		
Esaki 2006	48	106 (172)	44	95 (172)		100.0 %	.00 [ -59.36, 8 .36 ]
Subtotal (95% CI)	48		44			100.0 %	11.00 [ -59.36, 81.36 ]
Heterogeneity: not applic	able						
Test for overall effect: Z =	= 0.31 (P = 0.76	6)					
5 Seventh post-operative	day						
Esaki 2006	48	85 (126)	44	89 (126)		100.0 %	-4.00 [ -55.54, 47.54 ]
Subtotal (95% CI)	48		44		-	100.0 %	-4.00 [ -55.54, 47.54 ]
Heterogeneity: not applic	able						
Test for overall effect: Z =	= 0.15 (P = 0.88)	8)					
Test for subgroup differer	nces: $Chi^2 = 0.3$	9, df = 4 (P = 0	.98), I <sup>2</sup> =0.0%				
				I		1	
				-100	-50 0 50	100	
				Favours	30 minutes Favours 15	minutes	

Comparison: 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC

Outcome: 12 ALT (alanine transaminase) (IU/litre)



Methods of vascular occlusion for elective liver resections (Review)

Copyright  $\textcircled{\sc 0}$  2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Comparison: 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC

Outcome: 12 ALT (alanine transaminase) (IU/litre)



Comparison: 4 30 minutes intermittent PTC versus 15 minutes intermittent PTC

Outcome: 12 ALT (alanine transaminase) (IU/litre)



### Analysis 5.1. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 1 Bilirubin (micromole/litre).

Review: Methods of vas	cular occlusion	for elective live	resections					
Comparison: 5 20 minu	ites intermittent	PTC versus 10	minutes inten	mittent PTC				
Outcome: I Bilirubin (n	nicromole/litre)							
Study or subgroup	20 minutes N	Mean(SD)	10 minutes N	Mean(SD)	Mear IV,Fixed	n Difference 1,95% Cl	Weight	Mean Difference IV,Fixed,95% Cl
I Second post-operative of	day					_		
Brooks 2007	4	71.6 (45)	5	37.3 (26.3)			100.0 %	34.30 [ -15.46, 84.06 ]
<b>Subtotal (95% CI)</b> Heterogeneity: not applica Test for overall effect: Z =	<b>4</b> able 1.35 (P = 0.18)	)	5		_		100.0 %	34.30 [ -15.46, 84.06 ]
				-10	0 -50 C	50 10	00	
				Favours	20 minutes	Favours 10 m	ninutes	

Comparison: 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC

Outcome: I Bilirubin (micromole/litre)



### Analysis 5.2. Comparison 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC, Outcome 2 ALT (alanine transaminase) (IU/litre).

lar occlusion for elective	e liver resections			
s intermittent PTC versu	us 10 minutes intermittent PTC			
transaminase) (IU/litre)				
) minutes	10 minutes	Mean Difference	Weight	Mean Difference
N Mean(SD)	N Mean(SD)	IV,Fixed,95% CI		IV,Fixed,95% CI
4 903.4 (933.4)	) 5 416.5 (298.6)		100.0 %	486.90 [ -464.52, 1438.32 ]
<b>4</b> 00 (P = 0.32)	5		100.0 % 48	6.90 [ -464.52, 1438.32 ]
	-100	D -500 0 500 IC	00	
	Favours 2	20 minutes Favours 10 r	ninutes	
	lar occlusion for elective s intermittent PTC versu transaminase) (IU/litre) ) minutes N Mean(SD) , 4 903.4 (933.4) <b>4</b> 00 (P = 0.32)	lar occlusion for elective liver resections s intermittent PTC versus 10 minutes intermittent PTC transaminase) (IU/litre) D minutes 10 minutes N Mean(SD) N Mean(SD) 4 903.4 (933.4) 5 416.5 (298.6) 4 5 e 000 (P = 0.32) -1000 Favours 1	lar occlusion for elective liver resections s intermittent PTC versus 10 minutes intermittent PTC transaminase) (IU/litre) 0 minutes I0 minutes Mean Difference N Mean(SD) N Mean(SD) IV,Fixed,95% CI 4 903.4 (933.4) 5 416.5 (298.6) 4 5 9 00 (P = 0.32) -1000 -500 0 500 10 Favours 20 minutes Favours 10 r	lar occlusion for elective liver resections s intermittent PTC versus 10 minutes intermittent PTC transaminase) (IU/litre) 0 minutes 10 minutes Mean Difference Weight N Mean(SD) N Mean(SD) IV.Fixed.95% CI 4 903.4 (933.4) 5 416.5 (298.6) 4 5 100.0 % 48 00 (P = 0.32) -1000 -500 0 500 1000 Favours 20 minutes Favours 10 minutes

Comparison: 5 20 minutes intermittent PTC versus 10 minutes intermittent PTC

Outcome: 2 ALT (alanine transaminase) (IU/litre)



### Analysis 6.1. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion, Outcome 1 Mortality.

Review: Methods of vascular occlusion for elective liver resections Comparison: 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion Outcome: I Mortality Risk Ratio IPC Risk Ratio Study or subgroup Intermittent occlusion Weight n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI Petrowsky 2006 0/37 100.0 % 3.08 [ 0.13, 73.24 ] 1/36 Smyrniotis 2006 0/27 0/27 0.0 % 0.0 [ 0.0, 0.0 ] Total (95% CI) 63 64 100.0 % 3.08 [ 0.13, 73.24 ] Total events: I (IPC), 0 (Intermittent occlusion) Heterogeneity:  $Chi^2 = 0.0$ , df = 0 (P = 1.00);  $I^2 = 0.0\%$ Test for overall effect: Z = 0.70 (P = 0.49) 0.01 0.1 1.0 10.0 100.0 Favours IPC Favours intermittent

## Analysis 6.2. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion, Outcome 2 Liver failure.

Review: Methods of vascular occlusion for elective liver resections

Comparison: 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion

Outcome: 2 Liver failure

Study or subgroup	IPC	Intermittent occlusion		Risk Ratio		Weight	Risk Ratio
	n/N	n/N		M-H,Fixed,95%	CI		M-H,Fixed,95% Cl
Petrowsky 2006	0/36	2/37	-			100.0 %	0.21 [ 0.01, 4.14 ]
Total (95% CI)	36	37		-		100.0 %	0.21 [ 0.01, 4.14 ]
Total events: 0 (IPC), 2 (In	termittent occlu	sion)					
Heterogeneity: not applica	ible						
Test for overall effect: $Z =$	1.03 (P = 0.30)						
			0.0010	0.1 1.0 10.0	1000.0		

Favours IPC Favours intermittent

## Analysis 6.3. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion, Outcome 3 Peri-operative morbidity.

Review: Methods of vascular occlusion for elective liver resections

Comparison: 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion

Outcome: 3 Peri-operative morbidity

Study or subgroup	IPC	Intermittent occlusion	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% CI
I Abdominal collections					
Petrowsky 2006	4/36	3/37		100.0 %	1.37 [ 0.33, 5.70 ]
Subtotal (95% CI)	36	37	-	100.0 %	1.37 [ 0.33, 5.70 ]
Total events: 4 (IPC), 3 (Inten	mittent occlusion)	)			
Heterogeneity: not applicable	:				
Test for overall effect: $Z = 0.4$	43 (P = 0.66)				
2 Wound infection					
Petrowsky 2006	2/36	3/37		100.0 %	0.69 [ 0.12, 3.86 ]
Subtotal (95% CI)	36	37	-	100.0 %	0.69 [ 0.12, 3.86 ]
Total events: 2 (IPC), 3 (Inten	mittent occlusion)	)			
Heterogeneity: not applicable	:				
Test for overall effect: $Z = 0.4$	43 (P = 0.67)				
			0.01 0.1 1.0 10.0 100.0		
			Favours IPC Favours intermit	tent	
					(Continued )

Methods of vascular occlusion for elective liver resections (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study or subgroup	IPC	Intermittent occlusion	Risk Ratio	Weight	( Continued) Risk Ratio	
, , ,	n/N	n/N	M-H,Fixed,95% Cl	0	M-H,Fixed,95% Cl	
3 Pulmonary complications						
Petrowsky 2006	3/36	1/37		11.0 %	3.08 [ 0.34, 28.28 ]	
Smyrniotis 2006	6/27	8/27		89.0 %	0.75 [ 0.30, 1.87 ]	
Subtotal (95% CI)	63	64	+	100.0 %	1.01 [ 0.44, 2.29 ]	
Total events: 9 (IPC), 9 (Interr	nittent occlusior	ר)				
Heterogeneity: Chi <sup>2</sup> = 1.38, d	f = 1 (P = 0.24)	); I <sup>2</sup> =27%				
Test for overall effect: $Z = 0.0$	I (P = 0.99)					
4 Bile leak						
Petrowsky 2006	4/36	3/37		59.7 %	1.37 [ 0.33, 5.70 ]	
Smyrniotis 2006	3/27	2/27	<b>_</b>	40.3 %	I.50 [ 0.27, 8.28 ]	
Subtotal (95% CI)	63	64	-	100.0 %	1.42 [ 0.48, 4.25 ]	
Total events: 7 (IPC), 5 (Interr	nittent occlusior	ר)				
Heterogeneity: Chi <sup>2</sup> = 0.01, d	f = 1 (P = 0.94)	); I <sup>2</sup> =0.0%				
Test for overall effect: $Z = 0.6$	3 (P = 0.53)					

0.01 0.1 1.0 10.0 100.0 Favours IPC Favours intermittent

Review: Methods of vascular occlusion for elective liver resections

Comparison: 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion

Outcome: 3 Peri-operative morbidity

M-H,Fixed,95% Cl
1.37 [ 0.33, 5.70 ]
37 [ 0.33, 5.70 ]

Comparison: 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion

Outcome: 3 Peri-operative morbidity

Study or subgroup	IPC n/N	Intermittent occlusion n/N	Risk Ratio M-H.Fixed,95% Cl	Weight	Risk Ratio M-H.Fixed.95% Cl
2 Wound infection					
Petrowsky 2006	2/36	3/37	— <u>—</u>	100.0 %	0.69 [ 0.12, 3.86 ]
Subtotal (95% CI)	36	37	-	100.0 %	0.69 [ 0.12, 3.86 ]
Total events: 2 (IPC), 3 (Intern	nittent occlusic	n)			
Heterogeneity: not applicable Test for overall effect: Z = 0.4	3 (P = 0.67)				
	. ,				
			0.01 0.1 1.0 10.0 100.0		
			ravours inc ravours intermitten		
Review: Methods of vascula	r occlusion for	elective liver resections			
Comparison: 6 Ischaemic p	reconditioning	followed by continuous occlusi	on (IPC) versus intermittent occlusion		
Outcome: 3 Peri-operative	morbidity				
Study or subgroup	IPC	Intermittent occlusion	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% Cl
3 Pulmonary complications Petrowsky 2006	3/36	1/37		11.0 %	3.08 [ 0.34, 28.28 ]
Smyrniotis 2006	6/27	8/27		89.0 %	075[030]87]
Subtotal (95% CI)	63	64	-	100.0 %	1 01 [ 0 44 2 29 ]
Total events: 9 (IPC), 9 (Intern	nittent occlusic	n)		100.0 /0	1.01 [ 0.11, 2.27 ]
Heterogeneity: $Chi^2 = 1.38$ , d	f = 1 (P = 0.24)	i); l <sup>2</sup> =27%			
lest for overall effect: $\angle = 0.0$	T (P = 0.99)				
			0.01 0.1 1.0 10.0 100.0		
			Favours IPC Favours intermitten		

Comparison: 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion

Outcome: 3 Peri-operative morbidity

Study or subgroup	IPC	Intermittent occlusion		Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fi	xed,95% Cl		M-H,Fixed,95% Cl
4 Bile leak						
Petrowsky 2006	4/36	3/37	_	-	59.7 %	1.37 [ 0.33, 5.70 ]
Smyrniotis 2006	3/27	2/27			40.3 %	1.50 [ 0.27, 8.28 ]
Subtotal (95% CI)	63	64	-	-	100.0 %	1.42 [ 0.48, 4.25 ]
Total events: 7 (IPC), 5 (Inter	mittent occlusi	on)				
Heterogeneity: $Chi^2 = 0.01$ , o	df = 1 (P = 0.9)	4); I <sup>2</sup> =0.0%				
Test for overall effect: $Z = 0.6$	63 (P = 0.53)					
			0.01 0.1	1.0 10.0 100.	0	

Favours IPC Favours intermittent

# Analysis 6.4. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion, Outcome 4 Number needing transfusion.

Review: Methods of vascular occlusion for elective liver resections

Comparison: 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion

Outcome: 4 Number needing transfusion

Study or subgroup	IPC n/N	Intermittent occlusion n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
Petrowsky 2006	9/36	/37		100.0 %	0.84 [ 0.40, 1.78 ]
Total (95% CI) Total events: 9 (IPC), 11 (I Heterogeneity: not applica	<b>36</b> ntermittent occl ble	37 usion)		100.0 %	0.84 [ 0.40, 1.78 ]
Test for overall effect: $Z =$	0.45 (P = 0.65)				
			0.2 0.5 1.0 2.0 5.0 Favours IPC Favours intermittent		

### Analysis 6.5. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion, Outcome 5 Number of units transfused.

Review: Methods of vascular occlusion for elective liver resections

Comparison: 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion

Outcome: 5 Number of units transfused

Study or subgroup	IPC	Inter	mittent occlusion		Mea	n Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fixe	ed,95% Cl		IV,Fixed,95% CI
Petrowsky 2006	36	1.7 (1.8)	37	2.9 (3)		-	57.6 %	-1.20 [ -2.33, -0.07 ]
Smyrniotis 2006	27	0 (1.8)	27	0 (3)			42.4 %	0.0 [ -1.32, 1.32 ]
Total (95% CI)	63		64		•	-	100.0 %	-0.69 [ -1.55, 0.17 ]
Heterogeneity: Chi <sup>2</sup> =	i 1.83, df	$=   (P = 0. 8);  ^2 = 45$	5%					
Test for overall effect:	Z = 1.58	(P = 0.11)						
					<u> </u>			
					-4 -2	0 2 4		

-2 0 Favours IPC Favours intermittent

### Analysis 6.6. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion, Outcome 6 Hospital stay (in days).

Review: Methods of vascular occlusion for elective liver resections

Comparison: 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion

Outcome: 6 Hospital stay (in days)

Study or subgroup	IPC N	Int Mean(SD)	ermittent occlusion N	Mean(SD)	Mean Difference IV,Random,95% CI	Weight	Mean Difference IV,Random,95% CI
Petrowsky 2006	36	14.7 (9.6)	37	12.7 (8.5)		30.1 %	2.00 [ -2.16, 6.16 ]
Smyrniotis 2006	27	10 (4)	27	(3)		69.9 %	-1.00 [ -2.89, 0.89 ]
Total (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect:	63 : 1.78; Cr Z = 0.07	ni <sup>2</sup> = 1.65, df = 1 (P (P = 0.94)	<b>64</b> = 0.20); I <sup>2</sup> =40%		-10 -5 0 5 1 Favours IPC Favours inter	100.0 %	-0.10 [ -2.79, 2.60 ]

## Analysis 6.7. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion, Outcome 7 ITU stay (in days).

Review: Methods of vascular occlusion for elective liver resections

Comparison: 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion

Outcome: 7 ITU stay (in days)

Study or subgroup	IPC		Intermittent occlusion	1	Mean Difference	Weight	Mean Difference	
	Ν	Mean(SD)	Ν	Mean(SD)	IV,	Fixed,95% Cl		IV,Fixed,95% CI
Petrowsky 2006	36	4 (7.2)	37	1.8 (3)			57.2 %	2.20 [ -0.34, 4.74 ]
Smyrniotis 2006	27	0 (7.2)	27	0 (3)		-	42.8 %	0.0 [ -2.94, 2.94 ]
Total (95% CI)	63		64			•	100.0 %	1.26 [ -0.66, 3.18 ]
Heterogeneity: Chi <sup>2</sup> =	1.23, df	= I (P = 0.27); I	2 =19%					
Test for overall effect:	Z = 1.28	(P = 0.20)						
					-10 -5	0 5	10	

Favours IPC

Favours intermittent

## Analysis 6.8. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion, Outcome 8 Operating time.

Review: Methods of vascular occlusion for elective liver resections

Comparison: 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion

Outcome: 8 Operating time

Study or subgroup I	IPC N	Mean(SD)	Intermittent occlusion N	Mean(SD)	Mean IV,Randon	Difference n,95% Cl	Weight	Mean Difference IV,Random,95% Cl
Petrowsky 2006	36	316 (126)	37	300 (116)			29.0 %	6.00 [ -39.60, 71.60 ]
Smyrniotis 2006	27	210.8 (30.9)	27	236.8 (27.8)	-		71.0 %	-26.00 [ -41.68, -10.32 ]
Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 4 Test for overall effect: Z	<b>63</b> 147.67 = 0.7	'; Chi <sup>2</sup> = 2.03, d 2 (P = 0.47)	<b>64</b> f = 1 (P = 0.15); I <sup>2</sup> =51%		100 -50 O Favours IPC	50 I Favours inte	100.0 %	-13.82 [ -51.17, 23.54 ]

## Analysis 6.9. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion, Outcome 9 Blood loss (ml).

Review: Methods of vascular occlusion for elective liver resections

Comparison: 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion

Outcome: 9 Blood loss (ml)

Study or subgroup	IPC	Inter	mittent occlusion		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fixed,95% CI		IV,Fixed,95% CI
I Transection							
Petrowsky 2006	36	146 (240)	37	250 (300)		100.0 %	-104.00 [ -228.46, 20.46 ]
Subtotal (95% CI)	36		37		•	100.0 %	-104.00 [ -228.46, 20.46 ]
Heterogeneity: not applic	able						
Test for overall effect: Z =	= 1.64 (	P = 0.10)					
2 Operative							
Petrowsky 2006	36	426 (450)	37	492 (460)		26.3 %	-66.00 [ -274.75, 142.75 ]
Smyrniotis 2006	27	520 (247)	27	720 (220)	-	73.7 %	-200.00 [ -324.76, -75.24 ]
Subtotal (95% CI)	63		64		•	100.0 %	-164.73 [ -271.83, -57.64 ]
Heterogeneity: $Chi^2 = 1$ .	17, df =	$  (P = 0.28);  ^2 =$	14%				
Test for overall effect: Z =	= 3.01 (	P = 0.0026)					
Test for subgroup differer	nces: Cł	$m^2 = 0.53$ , $df = 1$ (F	P = 0.47), l <sup>2</sup> =0.0%				
						1	
				-1000	) -500 0 500 I	000	

Favours IPC

Favours intermittent

Review: Methods of vascular occlusion for elective liver resections

Comparison: 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion

Outcome: 9 Blood loss (ml)

Study or subgroup	IPC N	Mean(SD)	Intermittent occlusion N	Mean(SD)	Mear IV,Fixe	n Difference d,95% Cl	Weight	Mean Difference IV,Fixed,95% Cl
l Transection Petrowsky 2006	36	146 (240)	37	250 (300)	-		100.0 %	-104.00 [ -228.46, 20.46 ]
Subtotal (95% CI) Heterogeneity: not applic Test for overall effect: Z =	<b>36</b> able = 1.64	(P = 0.10)	37		•		100.0 %	-104.00 [ -228.46, 20.46 ]
				-1000 Fav	-500 ( ours IPC	) 500 H	000 rmittent	

Methods of vascular occlusion for elective liver resections (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Comparison: 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion

Outcome: 9 Blood loss (ml)



## Analysis 6.10. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion, Outcome 10 Bilirubin (micromole/litre).

Review: Methods of vascular occlusion for elective liver resections

Comparison: 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion

Outcome: 10 Bilirubin (micromole/litre)

Study or subgroup	IPC		Intermittent occlusion			Mea	n Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)		IV,Fixe	d,95% Cl		IV,Fixed,95% CI
I First post-operative day									
Petrowsky 2006	36	50.4 (41.4)	37	48.6 (81.5)			•	2.2 %	1.80 [ -27.74, 31.34 ]
Smyrniotis 2006	27	39.5 (6.7)	27	38.5 (9.6)		-	-	97.8 %	1.00 [ -3.42, 5.42 ]
Subtotal (95% CI)	63		64				•	100.0 %	1.02 [ -3.35, 5.38 ]
Heterogeneity: $Chi^2 = 0.00$	), df = 1	(P = 0.96); l <sup>2</sup> =	=0.0%						
Test for overall effect: Z =	0.46 (P	= 0.65)							
2 Third post-operative day									
Smyrniotis 2006	27	52.9 (7.6)	27	52.4 (8.6)		-	-	100.0 %	0.50 [ -3.83, 4.83 ]
Subtotal (95% CI)	27		27				•	100.0 %	0.50 [ -3.83, 4.83 ]
Heterogeneity: not applicat	ble								
Test for overall effect: Z =	0.23 (P	= 0.82)							
					-20	-10 (	) 10 2	0	
					Favou	rs IPC	Favours inter	mittent	
									(Continued)

Methods of vascular occlusion for elective liver resections (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Study or subgroup	IPC N	Mean(SD)	Intermittent occlusion N	n Mean(SD)	Mean Difference IV,Fixed,95% CI	Weight	( Continued) Mean Difference IV,Fixed,95% Cl
3 Sixth post-operative day							
Smyrniotis 2006	27	34.3 (9.1)	2	7 30.5 (7)	-	100.0 %	3.80 [ -0.53, 8.13 ]
Subtotal (95% CI)	27		27	7	•	100.0 %	3.80 [ -0.53, 8.13 ]
Heterogeneity: not applica Test for overall effect: $Z =$	ble 1 72 (F	P = 0.085					
Test for subgroup difference	es: Chi	$i^2 = 1.29$ , df = 1	2 (P = 0.52), I <sup>2</sup> =0.0%				
						1	
					-20 -10 0 10	20	
					Favours IPC Favours int	ermittent	
Review: Methods of vas	cular o	cclusion for ele	ctive liver resections				
Companying (Jackson)			·····				
Comparison: 6 ischaemi	c preco	onaltioning tolic	wea by continuous occi	usion (IPC) versu	s intermittent occlusion		
Outcome: 10 Bilirubin (i	microm	nole/litre)					
Study on wheneve			laterreittent e celusien		Maan Difference	\ (o; abt	Maan Difference
study or subgroup	N	Mean(SD)	N	Mean(SD)	IV,Fixed,95% CI	vveignt	IV,Fixed,95% CI
L First past appretive day		. ,		. ,			
Petrowsky 2006	36	50.4 (41.4)	37	48.6 (81.5)		2.2 %	1.80 [ -27.74, 31.34 ]
Smyrniotis 2006	27	39.5 (6.7)	27	38.5 (9.6)		97.8 %	1.00 [ -3.42. 5.42 ]
Subtotal (95% CI)	63		64		•	100.0 %	1 02 [ -3 35 5 38 ]
Heterogeneity: $Chi^2 = 0.00$	0, df =	I (P = 0.96); I <sup>2</sup>	=0.0%			100.0 /0	1.02 [ -5.55, 5.50 ]
Test for overall effect: $Z =$	0.46 (F	P = 0.65)					
						i	
					-20 -10 0 10 2	20	
					Favours IFC Favours Inte	ermittent	

Comparison: 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion

Outcome: 10 Bilirubin (micromole/litre)

Study or subgroup	IPC		Intermittent occlusion		Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fixed,95% CI		IV,Fixed,95% CI
2 Third post-operative day							
Smyrniotis 2006	27	52.9 (7.6)	27	52.4 (8.6)		100.0 %	0.50 [ -3.83, 4.83 ]
Subtotal (95% CI)	27		27		+	100.0 %	0.50 [ -3.83, 4.83 ]
Heterogeneity: not applicat	ole						
Test for overall effect: Z =	0.23 (F	? = 0.82)					
					-20 -10 0 10 20		
					Favours IPC Favours intern	nittent	
Deviews Methodo of voo		alusian fan al	sti je li jeje posesti opo				
Review: Methods of Vaso	ular oc	clusion for ele	cuve liver resections				
Comparison: 6 Ischaemi	c preco	onditioning foll	owed by continuous occlu	sion (IPC) versu	s intermittent occlusion		
Outcome: 10 Bilirubin (r	nicrom	iole/litre)					
Study or subgroup	IPC N	Mean(SD)	Intermittent occlusion	Mean(SD)	Mean Difference	Weight	Mean Difference
		T lean(SD)	IN IN	T leal(SD)	14,11XE0,7578 CI		14,11Xed,7576 CI
3 Sixth post-operative day Smyrpiotis 2006	27	343 (91)	27	30.5 (7)	_	100.0 %	380[-053 813]
S 1 4 4 1 (050/ CI)	27	51.5 (7.1)	27	50.5 (7)		100.0 %	3.00 [ 0.53, 0.13 ]
Heterogeneity: not applicat	Z/		2/		-	100.0 %	5.80 [ -0.55, 8.15 ]
Test for overall effect: Z =	1.72 (F	P = 0.085)					
					-20 -10 0 10 20		
					Favours IPC Favours intern	hittent	

Methods of vascular occlusion for elective liver resections (Review)

Copyright @ 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

# Analysis 6.11. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion, Outcome 11 Prothrombin activity (percentage of normal).

Review: Methods of vascular occlusion for elective liver resections

Comparison: 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion

Outcome: II Prothrombin activity (percentage of normal)

Study or subgroup	IPC	Intermittent occlusion			Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fixed,95% CI		IV,Fixed,95% CI
First post-operative day							
Petrowsky 2006	36	-74.3 (18.6)	37	-72.4 (17)	-	14.7 %	-1.90 [ -10.08, 6.28 ]
Smyrniotis 2006	27	-48 (6.6)	27	-47.1 (6.1)		85.3 %	-0.90 [ -4.29, 2.49 ]
Subtotal (95% CI)	63		64		•	100.0 %	-1.05 [ -4.18, 2.09 ]
Heterogeneity: Chi <sup>2</sup> = 0.05	5, df =	$  (P = 0.82);  ^2 = 0.0$	)%				
Test for overall effect: Z =	0.65 (P	= 0.51)					
2 Third post-operative day							
Smyrniotis 2006	27	-65 (6.9)	27	-64.9 (5.3)	•	100.0 %	-0.10 [ -3.38, 3.18 ]
Subtotal (95% CI)	27		27		•	100.0 %	-0.10 [ -3.38, 3.18 ]
Heterogeneity: not applicat	ble						
Test for overall effect: Z =	0.06 (P	= 0.95)					
3 Sixth post-operative day							
Smyrniotis 2006	27	-74.9 (5.3)	27	-77.2 (6.7)	-	100.0 %	2.30 [ -0.92, 5.52 ]
Subtotal (95% CI)	27		27		•	100.0 %	2.30 [ -0.92, 5.52 ]
Heterogeneity: not applicat	ble						
Test for overall effect: Z =	1.40 (P	= 0.16)					
Test for subgroup difference	es: Chi <sup>2</sup>	<sup>2</sup> = 2.24, df = 2 (P	= 0.33), I <sup>2</sup> = I I%				
				1			
				-100	-50 0 50 10	00	

Favours IPC Favours intermittent

Comparison: 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion

Outcome: II Prothrombin activity (percentage of normal)

Study or subgroup	IPC N	Mean(SD)	Intermittent occlu N	usion	Mean(SD)	Mea IV,Fixe	n Difference d,95% Cl	Weight	Mean Difference IV,Fixed,95% Cl
l First post-operative day Petrowsky 2006	36	-74.3 (18.6)		37	-72.4 (17)	4	-	14.7 %	-1.90 [ -10.08, 6.28 ]
Smyrniotis 2006	27	-48 (6.6)		27	-47.1 (6.1)		•	85.3 %	-0.90 [ -4.29, 2.49 ]
Subtotal (95% CI)	63	( )		64	( )		•	100.0 %	-1.05 [ -4.18, 2.09 ]
Heterogeneity: $Chi^2 = 0.0$ . Test for overall effect: Z =	5, df = 0.65 (l	(P = 0.82); P = 0.51)	1 <sup>2</sup> =0.0%						
						-100 -50	0 50 IC	00	
						Favours IPC	Favours inter	mittent	
Review: Methods of vas	cular o	cclusion for el	ective liver resection	c					
Concerning (Josh and							- duri - u		
Companison: 6 iscnaemi	ic prec	onditioning toi	lowed by continuous	s occiu	sion (IPC) versi	us intermittent o	cciusion		
Outcome: 11 Prothrom	bin act	ivity (percenta	ge of normal)						
Study or subgroup	IPC		Intermittent occlu	sion		Mea	n Difference	Weight	Mean Difference
study of subgroup	N	Mean(SD)	N	51011	Mean(SD)	IV,Fixe	d,95% Cl	V Volgi IC	IV,Fixed,95% Cl
2 Third post-operative day	,								
Smyrniotis 2006	27	-65 (6.9)		27	-64.9 (5.3)		-	100.0 %	-0.10 [ -3.38, 3.18 ]
Subtotal (95% CI)	27			27		•	-	100.0 %	-0.10 [ -3.38, 3.18 ]
Heterogeneity: not applica	ble								
Test for overall effect: $Z =$	0.06 (I	P = 0.95)							
						-100 -50 (	0 50 10	0	
						Favours IPC	Favours interr	nittent	

Comparison: 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion

Outcome: II Prothrombin activity (percentage of normal)



#### Analysis 6.12. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion, Outcome 12 AST (IU/L).

Review: Methods of vascular occlusion for elective liver resections

Comparison: 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion

Outcome: 12 AST (IU	I/L)							
Study or subgroup	IPC N	Mean(SD)	Intermittent occlusion N	Mean(SD)	Mean D IV,Fixed,95	ifference 5% Cl	Weight	Mean Difference IV,Fixed,95% Cl
I First post-operative day	у							
Petrowsky 2006	36	645 (390)	37	528 (352.8)		-	31.5 %	7.00 [ -53.74, 287.74 ]
Smyrniotis 2006	27	615 (232)	27	595 (201)			68.5 %	20.00 [ -95.78, 135.78 ]
Subtotal (95% CI)	63		64		-	-	100.0 %	50.55 [ -45.27, 146.38 ]
Heterogeneity: Chi <sup>2</sup> = 0. Test for overall effect: Z 2 Third post-operative d	.85, df = = 1.03 (F ay	(P = 0.36);   P = 0.30)	2 =0.0%					
Smyrniotis 2006	27	310 (193)	27	244 (108)		-	100.0 %	66.00 [ -17.42, 149.42 ]
Subtotal (95% CI) Heterogeneity: not applie Test for overall effect: 7	<b>27</b> cable = 1.55 (F	P = 0   2	27		-		100.0 %	66.00 [ -17.42, 149.42 ]
3 Sixth post-operative da	ay	0.12)						
Smyrniotis 2006	27	45 (9.5)	27	46 (9)	•		100.0 %	-1.00 [ -5.94, 3.94 ]
				-2	00 -100 0 Favours IPC	100 20 Favours inter	00 mittent	(Continued )
Mothods of vascular of	elucion	for elective	liver recestions (Peu	iow)				145

(... Continued) Mean Difference Study or subgroup IPC Intermittent occlusion Mean Difference Weight Ν Mean(SD) Ν Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI Subtotal (95% CI) -1.00 [ -5.94, 3.94 ] 27 27 100.0 % Heterogeneity: not applicable Test for overall effect: Z = 0.40 (P = 0.69) Test for subgroup differences:  $Chi^2 = 3.57$ , df = 2 (P = 0.17),  $I^2 = 44\%$ -200 -100 0 100 200 Favours IPC Favours intermittent Review: Methods of vascular occlusion for elective liver resections Comparison: 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion Outcome: 12 AST (IU/L) Study or subgroup IPC Mean Difference Weight Mean Difference Intermittent occlusion IV,Fixed,95% CI IV,Fixed,95% CI N Mean(SD) Ν Mean(SD) I First post-operative day | | 7.00 [ -53.74, 287.74 ] Petrowsky 2006 36 645 (390) 37 528 (352.8) 31.5 % Smyrniotis 2006 27 615 (232) 595 (201) 68.5 % 20.00 [ -95.78, 135.78 ] 27 Subtotal (95% CI) 63 100.0 % 50.55 [ -45.27, 146.38 ] 64 Heterogeneity:  $Chi^2 = 0.85$ , df = 1 (P = 0.36);  $l^2 = 0.0\%$ Test for overall effect: Z = 1.03 (P = 0.30) -200 -100 0 100 200 Favours IPC Favours intermittent

Comparison: 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion

Outcome: 12 AST (IU/L)

Study or subgroup	IPC N	Mean(SD)	Intermittent occlusion N	Mean(SD)	Mean Difference IV,Fixed,95% Cl	Weight	Mean Difference IV,Fixed,95% Cl
2 Third post-operative da	У						
Smyrniotis 2006	27	310 (193)	27	244 (108)		100.0 %	66.00 [ -17.42, 149.42 ]
Subtotal (95% CI)	27		27		-	100.0 % 66	5.00 [ -17.42, 149.42 ]
Heterogeneity: not applic	able						
Test for overall effect: Z =	1.55	(P = 0.12)					
						L	
				-20	Eavours IPC Eavours inte	rmittent	
Review: Methods of va	scular	occlusion for	elective liver resections				
Concerning (Johnson	·						
Comparison: 6 ischaem	lic pre	conditioning f	ollowed by continuous oc	ciusion (IPC) ver	sus intermittent occiusion		
Outcome: 12 AST (IU/	L)						
Study or subgroup	IPC	M (CD)	Intermittent occlusior	M (CD)	Mean Differen	ice Weight	Mean Difference
	IN	I*lean(SD)	IN	I*lean(SD)	IV,FIXed,95% CI		IV,FIXEd,95% CI
3 Sixth post-operative day	/						
Smyrniotis 2006	27	45 (9.5)	27	46 (9)		100.0 %	-1.00 [ -5.94, 3.94 ]
Subtotal (95% CI)	27		27			100.0 %	-1.00 [ -5.94, 3.94 ]
Heterogeneity: not applica	able						
Test for overall effect: Z =	0.40	(P = 0.69)					
					200 100 0 100	200	
					Favours IPC Favours	s intermittent	

# Analysis 6.13. Comparison 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion, Outcome 13 ALT (IU/L).

Review: Methods of vascular occlusion for elective liver resections

Comparison: 6 Ischaemic preconditioning followed by continuous occlusion (IPC) versus intermittent occlusion

Outcome: 13 ALT (IU/L)



## APPENDICES

## Appendix I. Search strategies

Database	Period	Search strategy used
The Cochrane Hepato-Biliary Group Con- trolled Trials Register	August 2008	(((occlusion OR clamping OR exclusion) AND (vas- cular OR vessel OR arter* OR venous OR vein OR hepatic or portal)) OR pringle OR ((ischaemi* OR is- chemi*) AND (precondition*))) AND (liver OR hep- atic) AND (segmentectomy OR resection OR trans- plant* OR graft*)
Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Li- brary	Issue 3, 2008	<ul> <li>#1 ((occlusion OR clamping OR exclusion) AND (vascular OR vessel OR arter* OR venous OR vein OR hepatic or portal)) OR pringle in All Fields in all products</li> <li>#2 (ischaemi* OR ischemi*) AND precondition* in All Fields in all products</li> <li>#3 MeSH descriptor Ischemic Preconditioning explode all trees in MeSH products</li> <li>#4 MeSH descriptor Ischemia explode all trees in MeSH products</li> <li>#5 (#1 OR #2 OR #3 OR #4)</li> <li>#6 liver OR hepatic in All Fields in all products</li> <li>#7 MeSH descriptor Liver explode all trees in MeSH products</li> <li>#8 MeSH descriptor Liver Diseases explode all trees in MeSH products</li> <li>#9 MeSH descriptor Liver Neoplasms explode all trees in MeSH products</li> <li>#10 (#6 OR #7 OR #8 OR #9)</li> <li>#11 segmentectomy OR resection OR transplant* OR graft* in All Fields in all products</li> <li>#14 MeSH descriptor Liver Transplantation explode all trees in MeSH products</li> </ul>
MEDLINE (PubMed; http://www.ncbi.nlm.nih.gov/sites/entrez/)	January 1950 to August 2008	((((occlusion OR clamping OR exclusion) AND (vas- cular OR vessel OR arter* OR venous OR vein OR hepatic or portal)) OR pringle) OR (((ischaemi* OR ischemi*) AND precondition*) OR "ischemic pre-

(Continued)

		conditioning"[MeSH Terms] OR "ischemia"[MeSH Terms])) AND ((("Liver"[MeSH] OR "Liver Neo- plasms"[MeSH] OR "Liver Diseases"[MeSH] OR liver OR hepatic) AND (segmentectomy OR resection OR transplant* OR graft*)) OR "Hepatectomy"[MeSH] OR "Liver Transplantation"[MeSH]) AND ((random- ized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR drug therapy [sh] OR randomly [tiab] OR trial [tiab] OR groups [tiab]) AND humans [mh])	
EM- BASE (NHS National Library for Health; http://www.library.nhs.uk/booksandjournal	January 1974 to August 2008	1 (((occlusion OR clamping OR exclusion) AND (vas- cular OR vessel OR arter* OR venous OR vein OR hepatic OR portal)) OR pringle).af 2 ((ischaemi* OR ischemi*) AND precondition*).af 3 exp REPERFUSION INJURY/ 4 exp ISCHEMIC PRECONDITIONING/ 5 exp ISCHEMIA/ 6 1 OR 2 OR 3 OR 4 OR 5 7 (((liver OR hepatic OR hepato) AND (segmentec- tomy OR resection OR transplant* OR graft*)) OR hepatectomy).af 8 exp LIVER RESECTION/ 9 exp LIVER TRANSPLANTATION/ 10 7 OR 8 OR 9 11 6 AND 10 12 exp CROSSOVER PROCEDURE/ 13 exp DOUBLE BLIND PROCEDURE/ 14 exp SINGLE BLIND PROCEDURE/ 15 exp RANDOMIZED CONTROLLED TRIAL/ 16 (RANDOM* OR FACTO- RIAL* OR CROSSOVER* OR CROSS AND OVER* OR PLACEBO* OR (DOUBL* AND BLIND*) OR (SINGL* AND BLIND*) OR ASSIGN* OR ALLO- CAT* OR VOLUNTEER*).af 17 12 OR 13 OR 14 OR 15 OR 16 18 11 AND 17	
Science Citation Index Expanded (http://apps.isiknowledge.com/WOS <sup>·</sup> Adva	January 1970 to August 2008	<ul> <li>#1 TS=(((occlusion OR clamping OR exclusion) AND (vascular OR vessel OR arter* OR venous OR vein OR hepatic or portal)) OR pringle)</li> <li>#2 TS=((ischaemi* OR ischemi*) AND precondition*)</li> <li>#3 #2 OR #1</li> <li>#4 TS=(liver OR hepatic)</li> <li>#5 TS=(segmentectomy OR resection OR transplant* OR graft*)</li> </ul>	lvancedSearch)

#### (Continued)

		#6 #5 AND #4 #7 #6 AND #3 #8 TS=(random* OR blind*OR placebo* OR meta- analysis) #9 #8 AND #7
Lilacs (http://www.bireme.br/php/index.php?lang	August 2008	liver OR hepatic [Palavras] and segmentectomy OR re- section OR transplant OR graft [Palavras] and (occlu- sion OR clamping OR exclusion OR pringle [Palavras]

#### HISTORY

Protocol first published: Issue 1, 2007

Review first published: Issue 1, 2009

31 August 2008	Amended	Searches for new trails were performed in August 2008.
23 April 2008	Amended	Converted to new review format.

#### CONTRIBUTIONS OF AUTHORS

K Gurusamy wrote the review after identifying the trials for inclusion, extracting data, and performing the statistical analysis. H Sheth and Y Kumar independently identified trials and extracted the data from the trials. D Sharma and BR Davidson critically commented on the review and made suggestions to improve the review.

### DECLARATIONS OF INTEREST

BR Davidson is currently performing a pilot study to evaluate the benefit of remote ischaemic preconditioning in liver resection surgery and transplantation.

## SOURCES OF SUPPORT

#### Internal sources

• None, Not specified.

#### **External sources**

• None, Not specified.

### DIFFERENCES BETWEEN PROTOCOL AND REVIEW

Two new outcomes, ie, operating time and haemodynamic parameters, were added because procedures, such as hepatic vascular exclusion, involve additional procedure and may increase the operating time and may cause haemodyanmic instability.

#### Differences between previous version and current version

The outcomes have been revised and ordered according to the clinical significance. The non-clinical outcomes ie, mediators of ischaemiareperfusion injury (eg, neutrophil count, reactive oxygen species; apoptosis and mediators of apoptosis; and evidence for breakdown of adenosine 5'-triphosphate (ATP) (adenosine, metabolites of adenosine like xanthine, hypoxanthine) have been removed in order to improve the flow and give importance to clinical outcomes. The methods of assessment of risk of bias have been updated in line with the updated Cochrane Handbook (Higgins 2008) and the Cochrane Hepato-Bilairy Group Module (Gluud 2008). Imputation of standard deviation has been performed, and trials, which could not be included for meta-analysis previously, have been now included for meta-analysis. Risk ratios rather than odds ratios have been calculated. Minor errors in data extraction and data entry have been corrected.

#### NOTES

The present 'Methods of vascular occlusion for elective liver resections' together with 'Vascular occlusion for liver resection' and 'Ischaemic pre-conditioning for liver resections performed under vascular occlusion' reviews is one of the three new, up-to-date reviews evolved from the previously published in 2007 review with the same title 'Methods of vascular occlusion for elective liver resections' review (Gurusamy 2007).